UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October ~~2, 2005~~1, 2006 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________to_______ COMMISSION FILE NUMBER 1-3619 ----
PFIZER INC. (Exact name of registrant as specified in its charter)

DELAWARE (State of Incorporation)	13-5315170 (I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017 (Address of principal executive offices) (zip code) (212) 573-2323 (Registrant's telephone number) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. YES X NO Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, ~~(as defined~~or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange ~~Act).~~Act (Check one): ~~YES~~Large accelerated filer X NO Accelerated Filer Non-accelerated filer Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES NO X At ~~November 4, 2005, 7,371,396,380~~October 31, 2006, 7,210,444,662 shares of the issuer's voting common stock were outstanding.

FORM 10-Q

For the Quarter Ended
October ~~2, 2005~~1, 2006

Table of Contents

PART I. FINANCIAL INFORMATION	Page

Item 1.

Financial Statements:

Condensed Consolidated Statements of Income for the three months and nine months ended October 1, 2006 and October 2, 2005 ~~and September 26, 2004~~	3

Condensed Consolidated Balance Sheets atas of October ~~2, 2005~~1, 2006 and December 31, ~~2004~~2005	4

Condensed Consolidated Statements of Cash Flows for the nine months ended October 1, 2006 and October 2, 2005 ~~and September 26, 2004~~	5

Notes to Condensed Consolidated Financial Statements	6

Review Report of Independent Registered Public Accounting Firm	1825

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations	1926

Item 3.
Quantitative and Qualitative Disclosures About Market Risk	57

Item 4.

Controls and Procedures	4757

PART II. OTHER INFORMATION

Item 1.
Legal Proceedings	58

~~Legal Proceedings~~Item 1A.
Risk Factors	4759

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds	5059

Item 3.
Defaults Upon Senior Securities	59

Item 4.
Submission of Matters to a Vote of Security Holders	59

Item 5.
Other Information	59

Item 6.

Exhibits	5060

Signature	5161

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)

		Three Months Ended				Nine Months Ended				Three Months Ended				Nine Months Ended
(millions of dollars, except per common share data)		Oct. 2, 2005		Sept. 26, 2004		Oct. 2, 2005		Sept. 26, 2004
(millions, except per common share data)										Oct. 1, 2006		Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005

Revenues	$	12,189	$	12,831	$	37,705	$	37,593	$	12,280	$	11,263	$	35,768	$	34,858

Costs and expenses:
Cost of sales^(a)		1,908		1,640		6,180		5,185		1,962		1,611		5,423		5,250
Selling, informational and administrative expenses^(a)		3,931		4,036		12,242		12,227		3,751		3,526		11,027		10,958
Research and development expenses^(a)		1,783		1,888		5,421		5,356		1,902		1,739		5,187		5,287
Amortization of intangible assets^(a)		836		843		2,576		2,496		798		833		2,446		2,569
Merger-related in-process research and development charges		1,390		--		1,652		955		-		1,390		513		1,652
Restructuring charges and merger-related costs		307		190		796		726		249		303		816		782
Other (income)/deductions - net		(163)		283		669		140		(343)		(151)		(958)		703

Income from continuing operations before provision for taxes on income, and minority interests		2,197		3,951		8,169		10,508
Income from continuing operations before provision for taxes on income and minority interests										3,961		2,012		11,314		7,657

Provision for taxes on income		591		650		2,815		2,040		717		530		1,769		2,642

Minority interests		4		3		9		7		5		3		10		6

Income from continuing operations		1,602		3,298		5,345		8,461		3,239		1,479		9,535		5,009

Discontinued operations:
(Loss)/income from discontinued operations - net of tax		(16)		(3)		(37)		27
Income from discontinued operations - net of tax										120		107		330		299
Gains on sales of discontinued operations - net of tax		3		46		44		48		3		3		23		44

Discontinued operations - net of tax		(13)		43		7		75		123		110		353		343

Net income	$	1,589	$	3,341	$	5,352	$	8,536	$	3,362	$	1,589	$	9,888	$	5,352

Earnings per common share - Basic:
Earnings per common share - basic:
Income from continuing operations	$	0.22	$	0.44	$	0.73	$	1.12	$	0.45	$	0.20	$	1.31	$	0.68
Discontinued operations - net of tax		--		0.01		--		0.01		0.02		0.02		0.05		0.05
Net income	$	0.22	$	0.45	$	0.73	$	1.13	$	0.47	$	0.22	$	1.36	$	0.73

Earnings per common share - Diluted:
Earnings per common share - diluted:
Income from continuing operations	$	0.22	$	0.43	$	0.72	$	1.11	$	0.44	$	0.20	$	1.30	$	0.67
Discontinued operations - net of tax		--		0.01		--		0.01		0.02		0.02		0.05		0.05
Net income	$	0.22	$	0.44	$	0.72	$	1.12	$	0.46	$	0.22	$	1.35	$	0.72

Weighted-average shares used to calculate earnings per common share:
Basic		7,333		7,501		7,372		7,554		7,228		7,333		7,275		7,372

Diluted		7,382		7,569		7,424		7,642		7,251		7,382		7,306		7,424

Cash dividends paid per common share	$	0.19	$	0.17	$	0.57	$	0.51	$	0.24	$	0.19	$	0.72	$	0.57

^(a)	~~Includes~~Exclusive of amortization of intangible assets, except as disclosed in Note ~~11B,~~ 12B, Goodwill and Other Intangible ~~Assets:~~Assets: Other Intangible Assets.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

(millions of dollars)		Oct. 2, 2005*		Dec. 31, 2004**		Oct. 1, 2006*		Dec. 31, 2005**
ASSETS
Current Assets
Cash and cash equivalents	$	959	$	1,808	$	1,177	$	2,247
Short-term investments		12,430		18,085		11,654		19,979
Accounts receivable, less allowance for doubtful accounts: 2005 - $181; 2004 - $205		9,348		9,367
Accounts receivable, less allowance for doubtful accounts						9,177		9,103
Short-term loans		611		653		460		510
Inventories		6,556		6,660		6,167		5,478
Prepaid expenses and taxes		2,724		2,939		3,281		2,859
Assets held for sale		140		182
Assets of discontinued operations and other assets held for sale						6,805		6,659
Total current assets		32,768		39,694		38,721		46,835
Long-term investments and loans		2,784		3,873		2,845		2,497
Property, plant and equipment, less accumulated depreciation: 2005 - $9,199; 2004 - $8,534		17,519		18,385
Property, plant and equipment, less accumulated depreciation						16,417		16,233
Goodwill		23,806		23,756		21,051		20,985
Identifiable intangible assets, less accumulated amortization		28,976		33,251		25,323		26,244
Other assets, deferred taxes and deferred charges		4,490		4,725		4,228		4,176
Total assets	$	110,343	$	123,684	$	108,585	$	116,970

LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities
Short-term borrowings, including current portion of long-term debt: 2005 - $1,401; 2004 - $907	$	6,729	$	11,266
Short-term borrowings, including current portion of long-term debt					$	2,508	$	11,589
Accounts payable		1,809		2,672		1,742		2,073
Dividends payable		3		1,418		2		1,772
Income taxes payable		4,226		1,963		5,209		3,618
Accrued compensation and related items		1,636		1,939		1,533		1,602
Other current liabilities		5,990		7,136		5,271		6,521
Liabilities held for sale		2		64
Liabilities of discontinued operations and other liabilities held for sale						1,423		1,237
Total current liabilities		20,395		26,458		17,688		28,412

Long-term debt		5,414		7,279		5,561		6,347
Pension benefit obligations		2,771		2,821		2,636		2,681
Postretirement benefit obligations		1,442		1,450		1,368		1,424
Deferred taxes on income		10,780		12,632
Deferred taxes						8,838		9,707
Other noncurrent liabilities		2,734		4,766		2,782		2,635
Total liabilities		43,536		55,406		38,873		51,206

Shareholders' Equity
Preferred stock		175		193		146		169
Common stock		439		438		441		439
Additional paid-in capital		67,530		67,098		68,865		67,759
Employee benefit trust, at fair value		(970)		(1,229)		(845)		(923)
Treasury stock		(39,385)		(35,992)		(44,256)		(39,767)
Retained earnings		38,033		35,492		43,991		37,608
Accumulated other comprehensive income		985		2,278		1,370		479

Total shareholders' equity		66,807		68,278		69,712		65,764
Total liabilities and shareholders' equity	$	110,343	$	123,684	$	108,585	$	116,970

* Unaudited.

** Condensed from audited financial statements.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

		Nine Months Ended				Nine Months Ended
(millions of dollars)		Oct. 2, 2005		Sept. 26, 2004		Oct. 1, 2006		Oct. 2, 2005

Operating Activities:
Net income	$	5,352	$	8,536	$	9,888	$	5,352
Adjustments to reconcile net income to net cash provided by continuing operating activities:
Discontinued operations - net of tax		(7)		(75)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		4,143		3,782		4,026		4,143
Share-based compensation expense						506		121
Merger-related in-process research and development charges		1,652		955		513		1,652
Asset impairment charge and other costs associated with the suspension of Bextra sales		1,216		--
Deferred taxes		(279)		(471)
Other		193		479
Intangible asset impairments and other associated non-cash charges						--		1,216
Gains on disposal of investments, products and product lines						(201)		(58)
Gains on sales of discontinued operations						(37)		(72)
Deferred taxes from continuing operations						(1,333)		(1,088)
Other deferred taxes						67		(33)
Other non-cash adjustments						180		290
Changes in assets and liabilities (net of businesses acquired and divested)		(2,274)		(2,856)		(491)		(1,527)

Net cash provided by continuing operating activities		9,996		10,350
Net cash provided by operating activities						13,118		9,996

Investing Activities:
Purchases of property, plant and equipment		(1,493)		(1,526)		(1,438)		(1,493)
Purchases of short-term investments		(16,840)		(11,369)		(8,472)		(16,840)
Proceeds from redemptions of short-term investments		23,179		6,427		17,346		23,179
Purchases of long-term investments		(650)		(1,132)		(835)		(650)
Proceeds from sales of long-term investments		655		1,432
Proceeds from redemptions of long-term investments						229		655
Purchases of other assets		(392)		(613)		(118)		(392)
Proceeds from sales of other assets		6		267		3		6
Proceeds from the sales of businesses, products and product lines						22		108
Acquisitions, net of cash acquired		(2,104)		(1,443)		(1,989)		(2,104)
Proceeds from the sales of businesses and product lines		108		1,192
Other investing activities		238		32		(82)		238

Net cash provided by/(used in) investing activities		2,707		(6,733)
Net cash provided by investing activities						4,666		2,707

Financing Activities:
Increase in short-term borrowings, net		9		2,094		993		9
Principal payments on short-term borrowings		(5,274)		(238)		(11,721)		(5,274)
Proceeds from issuances of long-term debt		5		2,592		1,051		5
Principal payments on long-term debt		(1,042)		(29)		(55)		(1,042)
Proceeds from common stock issuances		45		53
Purchases of common stock		(3,415)		(4,787)		(4,496)		(3,415)
Cash dividends paid		(4,177)		(3,821)		(5,211)		(4,177)
Stock option transactions and other		301		856		593		346

Net cash used in financing activities		(13,548)		(3,280)		(18,846)		(13,548)
Effect of exchange-rate changes on cash and cash equivalents		(4)		7		(8)		(4)
Net (decrease)/increase in cash and cash equivalents		(849)		344
Net decrease in cash and cash equivalents						(1,070)		(849)
Cash and cash equivalents at beginning of period		1,808		1,520		2,247		1,808

Cash and cash equivalents at end of period	$	959	$	1,864	$	1,177	$	959

Supplemental Cash Flow Information:
Cash paid during the period for:
Income taxes	$	3,738	$	2,374	$	2,031	$	3,738
Interest		485		312		579		485

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Note 1:1. Basis of Presentation

~~General~~

We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month and nine-month periods ended August ~~28, 2005~~27, 2006 and August ~~22, 2004. The fiscal first quarter and nine months of 2005 had three additional business days compared to the fiscal first quarter and nine months of 2004.~~28, 2005.

We made certain reclassifications to the ~~2004~~2005 condensed consolidated financial statements to conform to the ~~2005~~2006 presentation. These reclassifications are primarily related to discontinued operations (see Note 3, Discontinued Operations), as well as to better reflect jurisdictional netting of deferred taxes.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in Pfizer's Annual Report on Form 10-K for the year ended December 31, ~~2004.~~2005.

Note 2. Acquisitions

On May 16, 2006, we completed the acquisition of all of the outstanding shares of Rinat Neuroscience Corp., a biologics company with several new central-nervous-system product candidates. In connection with the acquisition, as part of our preliminary purchase price allocation, we recorded $478 million, pre-tax, in ~~Share-Based Payments~~Merger-related in-process research and development charges.

On February 28, 2006, we completed the acquisition of the sanofi-aventis worldwide rights, including patent rights and production technology, to manufacture and sell Exubera, an inhaled form of insulin for use in adults with type 1 and type 2 diabetes, and the insulin-production business and facilities located in Frankfurt, Germany, previously jointly owned by Pfizer and sanofi-aventis, for approximately $1.4 billion (including transaction costs). In ~~accordance~~connection with the acquisition, as part of our final purchase price allocation, we recorded an intangible asset for developed technology rights of approximately $1.0 billion, inventory valued at $218 million and goodwill of approximately $166 million, all of which have been allocated to our Pharmaceutical segment. The amortization of the developed technology rights is primarily included in Cost of Sales. Prior to the acquisition, in connection with our collaboration agreement with sanofi-aventis, we recorded a research and development milestone due to us from sanofi-aventis of approximately $118 million ($71 million, after tax) in the first quarter of 2006 in Research and development expenses upon the approval of Exubera in January 2006 by the Food and Drug Administration (FDA).

On September 14, 2005, we completed the acquisition of all of the outstanding shares of Vicuron Pharmaceuticals, Inc. (Vicuron), a biopharmaceutical company focused on the development of novel anti-infectives, for approximately $1.9 billion in cash (including transaction costs). The allocation of the purchase price includes in-process research and development of approximately $1.4 billion, which was expensed and included in Merger-related in-process research and development charges, and goodwill of $243 million, which has been allocated to our Pharmaceutical segment. Neither of these items was deductible for tax purposes.

On April 12, 2005, we completed the acquisition of Idun Pharmaceuticals, Inc. (Idun), a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis, and on August 15, 2005, we completed the acquisition of all outstanding shares of Bioren Inc. (Bioren), which focuses on technology for optimizing antibodies. The aggregate cost of these and other smaller acquisitions was approximately $340 million for the nine months ended October 2, 2005.

Note 3. Discontinued Operations

We evaluate our businesses and product lines periodically for strategic fit within our operations. As a result of our evaluation, we decided to sell a number of businesses and product lines, certain of which qualified for Discontinued operations treatment:

•	In June 2006, we entered into an agreement to sell our Consumer Healthcare business for approximately $16.6 billion in cash. This business comprises substantially all of our former Consumer Healthcare segment and other associated amounts, such as purchase-accounting impacts and merger-related costs, and restructuring and implementation costs related to our Adapting to Scale (AtS) productivity initiative, previously reported in the Corporate/Other segment. In addition, certain manufacturing facility assets and liabilities, which were previously part of our Pharmaceutical or Corporate/Other segment, are included in the planned sale of the Consumer Healthcare business. In connection with the decision to sell this business, for all periods presented, the operating results associated with this business that will be discontinued have been reclassified into Discontinued operations - net of tax in the condensed consolidated statements of income, and the assets and liabilities associated with this business that will be sold have been reclassified into Assets/Liabilities of discontinued operations and other assets/liabilities held for sale, as appropriate, on the condensed consolidated balance sheets. The divestiture of the Consumer Healthcare business is expected to close in late 2006 and is subject to customary closing conditions, including receipt of regulatory approvals.

•	In the third quarter of 2005, we sold the last of three European generic pharmaceutical businesses, which we had included in our Pharmaceutical segment, for 4.7 million euros (approximately $5.6 million) and recorded a loss of $3 million ($2 million, net of tax) in Gains on sales of discontinued operations - net of tax in the condensed consolidated statement of income for the three months and nine months ended October 2, 2005.

•	In the first quarter of 2005, we sold the second of three European generic pharmaceutical businesses, which had been included in our Pharmaceutical segment, for 70 million euros (approximately $93 million) and recorded a gain of $57 million ($36 million, net of tax) in Gains on sales of discontinued operations - net of tax in the condensed consolidated statement of income. In addition, we recorded an impairment charge of $9 million ($6 million, net of tax) related to the last of the three European generic pharmaceutical businesses in Income from discontinued operations - net of tax in the condensed consolidated statement of income for the nine months ended October 2, 2005.

The following amounts, primarily related to our Consumer Healthcare business, have been segregated from continuing operations and included in Discontinued operations - net of tax in the condensed consolidated statements of income:

		Three Months Ended				Nine Months Ended
(in millions)		Oct. 1, 2006		Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005

Revenues	$	974	$	932	$	2,920	$	2,883

Pre-tax income of discontinued businesses	$	178	$	174	$	493	$	465
Provision for taxes on income		(58)		(67)		(163)		(166)
Income from discontinued operations - net of tax		120		107		330		299
Pre-tax gains on sales of discontinued businesses		6		7		37		72
Provision for taxes on gains		(3)		(4)		(14)		(28)
Gains on sales of discontinued operations - net of tax		3		3		23		44
Discontinued operations-net of tax	$	123	$	110	$	353	$	343

The following assets and liabilities, primarily related to our Consumer Healthcare business, have been segregated and included in Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations and other liabilities held for sale, as appropriate, in the condensed consolidated balance sheets:

(in millions)		Oct. 1, 2006		Dec. 31, 2005

Accounts receivable, less allowance for doubtful accounts	$	778	$	661
Inventories		518		561
Prepaid expenses and taxes		64		71
Property, plant and equipment, less accumulated depreciation		1,023		1,002
Goodwill		2,751		2,789
Identifiable intangible assets, less accumulated amortization		1,651		1,557
Other assets, deferred taxes and deferred charges		20		18
Assets of discontinued operations and other assets held for sale	$	6,805	$	6,659

Current liabilities	$	681	$	538
Other		742		699
Liabilities of discontinued operations and other liabilities held for sale	$	1,423	$	1,237

Net cash flows of our discontinued operations estimated from each of the categories of operating, investing and financing activities were not significant for the nine months ended October 1, 2006 and October 2, 2005.

Note 4. Adoption of New Accounting Standards

On January 1, 2006, we adopted the provisions of Statement of Financial Accounting Standards (SFAS) No. 123R, Share-Based Payment, as supplemented by the interpretation provided by SEC Staff Accounting Bulletin No. 107, issued in March 2005. (SFAS 123R replaced SFAS 123, ~~Accounting for~~ Stock-Based Compensation, issued in 1995.) We have elected the modified prospective application transition method of adoption and, as such, prior-period financial statements have not been restated. Under this method, the fair value of all stock options granted or modified after adoption must be recognized in the consolidated statement of income and total compensation cost related to nonvested awards not yet recognized, determined under the original provisions of SFAS 123, must also be recognized in the consolidated statement of income.

Prior to January 1, 2006, we ~~elect to account~~accounted for ~~our stock-based compensation~~stock options under Accounting ~~Principles~~Principle Board Opinion (APB) No. 25, Accounting for Stock Issued to Employees~~. The~~, an elective accounting policy permitted by SFAS 123. Under this standard, since the exercise price of our stock options granted ~~equals~~is set equal to the market price on the date of ~~grant; as such, there is no recorded compensation~~the grant, we did not record any expense ~~related~~ to ~~grants~~the condensed consolidated statement of ~~stock options.~~

The weighted-average fair value per stock option granted was $5.00 and $6.33 for the three months ended October 2, 2005 and September 26, 2004, and $5.15 and $6.88 for the nine months ended October 2, 2005 and September 26, 2004. We estimated the fair values, as required under GAAP, using the Black-Scholes option-pricing model, modified for dividends and using the assumptions below. Pro forma compensation expenseincome related to stock options, ~~subject~~unless certain original grant date terms were subsequently modified. However, as required, we disclosed, in the Notes to ~~accelerated vesting upon retirement is recognized over~~Condensed Consolidated Financial Statements, the ~~period of employment up to the vesting date~~pro forma expense impact of the grant. In the first quarter of 2005, we changed our method of estimating expected dividend yield from historical patterns of dividend payments to a method that reflects a constant dividend yield during the expected term of the option.

Three Months Ended
Nine Months Ended
Oct. 2,
2005
Sept. 26,
2004
Oct. 2,
2005
Sept. 26,
2004
Expected dividend yield
2.76%
2.98%
2.90%
2.90%
Risk-free interest rate
3.81%
3.36%
3.96%
3.32%
Expected stock price volatility
20.00%
22.88%
21.93%
22.15%
Expected term until exercise (years)
5.59
5.64
5.75
5.75

~~The following table shows the effect on results for the three-month and nine-month periods ended October 2, 2005 and September 26, 2004~~stock option grants as if we had applied the fair-value-based recognition provisions of SFAS ~~123 to measure stock-based compensation expense~~123.

The adoption of SFAS 123R primarily impacted our accounting for ~~the option grants:~~

Three Months Ended
Nine Months Ended
(millions of dollars, except per common share data)
Oct. 2,
2005
Sept. 26,
2004
Oct. 2,
2005
Sept. 26,
2004

Net income available to common shareholders used in the calculation of basic earnings per common share:
As reported under GAAP*
$
1,588
$
3,340
$
5,348
$
8,532
Compensation expense - net of tax
(104)
(148)
(356)
(421)
Pro forma
$
1,484
$
3,192
$
4,992
$
8,111

Basic earnings per common share:
As reported under GAAP*
$
0.22
$
0.45
$
0.73
$
1.13
Compensation expense - net of tax
(0.02)
(0.02)
(0.05)
(0.06)
Pro forma
$
0.20
$
0.43
$
0.68
$
1.07

Net income available to common shareholders used in the calculation of diluted earnings per common share:
As reported under GAAP*
$
1,588
$
3,340
$
5,349
$
8,531
Compensation expense - net of tax
(104)
(148)
(356)
(421)
Pro forma
$
1,484
$
3,192
$
4,993
$
8,110

Diluted earnings per common share:
As reported under GAAP*
$
0.22
$
0.44
$
0.72
$
1.12
Compensation expense - net of tax
(0.02)
(0.02)
(0.05)
(0.06)
Pro forma
$
0.20
$
0.42
$
0.67
$
1.06

Includes stock-based compensation expense, net of related tax benefits, of $81 million for the nine months ended October 2, 2005 ($28 million for the three months ended October 2, 2005) and $40 million for the nine months ended September 26, 2004 (none for the three months ended September 26, 2004).

~~Net income available to common shareholders used in the calculation of basic earnings per common share represents net income reduced by preferred~~ stock dividends - net of tax. Net income available to common shareholders used in the calculation of diluted earnings per common share represents net income reduced by the incremental allocation of shares to the Employee Stock Ownership Plans (ESOPs) acquired as part of the Pharmacia acquisition.options (see Note 14, Share-Based Payments).

Note 2:5. Asset Impairment Charge and Other Costs Associated with the Suspension of Bextra Sales

In the first nine months of 2005, we recorded charges totaling $1.2 billion ($762 million, net of tax) in connection with the decision to suspend sales ~~and marketing~~ of Bextra. ~~This decision resulted from an April 7, 2005 request from the U.S. Food and Drug Administration (FDA), as part of its safety review of all COX-2 medicines.~~

The pre-tax ~~charges~~charge included $1.1 billion related to the impairment of developed technology rights ~~associated with Bextra~~ and $7 million related to the write-off of machinery and equipment, both of which ~~are~~were included in Other (income)/deductions - net.In addition, in connection with the suspension, we ~~also~~ recorded $56 million in write-offs of inventory and exit costs, included in Cost of sales; $8 million related to the ~~costs~~cost of administering the suspension of sales, included in Selling, informational and administrative ~~expenses;~~expenses; and $212 million for an estimate of customer returns, primarily included against ~~Revenues.~~Revenues. Substantially all of these charges were recorded in the first quarter of 2005.

Note ~~3: Income Taxes~~

~~Income Tax Charge Associated with Repatriation Decision~~

~~In the first nine months of 2005, we recorded an income tax charge of $1.7 billion, included in~~ ~~Provision for taxes on income~~~~, in connection with our decision to repatriate about $36.7 billion of foreign earnings in accordance with the~~ ~~American Jobs Creation Act of 2004~~ (the Jobs Act). In the first quarter of 2005, we recorded an initial estimated income tax charge of $2.2 billion based on the decision to repatriate $28.3 billion of foreign earnings; in the second quarter of 2005, we reduced our original estimate of the tax charge by $863 million and revised the repatriation of foreign earnings to $28.1 billion, principally as a result of guidance issued by the U.S. Treasury in May 2005. In the second quarter of 2005, we also recorded an additional tax charge of $373 million, primarily due to our decision to repatriate an additional $8.6 billion of foreign earnings.

As of October 2, 2005, we intend to continue to permanently reinvest the earnings of our international subsidiaries and, therefore, we have not recorded a U.S. tax provision on the remaining amount of unremitted earnings.

~~Tax Contingencies~~

In the second quarter of 2005, we recorded a tax benefit of $586 million primarily related to the resolution of certain tax positions. We believe that the IRS audits of the Pfizer Inc. tax returns for the years 1999-2001 and the Warner-Lambert Company tax returns for the years 1999 through the date of the merger with Pfizer (June 19, 2000) are substantially complete. In connection with those audits, we are currently in the process of appealing one matter related to the tax deductibility of a breakup fee paid by Warner-Lambert Company in 2000.

~~The IRS has commenced the audit of the Pfizer Inc. tax returns for the years 2002, 2003 and 2004. The 2005 tax year is also currently under audit.~~

As previously disclosed, with respect to Pharmacia Corporation (formerly known as Monsanto Company), the IRS has completed and closed its income tax return examinations and appeals through 1999 and has commenced the audit of the tax returns for the years 2000 through the date of merger with Pfizer (April 16, 2003).

We periodically reassess the likelihood of assessments resulting from audits of federal, state and foreign income tax filings. We believe that our accruals for tax liabilities are adequate for all open years.

~~Note 4:~~6. Adapting to Scale Productivity Initiative

We incurred the following costs in connection with our Adapting to Scale (AtS) productivity initiative, which was ~~announced~~launched in ~~the second quarter of~~early 2005:

						Three Months Ended				Nine Months Ended
(millions of dollars)		Three Months Ended Oct. 2, 2005		Nine Months Ended Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005

Implementation costs^(a)	$	104	$	136	$	182	$	100	$	547	$	133
Restructuring charges^(b)		153		174		245		151		801		172
Total AtS costs	$	257	$	310	$	427	$	251	$	1,348	$	305

^(a)

Included in Cost of sales ($50 million), Selling, informational and administrative expenses ($63 million), Research and developmentexpenses ($70 million) and in Other (income)/deductions - net ($1 million income) for the three months ended October 1, 2006 and included in Cost of sales ($278 million), Selling, informational and administrative expenses ($160 million), Research and developmentexpenses ($132 million) and in Other (income)/deductions - net ($23 million income) for the nine months ended October 1, 2006. Included in Cost of sales ($36 million), Selling, informational and administrative expenses ($6056 million), and Research and development expenses ($8 million) for the three months ended October 2, 2005 and included in Cost of sales ($37 million),Selling, informational and administrative expenses~~($81~~ ($76 million), ~~and~~ Research and developmentexpenses ($1820 million) for the nine months ended October 2, 2005.

^(b)

Included in Restructuring charges and merger-related costs.

~~In connection with~~

Included in Discontinued operations - net of tax are additional pre-tax AtS costs of $2 million and $17 million for the ~~AtS initiative, Pfizer management has performed a comprehensive review of our processes, organizations, systems~~three months and ~~decision-making procedures, in a company-wide effort to improve performance~~nine months ended October 1, 2006 and ~~efficiency. We expect~~$7 million for the ~~costs associated with this multi-year effort to continue through 2008~~three months and to total approximately $4 billion to $5 billion, on a pre-tax basis. The actions associated with the AtS initiative will include restructuring charges, such as asset impairments, exit costs and severance costs (including any related impacts to our benefit plans, including settlements and curtailments) and associated implementation costs, such as accelerated depreciation charges, primarily associated with plant network optimization efforts, and expenses associated with system and process standardization and the expansion of shared services.nine months ended October 2, 2005.

Through October ~~2, 2005,~~1, 2006, the restructuring charges primarily relate to ~~employee termination costs at~~ our ~~manufacturing facilities in North America~~plant network optimization efforts and the restructuring of our U.S. marketing and worldwide research and development operations, while the implementation costs primarily relate to system and process standardization, ~~and to~~as well as the expansion of shared services.

The components of restructuring ~~costs~~charges associated with AtS follow:

(millions of dollars)		Nine Months Ended Oct. 2, 2005		Utilization Through Oct. 2, 2005		Accrual at Oct. 2, 2005	^(a)		Costs Incurred Through Oct. 1, 2006		Utilization Through Oct. 1, 2006		Accrual as of Oct. 1, 2006	^(a)

Employee termination costs	$	106	$	49	$	57		$	751	$	626	$	125
Asset impairments		62		62		--			386		386		--
Other		6		--		6			102		50		52
	$	174	$	111	$	63
Total								$	1,239	$	1,062	$	177

^(a)	Included in Other current liabilities.

During the three months and nine months ended October ~~2, 2005,~~1, 2006, we expensed ~~$85~~$118 million and $449 million for Employee termination costs, ~~$62~~$86 million and $263 million for Asset impairments, and $6$41 million and $89 million in Other. Through October ~~2, 2005,~~1, 2006, Employee termination costs represent the approved reduction of the workforce by ~~922~~5,728 employees, mainly in manufacturing, sales and research. We notified affected individuals and ~~903~~5,325 employees were terminated as of October ~~2, 2005.~~1, 2006. Employee termination costs are recorded as incurred and include accrued severance benefits, pension and postretirement benefits. Asset impairments primarily include charges to write off inventory and write down ~~intangible assets, and~~ property, plant and equipment. Other primarily includes costs to exit certain activities.

Note 5:7. Merger-Related Costs

We incurred the following merger-related costs:

		Three Months Ended				Nine Months Ended
(millions of dollars)		Oct. 1, 2006		Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005

Integration costs	$	3	$	91	$	8	$	384
Restructuring charges		1		61		7		226
Total merger-related costs^(a)	$	4	$	152	$	15	$	610

^(a)	Included in Restructuring charges and merger-related costs. Amounts in 2005 primarily relate to our acquisition of Pharmacia Corporation (Pharmacia), which was completed on April 16, 2003.

Included in Discontinued operations - net of tax is a downward adjustment of additional pre-tax merger-related costs ~~primarily~~of $(2) million for the three months ended October 1, 2006 and additional pre-tax merger-related costs of $3 million for the nine months ended October 1, 2006. Included in ~~connection with our acquisition~~Discontinued operations - net of ~~Pharmacia Corporation (Pharmacia), which was completed on April 16, 2003:~~

Three Months Ended
Nine Months Ended
(millions of dollars)
Oct. 2,
2005
Sept. 26,
2004
Oct. 2,
2005
Sept. 26,
2004

Integration costs^(a)
$
93
$
113
$
390
$
367
Restructuring costs^(a)
61
77
232
359
Total merger-related costs
$
154
$
190
$
622
$
726

^(a)
Included in Restructuring charges and merger-related costs.

~~In connection with~~tax were additional pre-tax merger-related costs of $9 million and $25 million for the ~~acquisition of Pharmacia, Pfizer management approved plans to restructure~~three months and integrate the operations of both legacy Pfizer and legacy Pharmacia to combine operations, eliminate duplicative facilities and reduce costs. Total merger-related expenditures expected to be incurred during 2003 through 2005 to achieve anticipated synergies are about $5.1 billion, on a pre-tax basis, with $5.0 billion incurred throughnine months ended October 2, 2005. ~~The restructuring of our operations as a result of our acquisition of Pharmacia includes consulting, systems integrations,~~

Restructuring charges included severance, costs of vacating duplicative facilities, contract termination and other exit costs.

~~Through April 15, 2004,~~Note 8. Taxes on Income

A. Taxes on Income

In the third quarter of 2006, we recorded ~~restructuring costs associated~~a decrease to the 2005 estimated U.S. tax provision related to the repatriation of foreign earnings, due primarily to the receipt of information that raised our assessment of the likelihood of prevailing on the technical merits of a certain position and we recognized a tax benefit of $124 million.

On January 23, 2006, the Internal Revenue Service (IRS) issued final regulations on Statutory Mergers and Consolidations, which impacted certain prior-period transactions. In the first quarter of 2006, we recorded a tax benefit of $217 million, reflecting the total impact of these regulations.

In the first nine months of 2005, we recorded an income tax charge of $1.7 billion, included in Provision for taxes on income, in connection with ~~employee terminations and exiting certain activities~~our decision to repatriate about $37 billion of ~~legacy Pharmacia as liabilities assumed~~foreign earnings in accordance with the American Jobs Creation Act of 2004 (the Jobs Act). In the first quarter of 2005, we recorded an initial estimate of $2.2 billion based on the decision to repatriate $28.3 billion of foreign earnings; in the ~~purchase business combination and recorded an increase to goodwill. Changes to previous estimates~~second quarter of ~~restructuring costs included as part~~2005, we reduced our original estimate of the ~~purchase allocation~~tax charge by $490 million, due primarily to guidance issued by the U.S. Treasury in the second quarter of ~~Pharmacia are~~2005, partially offset by our decision to increase the amount of the repatriation.

As of October 1, 2006, we intend to permanently reinvest the earnings of our international subsidiaries and, therefore, we have not recorded as a reduction to goodwill or an expense to operations, as appropriate. Restructuring costs incurred for legacy Pfizer and restructuring costs incurred after April 15, 2004 for legacy Pharmacia are chargedU.S. tax provision on unremitted earnings.

B.Tax Contingencies

On January 25, 2006, the Company was notified by the IRS Appeals Division that a resolution had been reached on the matter that we were in the process of appealing related to the ~~results~~tax deductibility of ~~operations.~~a breakup fee paid by Warner-Lambert Company in 2000. As a result, in the first quarter of 2006 we recorded a tax benefit of approximately $441 million related to the resolution of this issue.

In the second quarter of 2005, we recorded a tax benefit of $586 million primarily related to the resolution of certain tax positions.

The IRS is currently conducting audits of the Pfizer Inc. tax returns for the years 2002, 2003 and 2004. The 2005 and 2006 tax years are also currently under audit under the IRS Compliance Assurance Process, a recently introduced real-time audit process.

With respect to Pharmacia Corporation, the IRS has completed audits of the tax returns for the years 2000 through 2002 and is currently conducting an audit for the 2003 tax year through the date of the merger with Pfizer (April 16, 2003).

Note 9. Comprehensive Income

The components of ~~merger-related restructuring costs associated with legacy Pfizer and legacy Pharmacia~~comprehensive income/(expense) follow:

(millions of dollars)
Total
Utilization
Through
Oct. 2,
2005
^(a)
Accrual at
Oct. 2,
2005
^(b)

Costs capitalized through April 15, 2004:
Employee termination costs
$
1,535
$
1,502
$
33
Other
624
517
107
$
2,159
$
2,019
$
140
Costs expensed:
Employee termination costs
$
590
$
508
$
82
Asset impairments
421
421
--
Other
96
74
22

$
1,107
$
1,003
$
104

		Three Months Ended				Nine Months Ended
(millions of dollars)		Oct. 1, 2006		Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005

Net income	$	3,362	$	1,589	$	9,888	$	5,352
Other comprehensive income/(expense):
Currency translation adjustment and other^(a)		(125)		(174)		873		(1,159)
Net unrealized gains/(losses) on derivative financial instruments^(b)		(19)		(13)		74		(40)
Net unrealized gains/(losses) on available-for-sale securities^(b)		(2)		5		(35)		(114)
Minimum pension liability^(b)		8		6		(21)		20
Total other comprehensive income/(expense)		(138)		(176)		891		(1,293)
Total comprehensive income	$	3,224	$	1,413	$	10,779	$	4,059

^(a)	Includes ~~insignificant~~changes in currency translation adjustments of nil and $21 million for the three months and nine months ended October 1, 2006, and ($12) million and ($37) million for the three months and nine months ended October 2, 2005, related to ~~original amounts established.~~discontinued operations.
^(b)	~~Included in~~ ~~Other current liabilities.~~Amounts associated with discontinued operations are not significant.

~~During the three months ended October 2, 2005 and September 26, 2004, we expensed $1 million and $53 million for~~ ~~Employee termination costs~~~~, $53 million and $8 million for~~ ~~Asset impairments~~~~, and $7 million and $16 million in~~ ~~Other~~~~. During the first nine months of 2005 and 2004, we expensed $73 million and $201 million for~~ ~~Employee termination costs~~~~, $131 million and $122 million for~~ ~~Asset impairments~~~~, and $22 million and $31 million in~~ ~~Other~~.~~Through October 2, 2005,~~ ~~Employee termination costs~~ represent the approved reduction of the legacy Pfizer and legacy Pharmacia work force by 17,086 employees, mainly in corporate, manufacturing, distribution, sales and research. We notified affected individuals and 16,385 employees were terminated as of October 2, 2005. ~~Employee termination costs~~ ~~are recorded as incurred and include accrued severance benefits and costs associated with change-in-control provisions of certain Pharmacia employment contracts.~~ ~~Asset impairments~~ ~~primarily include charges to write down property, plant and equipment.~~ ~~Other~~ ~~primarily includes costs to exit certain activities of legacy Pfizer and legacy Pharmacia.~~Note 10. Financial Instruments

~~Note 6: Acquisitions~~A. Long-Term Debt

On September 14, 2005, we completed the acquisition of all of the outstanding shares of Vicuron Pharmaceuticals, Inc. (Vicuron), a biopharmaceutical company focused on the development of novel anti-infectives, for approximately $1.9 billion in cash (including transaction costs). Vicuron has two products currently under New Drug Application (NDA) review by the FDA: anidulafungin for fungal infections and dalbavancin for Gram-positive infections. The allocation of the purchase price includes in-process research and development of approximately $1.4 billion, which was expensed and included in ~~Merger-related in-process research and development charges~~~~, and goodwill of $243 million, which has been allocated to our Human Health segment. Neither of these items is deductible for tax purposes.~~

On February 10, 2004, we completed the acquisition of all the outstanding shares of Esperion Therapeutics, Inc., (Esperion), a biopharmaceutical company, for $1.3 billion in cash (including transaction costs). The allocation of the purchase price included in-process research and development of $920 million, which was expensed, and goodwill of $235 million, which was allocated to our Human Health segment. Neither of these items was deductible for tax purposes. The aggregate cost of other smaller acquisitions was approximately $170 million for the nine months ended September 26, 2004.

~~Note 7: Dispositions~~

~~We evaluate our businesses and product lines periodically for strategic fit within our operations.~~ In ~~the first quarter of 2004, we decided to sell a number of businesses and product lines and we recorded the results of these operations in~~ ~~Discontinued operations~~ for 2005 and 2004. As of October 2, 2005, all of these discontinued operations have been sold. The impact of these divested businesses and product lines was not material to the consolidated operating results of Pfizer Inc in the periods presented.

~~Assets held for sale~~ ~~and~~ ~~Liabilities held for sal~~~~e on the balance sheet at October 2, 2005, relate primarily to assets in Europe that we intend to sell but that are not related to~~ ~~Discontinued operations~~.

~~Note 8: Comprehensive Income/(Expense)~~

~~The components of comprehensive income/(expense) follow:~~

Three Months Ended
Nine Months Ended
(millions of dollars)
Oct. 2,
2005
Sept. 26,
2004
Oct. 2,
2005
Sept. 26,
2004

Net income
$
1,589
$
3,341
$
5,352
$
8,536
Other comprehensive income/(expense):
Net unrealized gain/(loss) on available-for-sale securities arising during the period - net of tax
7
(30)
(98)
153
Currency translation adjustment and other
(183)
689
(1,195)
451
Total other comprehensive income/(expense)
(176)
659
(1,293)
604
Total comprehensive income/(expense)
$
1,413
$
4,000
$
4,059
$
9,140

~~Note 9: Financial Instruments~~

~~Derivative Financial Instruments and Hedging Activities~~

~~During the first nine months of 2005, we entered into the following incremental or new derivative and hedging activities:~~

~~Financial Instrument~~		~~Hedge Type~~	~~Hedged or Offset Item~~	~~Notional Amount~~ ~~(millions of dollars)~~	~~Maturity Date~~


~~Swaps~~		~~Net investment~~	~~Euro net investments~~	~~$1,255~~	~~Sept.-Oct.~~May 2006,
~~Forward-exchange contracts~~		--	~~Short-term foreign currency assets and liabilities~~^(a)	~~674~~	~~Through 2006~~
~~Forward-exchange contracts~~		~~Cash flow~~	~~Euro available-for-sale investments~~	~~493~~	~~Through 2006~~
~~Forward-exchange contracts~~		~~Cash flow~~	~~Danish krone available-for-sale investments~~	~~172~~	~~Through 2006~~

^(a)	Forward-exchange contracts used to offset short-term foreign currency assets and liabilities were primarily for intercompany transactions in euros, Australian dollars, U.K. pounds, Swedish krona and Canadian dollars for the nine months ended October 2, 2005.

These foreign exchange derivatives serve to protect net income and net investments against the impact of the translation into U.S. dollars of certain foreign exchange denominated transactions. There was no material ineffectiveness in any hedging relationship reported in earnings in the first nine months of 2005.

~~Long-Term Debt~~

~~In July 2005,~~ we decided to exercise Pfizer's option to call, at par-value plus accrued interest, $1 billion of senior unsecured floating-rate notes, which were included in Long-term debt atas of December 31, ~~2004.~~2005. Notice to call was given to the Trustees and the notes were redeemed in ~~September 2005.~~the third quarter of 2006.

On February 22, 2006, we issued the following Japanese yen fixed-rate bonds, to be used for general corporate purposes:

•	$508 million equivalent, senior unsecured notes, due February 2011, which pay interest semi-annually, beginning on August 22, 2006, at a rate of 1.2%; and

•	$466 million equivalent, senior unsecured notes, due February 2016, which pay interest semi-annually, beginning on August 22, 2006, at a rate of 1.8%.

The notes were issued under a $5 billion debt shelf registration filed with the SEC in November 2002. As of October 1, 2006, we had the ability to borrow approximately $1 billion by issuing debt securities under that debt shelf registration statement.

B. Derivative Financial Instruments and Hedging Activities

There was no material ineffectiveness in any hedging relationship reported in earnings in the first nine months of 2006.

Foreign Exchange Risk

During the first nine months of 2006, we entered into the following new or incremental hedging or offset activities:

Instrument^(a)	Primary Balance Sheet Caption	^(b)	Hedge Type	^(c)	Hedged or Offset Item	Notional Amount as of October 1, 2006 (millions of dollars)	Maturity Date
Forward	OCL		--		Short-term foreign currency assets and liabilities^(d)	$ 1,521	2006
Swaps	OCL		NI		Euro net investments	1,318	2007
Forward	OCL		CF		Yen available-for-sale investments	822	2006
LT yen debt	LTD		NI		Yen net investments	508	2011
Forward	Prepaid		CF		Euro intercompany loan	493	2006
LT yen debt	LTD		NI		Yen net investments	466	2016

^(a)	Forward = Forward-exchange contracts; LT yen debt = Long-term yen debt
^(b)	The primary balance sheet caption indicates the financial statement classification of the fair value amount associated with the financial instrument used to hedge foreign exchange risk. OCL = Other current liabilities; Prepaid = Prepaid expenses and taxes; LTD = Long-term debt
^(c)	NI = Net investment hedge; CF = Cash flow hedge
^(d)	Forward-exchange contracts used to offset short-term foreign currency assets and liabilities were primarily for intercompany transactions in euros, Japanese yen, U.K. pounds, Canadian dollars and Australian dollars.

These foreign-exchange instruments serve to protect us against the impact of the translation into U.S. dollars of certain foreign exchange denominated transactions.

Note ~~10:~~11. Inventories

The components of inventories follow:

(millions of dollars)
Oct. 2,
2005
Dec. 31,
2004

Finished goods
$
2,600
$
2,643
Work-in-process
2,714
2,703
Raw materials and supplies
1,242
1,314
Total inventories
$
6,556
$
6,660

~~A reclassification was made in 2004 from~~ ~~Finished goods~~ to ~~Work-in-process~~ ~~to better reflect the stage of completion.~~

(millions of dollars)			Oct. 1, 2006		Dec. 31, 2005

Finished goods		$	2,160	$	1,756
Work-in-process			2,993		2,373
Raw materials and supplies			1,014		1,349
Total inventories^(a)		$	6,167	$	5,478

^(a)	Increase primarily due to the acquisition of sanofi-aventis' Exubera inventory, the build-up of inventory in advance of product launches and the impact of foreign exchange, partially offset by the impact of our inventory-reduction initiative.

Note ~~11:~~12. Goodwill and Other Intangible Assets

A. Goodwill

The changes in the carrying amount of goodwill by segment for the nine months ended October ~~2, 2005~~1, 2006 follow:

(millions of dollars)
Human
Health
Consumer
Healthcare
Animal
Health
Other
Total

Balance, December 31, 2004
$
20,966
$
2,701
$
79
$
10
$
23,756
Other^(a)
13
62
(25)
--
50
Balance, October 2, 2005
$
20,979
$
2,763
$
54
$
10
$
23,806

(millions of dollars)		Pharmaceutical		Animal Health		Other		Total

Balance, December 31, 2005	$	20,919	$	56	$	10	$	20,985
Additions^(a)		166		--		--		166
Other^(b)		(112)		5		7		(100)
Balance, October 1, 2006	$	20,973	$	61	$	17	$	21,051

^(a)	Primarily related to Exubera.
^(b)	Includes a reduction to goodwill related to the ~~acquisition~~resolution of ~~Vicuron,~~certain tax positions and the impact of foreign ~~exchange and reductions to goodwill as a result of adjusting certain purchase accounting liabilities.~~exchange.

B. Other Intangible Assets

The components of identifiable intangible assets, primarily included in our ~~Human Health~~Pharmaceutical segment, follow:

		Oct. 2, 2005				Dec. 31, 2004				Oct. 1, 2006				Dec. 31, 2005
(millions of dollars)		Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization

Finite-lived intangible assets:
Developed technology rights	$	31,102	$	(8,070)	$	33,137	$	(5,967)	$	32,440	$	(11,459)	$	30,729	$	(8,810)
Brands		1,057		(48)		1,037		(14)		887		(85)		885		(51)
License agreements		165		(28)		158		(17)		191		(38)		152		(27)
Trademarks		157		(92)		134		(90)		111		(71)		106		(65)
Other^(a)		436		(205)		390		(186)		517		(255)		446		(203)
Total amortized finite-lived intangible assets		32,917		(8,443)		34,856		(6,274)		34,146		(11,908)		32,318		(9,156)
Indefinite-lived intangible assets:
Brands		3,898		--		4,012		--		2,989		--		2,990		--
License agreements		316		--		356		--
Trademarks		227		--		235		--		79		--		79		--
Other^(b)		61		--		66		--		17		--		13		--
Total indefinite-lived intangible assets		4,502		--		4,669		--		3,085		--		3,082		--
Total identifiable intangible assets	$	37,419	$	(8,443)	$	39,525	$	(6,274)	$	37,231	$	(11,908)	$	35,400	$	(9,156)

Total identifiable intangible assets, less accumulated amortization

25,323

~~28,976~~

~~33,251~~26,244

^(a)	Includes patents, non-compete agreements, customer contracts and other intangible assets.
^(b)	Includes pension-related intangible assets.

In the first nine months of 2006, we acquired the sanofi-aventis worldwide rights, including patent rights and production technology, to manufacture and sell Exubera. In connection with the acquisition, we recorded an intangible asset for developed technology rights of approximately $1.0 billion. The amortization of these developed technology rights are primarily included in Cost of sales.

In the first nine months of 2005, we recorded an impairment charge of $1.1 billion in Other (income)/deductions - netrelated to the developed technology rights for Bextra, a selective COX-2 inhibitor (included in our Pharmaceutical segment) in connection with the decision to suspend sales of Bextra (see Note 2, 5, Asset Impairment Charge and Other Costs Associated with the Suspension of Bextra ~~Sales) which was included in~~ ~~Other (income)/deductions - net~~Sales).

Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute our products are included in Amortization of intangible assets as they benefit multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function are included in Cost of sales, Selling, informational and administrative expenses or Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was ~~$859~~$851 million and $856 million for the three months ended October 1, 2006 and October 2, 2005, and ~~September 26, 2004 and~~ $2.6 ~~billion and $2.5~~ billion for the nine months ended October 1, 2006 and October 2, 2005.

Included in Discontinued operations - net of tax is additional pre-tax amortization expense for finite-lived intangible assets of nil and $3 million for the three months ended October 1, 2006 and October 2, 2005 and ~~September 26, 2004.~~$7 million for the nine months ended October 1, 2006 and October 2, 2005.

The annual amortization expense expected for the fiscal years ~~2005~~2006 through ~~2010~~2011 is ~~$3.5 billion in 2005,~~ $3.4 billion in ~~2006 and 2007, $2.7~~2006; $3.3 billion in ~~2008~~2007; $2.8 billion in 2008; and $2.5 billion in 2009, 2010 and ~~2010.~~2011.

Note ~~12:~~13. Benefit Plans

The components of net periodic benefit cost of the U.S. and international pension plans and the postretirement plans, which provide medical and life insurance benefits to retirees and their eligible dependents, for the three months ended October 1, 2006 and October 2, 2005 ~~and September 26, 2004~~ follow:

		Pension Plans																Pension Plans
		U.S. Qualified				U.S. Supplemental (Non-Qualified)				International				Postretirement Plans				U.S. Qualified				U.S. Supplemental (Non-Qualified)				International				Postretirement Plans
(millions of dollars)		2005		2004		2005		2004		2005		2004		2005		2004		2006		2005		2006		2005		2006		2005		2006		2005

Service cost	$	80	$	71	$	9	$	8	$	71	$	67	$	10	$	7	$	91	$	80	$	10	$	9	$	78	$	71	$	11	$	10
Interest cost		104		98		15		15		76		71		28		18		110		104		15		15		79		76		32		28
Expected return on plan assets		(148)		(143)		--		--		(77)		(74)		(6)		(4)		(157)		(148)		--		--		(82)		(77)		(7)		(6)
Amortization of:
Prior service costs/(gains)		4		5		--		--		(1)		3		1		--
Prior service costs/(credits)																		2		4		(1)		--		(1)		(1)		--		1
Net transition obligation		--		--		--		--		1		--		--		--		--		--		--		--		1		1		--		--
Actuarial losses		26		25		10		9		23		15		4		--		31		26		13		10		28		23		11		4
Curtailments and settlements - net		3		--		--		--		1		18		--		--		12		3		--		--		--		1		2		--
Special termination benefits		1		--		--		--		1		--		1		--		1		1		--		--		7		1		2		1
Less: amounts included in discontinued operations																		(4)		(3)		(1)		(1)		6		5		(1)		(1)
Net periodic benefit costs	$	70	$	56	$	34	$	32	$	95	$	100	$	38	$	21	$	86	$	67	$	36	$	33	$	116	$	100	$	50	$	37

The components of net periodic benefit cost of the U.S. and international pension plans and the postretirement plans, which provide medical and life insurance benefits to retirees and their eligible dependents, for the nine months ended October 1, 2006 and October 2, 2005 ~~and September 26, 2004~~ follow:

		Pension Plans																Pension Plans
		U.S. Qualified				U.S. Supplemental (Non-Qualified)				International				Postretirement Plans				U.S. Qualified				U.S. Supplemental (Non-Qualified)				International				Postretirement Plans
(millions of dollars)		2005		2004		2005		2004		2005		2004		2005		2004		2006		2005		2006		2005		2006		2005		2006		2005

Service cost	$	239	$	215	$	28	$	25	$	224	$	197	$	29	$	27	$	277	$	239	$	32	$	28	$	227	$	224	$	35	$	29
Interest cost		310		293		44		44		234		214		84		80		334		310		45		44		229		234		95		84
Expected return on plan assets		(445)		(429)		--		--		(238)		(215)		(17)		(15)		(472)		(445)		--		--		(238)		(238)		(21)		(17)
Amortization of:
Prior service costs/(gains)		11		13		1		1		(2)		7		1		1
Prior service costs/(credits)																		6		11		(2)		1		(1)		(2)		1		1
Net transition obligation		--		--		--		--		2		1		--		--		--		--		--		--		2		2		--		--
Actuarial losses		77		74		29		27		71		42		14		12		90		77		34		29		79		71		28		14
Curtailments and settlements - net		3		--		--		--		11		(1)		--		--		37		3		--		--		9		11		17		--
Special termination benefits		1		--		--		--		11		--		1		--		11		1		--		--		18		11		7		1
Less: amounts included in discontinued operations																		(12)		(11)		(2)		(2)		(2)		(2)		(3)		(3)
Net periodic benefit costs	$	196	$	166	$	102	$	97	$	313	$	245	$	112	$	105	$	271	$	185	$	107	$	100	$	323	$	311	$	159	$	109

For the first nine months of ~~2005,~~2006, we contributed from the Company's general assets ~~$52~~$450 million to our U.S. qualified pension plans, ~~$301 million to our international pension plans, $124~~$70 million to our U.S. supplemental (non-qualified) pension plans, $401 million to our international pension plans and ~~$123~~$218 million to our postretirement plans. ~~As of October 2, 2005,~~

During 2006, we expect to contribute, from the Company's general assets, ~~during 2005,~~ a total ~~(inclusive~~of $454 million to our U.S. qualified pension plans, $77 million to our U.S. supplemental (non-qualified) pension plans, $483 million to our international pension plans and $260 million to our postretirement plans. Contributions expected to be made for 2006 are inclusive of amounts contributed during the first nine months of 2005) of $53 million to our U.S. qualified pension plans, $396 million to our international pension plans, $137 million to our U.S. supplemental (non-qualified) pension plans and $166 million to our postretirement plans.2006. The contributions from the Company's general assets include direct employer benefit payments. Amounts associated with discontinued operations are not significant.

Note 14. Share-Based Payments

Our compensation programs can include share-based payments. In 2006 and 2005, the primary share-based awards and their generalterms and conditions are as follows:

•	Stock options, which entitle the holder to purchase, at the end of a vesting term, a specified number of shares of Pfizer common stock at a price per share set equal to the market price of Pfizer common stock on the date of grant.

•	Restricted stock units (RSUs), which entitle the holder to receive, at the end of a vesting term, a specified number of shares of Pfizer common stock, including shares resulting from dividend equivalents paid on such RSUs.

•	Performance share awards (PSAs) and performance-contingent share awards (PCSAs), which entitle the holder to receive, at the end of a vesting term, a number of shares of Pfizer common stock, within a range of shares from zero to a specified maximum, calculated using a non-discretionary formula that measures Pfizer's performance relative to an industry peer group.

•	Restricted stock grants, which entitle the holder to receive, at the end of a vesting term, a specified number of shares of Pfizer common stock, and which also entitle the holder to receive dividends paid on such grants.

The Company's shareholders approved the Pfizer Inc. 2004 Stock Plan (the 2004 Plan) at the Annual Meeting of Shareholders held on April 22, 2004 and, effective upon that approval, new stock option and other share-based awards may be granted only under the 2004 Plan. The 2004 Plan allows a maximum of 3 million shares to be awarded to any employee per year and 475 million shares in total. RSUs, PSAs, PCSAs and restricted stock grants count as three shares while stock options count as one share under the 2004 Plan toward the maximums.

In the past, we had various employee stock and incentive plans under which stock options and other share-based awards were granted. Stock options and other share-based awards that were granted under prior plans and were outstanding on April 22, 2004 continue in accordance with the terms of the respective plans.

As of October 1, 2006, 313 million shares were available for award, which include 31 million shares available for award under the legacy Pharmacia Long-Term Incentive Plan, that reflect award cancellations returned to the pool of available shares for legacy Pharmacia commitments.

Although not required to do so, historically we have used authorized and unissued shares and, to a lesser extent, shares held in our Employee Benefit Trust to satisfy our obligations under these programs.

A. Impact on Net Income

The components of share-based compensation expense and the associated tax benefit follow:

		Three Months Ended				Nine Months Ended
(millions of dollars)		Oct. 1, 2006		Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005

Stock option expense	$	93	$	--	$	314	$	--
Restricted stock unit expense		53		34		142		85
Performance share awards and performance-contingent share awards expense		34		8		50		36
Share-based payment expense^(a)		180		42		506		121
Tax benefit for share-based compensation expense		(57)		(14)		(150)		(41)
Share-based payment expense, net of tax	$	123	$	28	$	356	$	80

^(a)	Included in Cost of sales, Selling, informational and administrative expense and Research and development expense, as appropriate, generally according to the expense classification of the employees' payroll costs.

Included in Discontinued operations - net of tax is share-based compensation expense as shown in the following table:

		Three Months Ended				Nine Months Ended
(millions of dollars)		Oct. 1, 2006		Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005

Share-based compensation expense	$	8	$	2	$	23	$	5
Tax benefit for share-based compensation expense		(3)		(1)		(7)		(2)
Share-based compensation expense, net of tax	$	5	$	1	$	16	$	3

Amounts capitalized as part of inventory cost were not significant. In the three months and nine months ended October 1, 2006, the impact of modifications under the AtS productivity initiative to share-based awards was not significant and, in the three months and nine months ended October 2, 2005, the impact of modifications under the Pharmacia restructuring program was not significant. Generally, these modifications resulted in an acceleration of vesting either in accordance with plan terms or at management's discretion.

B. Stock Options

Stock options, which entitle the holder to purchase, at the end of a vesting term, a specified number of shares of Pfizer common stock at a price per share set equal to the market price of Pfizer common stock on the date of grant, are accounted for at fair value at the date of grant in the income statement beginning in 2006. These fair values are generally amortized on an even basis over the vesting term into Cost of sales, Selling, informational and administrative expenses and Research and development expenses, as appropriate.

In 2005 and earlier years, stock options were accounted for under APB No. 25 using the intrinsic value method in the income statement and fair value information was disclosed. In these disclosures of fair value, we allocated stock option compensation expense based on the nominal vesting period, rather than the expected time to achieve retirement eligibility. In 2006, we changed our method of allocating stock option compensation expense to a method based on the substantive vesting period for all new awards, while continuing to allocate outstanding nonvested awards not yet recognized as of December 31, 2005 under the nominal vesting period method. Specifically, under this prospective change in accounting policy, compensation expense related to stock options granted prior to 2006 that are subject to accelerated vesting upon retirement eligibility is being recognized over the vesting term of the grant, even though the service period after retirement eligibility is not considered to be a substantive vesting requirement. The impact of this change was not significant.

All employees may receive stock option grants. In virtually all instances, stock options vest after three years of continuous service from the grant date and have a contractual term of ten years; for certain members of management, vesting typically occurs in equal annual installments after three, four and five years from the grant date. In all cases, even for stock options that are subject to accelerated vesting upon voluntary retirement, stock options must be held for at least one year from grant date before any vesting may occur. In the event of a divestiture, options held by employees of the divested business are immediately vested and are exercisable from three months to their remaining term, depending on various conditions.

The fair value of each stock option grant is estimated on the grant date using, for virtually all grants, the Black-Scholes-Merton option-pricing model. These fair values incorporate a number of valuation assumptions noted in the following table, shown at their weighted-average values:

	Three Months Ended		Nine Months Ended
	Oct. 1, 2006	Oct. 2, 2005	Oct. 1, 2006	Oct. 2, 2005

Expected dividend yield ^(a)	3.65%	2.76%	3.66%	2.90%
Risk-free interest rate ^(b)	4.87%	3.81%	4.59%	3.96%
Expected stock price volatility ^(c)	22.85%	20.00%	24.50%	21.93%
Expected term ^(d) (years)	10	5.59	6	5.75

^(a)	Determined using a constant dividend yield during the expected term of the option.
^(b)	Determined using the extrapolated yield on U.S. Treasury zero-coupon issues.
^(c)	Determined using implied volatility, after consideration of historical volatility.
^(d)	Determined using historical exercise and post-vesting termination patterns. In the third quarter of 2006, the use of historical patterns was deemed inappropriate as virtually all of the option-grant activity related to a single individual; instead, the contractual term of the options was used.

In the first quarter of 2006, we changed our method of estimating expected stock price volatility to reflect market-based inputs under emerging stock option valuation considerations. We use the implied volatility in a long-term traded option, after consideration of historical volatility. In 2005, we used an average term structure of volatility quoted to us by financial institutions, after consideration of historical volatility.

The following table summarizes all stock option activity during the nine months ended October 1, 2006:

	Shares (thousands)	Weighted- Average Exercise Price Per Share	Weighted- Average Remaining Contractual Term (years)	Aggregate Intrinsic Value^(a) (millions)

Outstanding, January 1, 2006	627,404	$33.51
Granted	69,202	26.20
Exercised	(33,451)	15.56
Forfeited	(7,600)	30.95
Cancelled	(53,720)	32.38
Outstanding, October 1, 2006	601,835	33.81	5.4	$589
Vested and expected to vest^(b), October 1, 2006	593,273	33.85	5.3	578
Exercisable, October 1, 2006	405,054	35.32	4.0	339

^(a)	Market price of underlying stock less exercise price.
^(b)	The number of options expected to vest takes into account an estimate of expected forfeitures.

The following table provides data related to all stock option activity:

			Three Months Ended				Nine Months Ended
(millions of dollars, except per stock option amounts and years)			Oct. 1, 2006		Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005

Weighted-average grant date fair value per stock option		$	5.70	$	5.00	$	5.42	$	5.15
Aggregate intrinsic value on exercise		$	165	$	101	$	336	$	397
Cash received upon exercise		$	230	$	64	$	497	$	326
Tax benefits realized related to exercise		$	45	$	21	$	98	$	124
Total compensation cost related to nonvested stock options not yet recognized, pre-tax^(a)		$	457		N/A	$	457		N/A
Weighted-average period in years over which stock option compensation cost is expected to be recognized^(b)			1.3		N/A		1.3		N/A

^(a)	The total compensation cost related to our Consumer Healthcare business is $22 million.
^(b)	The planned divestiture of our Consumer Healthcare business does not have a significant impact on this weighted-average period.

C. Restricted Stock Units

RSUs, which entitle the holder to receive, at the end of a vesting term, a specified number of shares of Pfizer common stock, including shares resulting from dividend equivalents paid on such RSUs, are accounted for at fair value at the date of grant. Most RSUs vest in substantially equal portions each year over five years of continuous service; the fair value related to each year's portion is then amortized evenly into Cost of sales, Selling, informational and administrative expenses and Research and development expenses, as appropriate. For certain members of senior and key management, vesting may occur after three years of continuous service.

The fair value of each RSU grant is estimated on the grant date using the average price of Pfizer common stock on the date of grant.

The following table summarizes all RSU activity during the nine months ended October 1, 2006:

(thousands of shares)	Shares	Weighted-Average Grant Date Fair Value Per Share

Nonvested, January 1, 2006	12,803	$26.89
Granted	12,682	26.15
Vested	(3,338)	27.32
Reinvested dividend equivalents	502	25.30
Forfeited	(1,215)	26.19
Nonvested, October 1, 2006	21,434	26.58

The following table provides data related to all RSU activity:

			Three Months Ended				Nine Months Ended
(millions of dollars, except per RSU amounts and years)			Oct. 1, 2006		Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005

Weighted-average grant date fair value per RSU		$	26.16	$	26.66	$	26.35	$	26.25
Total fair value of shares vested		$	1	$	1	$	91	$	2
Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax^(a)		$	335		N/A	$	335		N/A
Weighted-average period in years over which RSU cost is expected to be recognized^(b)			4.0		N/A		4.0		N/A

^(a)	The total compensation cost related to our Consumer Healthcare business is $17 million.
^(b)	The planned divestiture of our Consumer Healthcare business does not have a significant impact on this weighted-average period.

D. Performance Share Awards (PSAs) and Performance-Contingent Share Awards (PCSAs)

PSAs in 2006 and PCSAs prior to 2006 entitle the holder to receive, at the end of a vesting term, a number of shares of Pfizer common stock, within a specified range of shares, calculated using a non-discretionary formula that measures Pfizer's performance relative to an industry peer group. PSAs are accounted for at fair value at the date of grant in the income statement beginning with grants in 2006. Further, PSAs are generally amortized on an even basis over the vesting term into Cost of sales, Selling, informational and administrative expenses and Research and development expenses, as appropriate. For grants in 2005 and earlier years, PCSA grants are accounted for using the intrinsic value method in the income statement.

Senior and other key members of management may receive PSA and PCSA grants. In most instances, PSA grants vest after three years and PCSA grants vest after five years of continuous service from the grant date. In certain instances, PCSA grants vest over two to four years of continuous service from the grant date. The vesting terms are equal to the contractual terms.

The 2004 Plan limitations on the maximum amount of share-based awards apply to all awards including PSA and PCSA grants. In 2001, our shareholders approved the 2001 Performance-Contingent Share Award Plan (the 2001 Plan), allowing a maximum of 12.5 million shares to be awarded to all participants. This maximum was applied to awards for performance periods beginning after January 1, 2002 through 2004. The 2004 Plan is the only plan under which share-based awards may be granted in the future.

PSA grants made in 2006 will vest and be paid based on a non-discretionary formula that measures our performance using relative total shareholder return over a performance period relative to an industry peer group. If our minimum performance in the measure is below the threshold level relative to the peer group, then no shares will be paid. PCSA grants made prior to 2006 will vest and be paid based on a non-discretionary formula, which measures our performance using relative total shareholder return and relative change in diluted earnings per common share (EPS) over a performance period relative to an industry peer group. If our minimum performance in the measures is below the threshold level relative to the peer group, then no shares will be paid.

As of January 1, 2006, we measure PSA grants at fair value using the average price of Pfizer common stock on the date of grant times the target number of shares. The target number of shares is determined by reference to the fair value of share-based awards to similar employees in the industry peer group. We measure PCSA grants at intrinsic value whereby the probable award was allocated over the term of the award, then the resultant shares are adjusted to the fair value of our common stock at each accounting period until the date of payment.

The following table summarizes all PSA and PCSA activity during the nine months ended October 1, 2006, with the shares granted representing the maximum award that could be achieved:

(thousands of shares)	Shares	Weighted-Average Grant Date Value Per Share

Nonvested, January 1, 2006	13,366	$23.32
Granted	1,563	26.18
Vested	(1,583)	26.20
Reinvested dividend equivalents	29	25.17
Forfeited^(a)	(1,646)	26.12
Nonvested, October 1, 2006	11,729	28.07


^(a)	Forfeited includes 345 thousand shares that were forfeited by retirees. At the discretion of the Compensation Committee of the Company's Board of Directors, $9 million in cash was paid to such retirees, which amount was equivalent to the fair value of the forfeited shares prorated for the portion of the performance period that was completed prior to retirement.

The following table provides data related to all PSA and PCSA activity:

			Three Months Ended				Nine Months Ended
(millions of dollars, except per PCSA amounts and years)			Oct. 1, 2006		Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005

Weighted-average grant date intrinsic value per PCSA		$	28.36	$	24.97	$	28.36	$	24.97
Total intrinsic value of vested PCSA shares		$	--	$	--	$	50	$	56
Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax^(a)		$	15		N/A	$	15		N/A
Weighted-average period in years over which PSA cost is expected to be recognized^(b)			2.3		N/A		2. 3		N/A

^(a)	The total compensation cost related to our Consumer Healthcare business is nominal.
^(b)	The planned divestiture of our Consumer Healthcare business does not have a significant impact on this weighted-average period.

We entered into forward-purchase contracts that partially offset the potential impact on net income of our obligation under the pre-2006 PCSAs. At settlement date we will, at the option of the counterparty to each of the contracts, either receive our own stock or settle the contracts for cash. Other contract terms are as follows:

	Per Share	Maximum Maturity (years)
(thousands of shares)	Purchase Price	Oct. 1, 2006	Dec. 31, 2005

3,051	$33.85	0.6	--
3,051	33.84	--	0.4

The financial statements include the following items related to these contracts:

Prepaid expenses and taxes includes:

fair value of these contracts

Other (income)/deductions - net includes:

changes in the fair value of these contracts

E. Restricted Stock

Restricted stock grants, which entitle the holder to receive, at the end of a vesting term, a specified number of shares of Pfizer common stock, and which also entitle the holder to receive dividends paid on such grants, are accounted for at fair value at the date of grant.

Senior and key members of management received restricted stock awards prior to 2005. In most instances, restricted stock grants vest after three years of continuous service from the grant date. The vesting terms are equal to the contractual terms.

These awards have not been significant.

F. Transition Information

The following table shows the effect on results for the three months and nine months ended October 2, 2005 as if we had applied the fair-value-based recognition provisions of SFAS 123R to measure stock-based compensation expense for the option grants:

(millions of dollars, except per common share data)		Three Months Ended Oct. 2, 2005		Nine Months Ended Oct. 2, 2005

Net income available to common shareholders used in the calculation of basic earnings per common share:
As reported under GAAP^(a)	$	1,588	$	5,348
Compensation expense - net of tax^(b)		(104)		(356)
Pro forma	$	1,484	$	4,992
Basic earnings per common share:
As reported under GAAP^(a)	$	0.22	$	0.73
Compensation expense - net of tax^(b)		(0.02)		(0.05)
Pro forma	$	0.20	$	0.68
Net income available to common shareholders used in the calculation of diluted earnings per common share:
As reported under GAAP^(a)	$	1,588	$	5,349
Compensation expense - net of tax^(b)		(104)		(356)
Pro forma	$	1,484	$	4,993
Diluted earnings per common share:
As reported under GAAP^(a)	$	0.22	$	0.72
Compensation expense - net of tax^(b)		(0.02)		(0.05)
Pro forma	$	0.20	$	0.67

^(a)	Includes stock-based compensation expense, net of related tax effects, of $28 million and $81 million for the three months and nine months ended October 2, 2005.
^(b)	Pro forma compensation expense related to stock options that are subject to accelerated vesting upon retirement is recognized over the period of employment up to the vesting date of the grant.

Note ~~13:~~15. Earnings Per Common Share

Basic and diluted ~~earnings per common share (EPS)~~EPS were computed using the following common share data:

		Three Months Ended				Nine Months Ended				Three Months Ended				Nine Months Ended
(millions)		Oct. 2, 2005		Sept. 26, 2004		Oct. 2, 2005		Sept. 26, 2004		Oct. 1, 2006		Oct. 2, 2005		Oct. 1, 2006		Oct. 2, 2005

EPS Numerator - Basic:
Income from continuing operations	$	1,602	$	3,298	$	5,345	$	8,461	$	3,239	$	1,479	$	9,535	$	5,009
Less: Preferred stock dividends - net of tax		1		1		4		4		1		1		4		4
Income available to common shareholders from continuing operations		1,601		3,297		5,341		8,457		3,238		1,478		9,531		5,005
Discontinued operations - net of tax		(13)		43		7		75		123		110		353		343
Net income available to common shareholders	$	1,588	$	3,340	$	5,348	$	8,532	$	3,361	$	1,588	$	9,884	$	5,348

EPS Denominator - Basic:
Weighted-average number of common shares outstanding		7,333		7,501		7,372		7,554		7,228		7,333		7,275		7,372

EPS Numerator - Diluted:
Income from continuing operations	$	1,602	$	3,298	$	5,345	$	8,461	$	3,239	$	1,479	$	9,535	$	5,009
Less: ESOP contribution - net of tax		1		1		3		5		1		1		3		3
Income available to common shareholders from continuing operations		1,601		3,297		5,342		8,456		3,238		1,478		9,532		5,006
Discontinued operations - net of tax		(13)		43		7		75		123		110		353		343
Net income available to common shareholders	$	1,588	$	3,340	$	5,349	$	8,531	$	3,361	$	1,588	$	9,885	$	5,349

EPS Denominator - Diluted:
Weighted-average number of common shares outstanding		7,333		7,501		7,372		7,554		7,228		7,333		7,275		7,372
Common share equivalents: stock options, restricted stock units, stock issuable under employee compensation plans and convertible preferred stock		49		68		52		88		23		49		31		52
Weighted-average number of common shares outstanding and common share equivalents		7,382		7,569		7,424		7,642		7,251		7,382		7,306		7,424

Outstanding stock options, representing about 563 million shares and 564 million shares of common stock during the three-month and nine-month periods ended October 1, 2006 and about 563 million shares and 513 million shares of common stock during the three-month and nine-month periods ended October 2, 2005, ~~and about 391 million and 319 million shares of common stock during the three-month and nine-month periods ended September 26, 2004,~~ had exercise prices greater than the average market price of our common stock. ~~These~~Such options ~~were~~are excluded from the computation of diluted EPS for these periods because their inclusion would have had an ~~antidilutive~~anti-dilutive effect.

Also, in the diluted computation, income from continuing operations and net income are reduced by the incremental contribution to the ESOPs, which were acquired as part of our Pharmacia acquisition. This contribution is the after-tax difference between the income that the ESOPs would have received in preferred stock dividends and the dividend on the common shares assumed to have been outstanding.

Note ~~14:~~16. Segment Information

We operate in the following business segments:

~~Human Health~~Pharmaceutical

•	The ~~Human Health~~Pharmaceutical segment, which represents our pharmaceutical business, includes ~~treatments for~~products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye disease, endocrine disorders and allergies.

~~Consumer Healthcare~~

•	~~The Consumer Healthcare segment includes self-medications for oral care, upper respiratory health, tobacco dependence, gastrointestinal health, skin care, eye care and hair growth.~~

Animal Health

•	The Animal Health segment includes ~~treatments for~~products that prevent and treat diseases in livestock and companion animals.

Segment profit/(loss) is measured based on income from continuing operations before provision for taxes on income and minority ~~interests and certain~~interests. Certain costs, such as significant impacts of purchase accounting for acquisitions, merger-related costs and ~~restructuring charges and merger-related costs.~~costs related to our AtS productivity initiative, are included in Corporate/Other only. This methodology is utilized by management to evaluate ~~each business. Certain income/(expense) items that are excluded from the operating segments' profit/(loss) are considered corporate items and therefore are included in~~ ~~Corporate/Other~~.our businesses.

Revenues and profit/(loss) by segment for the three months and nine months ended October 1, 2006 and October 2, 2005, ~~and September 26, 2004,~~ follow:

		Three Months Ended						Nine Months Ended						Three Months Ended						Nine Months Ended
(millions of dollars)		Oct. 2, 2005			Sept. 26, 2004			Oct. 2, 2005			Sept. 26, 2004			Oct. 1, 2006			Oct. 2, 2005			Oct. 1, 2006			Oct. 2, 2005

Revenues:
Human Health	$	10,552		$	11,288		$	32,629		$	33,033
Consumer Healthcare		921			851			2,835			2,524
Pharmaceutical													$	11,485		$	10,547		$	33,417		$	32,617
Animal Health		503			475			1,576			1,387			562			503			1,656			1,576
Corporate/Other^(a)		213			217			665			649			233			213			695			665
Total revenues	$	12,189		$	12,831		$	37,705		$	37,593		$	12,280		$	11,263		$	35,768		$	34,858

Profit/(loss)
Human Health	$	4,876		$	5,332		$	14,811		$	15,269
Consumer Healthcare		169			170			457			483
Segment profit/(loss)^(b)
Pharmaceutical													$	5,492		$	4,869		$	16,253		$	14,799
Animal Health		85			82			288			237			100			85			315			288
Corporate/Other^(a)		(2,933)	^(b)		(1,633)	^(c)		(7,387)	^(b)		(5,481)	^(c)		(1,631)	^(c)		(2,942)	^(d)		(5,254)	^(c)		(7,430)	^(d)
Total profit/(loss)	$	2,197		$	3,951		$	8,169		$	10,508		$	3,961		$	2,012		$	11,314		$	7,657

^(a)	~~Includes certain income/(expense) items that are excluded from the operating segment profit/(loss) that are considered corporate items~~Corporate/Other includes our gelatin capsules business, our contract manufacturing business and ~~therefore, are included in~~a bulk pharmaceutical chemicals business. Corporate/Other~~. These items include~~ also includes interest income/(expense), corporate expenses (e.g., corporate administration costs), other income/(expense) ~~items,~~(e.g., realized gains and losses attributable to our investments in debt and equity securities), certain ~~equity-based~~performance-based compensation expenses not allocated to the business segments, share-based payments, significant impacts of purchase accounting for acquisitions, certain milestone payments, ~~Adapting to Scale restructuring charges and implementation costs,~~ merger-related costs, ~~and~~ intangible asset ~~impairments.~~impairments and costs related to our AtS productivity initiative.

^(b)	Segment profit/(loss) equals income from continuing operations before provision for taxes on income and minority interests. Certain costs, such as significant impacts of purchase accounting for acquisitions, merger-related costs and costs related to our AtS productivity initiative, are included in Corporate/Other only. This methodology is utilized by management to evaluate our businesses.

^(c)	For the three months and nine months ended October 1, 2006, Corporate/Other includes (i) significant impacts of purchase accounting for acquisitions of $803 million and $2.9 billion, including acquired in-process research and development charges and incremental intangible asset amortization and other charges, (ii) merger-related costs of $4 million and $15 million, (iii) restructuring charges and implementation costs associated with our AtS productivity initiative of $427 million and $1.3 billion, (iv) gain on disposals of investments and other of $86 million and $160 million, and (v) a research and development milestone due to us from sanofi-aventis of approximately $118 million in the first quarter of 2006.

^(d)	For the three months and nine months ended October 2, 2005, Corporate/Other includes (i) significant impacts of purchase accounting for acquisitions of $2.2 billion and $4.1 billion, including acquired in-process research and development charges, incremental intangible asset amortization and other charges, (ii) merger-related costs of ~~$154~~$152 million and ~~$622~~$610 million, (iii) restructuring charges and implementation costs associated with ~~the Adapting to Scale~~our AtS productivity initiative of ~~$257~~$251 million and ~~$310~~$305 million, and (iv) costs associated with the suspension of Bextra's sales ~~and marketing~~ of $3 million and $1.2 billion.

^(c)

~~For the three months and nine months ended September 26, 2004,~~ ~~Corporate/Other~~ includes (i) significant impacts of purchase accounting for acquisitions of $827 million and $3.4 billion, including acquired in-process research and development, incremental intangible asset amortization and other charges, (ii) merger-related costs of $190 million and $726 million and (iii) the operating results of a divested legacy Pharmacia research facility of $64 million in the first nine months of 2004 and a litigation-related charge of $369 million in the third quarter of 2004.

Revenues for each group of similar products follow:

		Three Months Ended					Nine Months Ended					Three Months Ended					Nine Months Ended
(millions of dollars)		Oct. 2, 2005		Sept. 26, 2004	% Change		Oct. 2, 2005		Sept. 26, 2004	% Change		Oct. 1, 2006		Oct. 2, 2005	% Change		Oct. 1, 2006		Oct. 2, 2005	% Change

HUMAN HEALTH
PHARMACEUTICAL
Cardiovascular and metabolic diseases	$	4,467	$	4,251	5%	$	13,664	$	12,335	11%	$	5,111	$	4,467	14%	$	14,628	$	13,664	7%
Central nervous system disorders		1,590		2,090	(24)		4,718		6,072	(22)		1,500		1,590	(6)		4,787		4,718	1
Arthritis and pain		545		1,274	(57)		1,729		3,596	(52)		706		548	29		1,974		1,736	14
Infectious and respiratory diseases		1,073		1,015	6		3,657		3,375	8		836		1,074	(22)		2,608		3,659	(29)
Urology		629		647	(3)		1,958		1,865	5		732		629	16		2,055		1,958	5
Oncology		507		368	38		1,499		1,049	43		540		507	7		1,550		1,499	3
Ophthalmology		338		304	11		1,011		874	16		376		338	11		1,065		1,011	5
Endocrine disorders		262		226	16		783		668	17		246		262	(6)		724		783	(7)
All other		874		919	(5)		2,853		2,723	5		1,102		865	26		3,042		2,832	7
Alliance revenue		267		194	38		757		476	59		336		267	26		984		757	30
Total Human Health		10,552		11,288	(7)		32,629		33,033	(1)
CONSUMER HEALTHCARE		921		851	8		2,835		2,524	12
Total Pharmaceutical												11,485		10,547	9		33,417		32,617	2
ANIMAL HEALTH		503		475	6		1,576		1,387	14		562		503	12		1,656		1,576	5
OTHER		213		217	(2)		665		649	2		233		213	9		695		665	5
Total revenues	$	12,189	$	12,831	(5)	$	37,705	$	37,593	--	$	12,280	$	11,263	9	$	35,768	$	34,858	3

REVIEW REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of Pfizer Inc:

We have reviewed the condensed consolidated balance sheet of Pfizer Inc and Subsidiary Companies as of October ~~2, 2005,~~1, 2006, the related condensed consolidated statements of income for the three-month and nine-month periods ended October 1, 2006 and October 2, 2005, ~~and September 26, 2004,~~ and the related condensed consolidated statements of cash flows for the nine-month periods ended October 1, 2006 and October 2, ~~2005 and September 26, 2004.~~2005. These condensed consolidated financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the condensed consolidated financial statements referred to above for them to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of Pfizer Inc and Subsidiary Companies as of December 31, ~~2004,~~2005, and the related consolidated statements of income, shareholders' equity, and cash flows for the year then ended (not presented herein); and in our report dated February 24, ~~2005,~~2006, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, ~~2004,~~2005, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

KPMG LLP

New York, New York
November ~~9, 2005~~3, 2006

Item 2. Management's Discussion and Analysis of Financial Condition and Results of ~~Operations.~~Operations (MD&A)

Introduction

Our MD&A is provided in addition to the accompanying condensed consolidated financial statements and footnotes to assist readers in understanding Pfizer's results of operations, financial condition and cash flows. The MD&A is organized as follows:

•	Overview of Our Consolidated Operating Results. This section, beginning on page 28, provides a general description of Pfizer's business; provides information about our operating environment and our response to key challenges; discusses significant licensing and new business development transactions, as well as the planned disposition of our Consumer Healthcare business; and summarizes our productivity initiatives.

•	Revenues. This section, beginning on page 32, provides an analysis of our products and revenues for the three months and nine months ended October 1, 2006 and October 2, 2005, as well as an overview of important product developments.

•	Costs and Expenses. This section, beginning on page 43, provides a discussion about our costs and expenses.

•	Provision for Taxes on Income. This section, beginning on page 45, provides a discussion of items impacting our tax provision for the periods presented.

•	Adjusted Income. This section, beginning on page 45, provides a discussion of an alternative view of performance used by management.

•	Financial Condition, Liquidity and Capital Resources. This section, beginning on page 50, provides an analysis of our balance sheets as of October 1, 2006 and December 31, 2005, and cash flows for the nine months ended October 1, 2006 and October 2, 2005, as well as a discussion of our outstanding debt and commitments that existed as of October 1, 2006 and December 31, 2005. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to help fund Pfizer's future commitments.

•	Outlook. This section, beginning on page 54, provides a discussion of forecasted financial performance.

•	Forward-Looking Information and Factors That May Affect Future Results. This section, beginning on page 55 provides a description of the risks and uncertainties that could cause actual results to differ materially from those discussed in forward-looking statements set forth in this report relating to the financial results, operations and business prospects of the Company. Such forward-looking statements are based on management's current expectations about future events, which are inherently susceptible to uncertainty and changes in circumstances. Also included in this section is a discussion of Legal Proceedings and Contingencies.

Components of the Condensed Consolidated Statement of Income follow:

		Third Quarter							First Nine Months							Three Months Ended							Nine Months Ended
(millions of dollars, except per common share data)		2005			2004		% Change		2005			2004		% Change		Oct. 1, 2006			Oct. 2, 2005		% Change		Oct. 1, 2006			Oct. 2, 2005		% Change

Revenues	$	12,189		$	12,831		(5)	$	37,705		$	37,593		--	$	12,280		$	11,263		9%	$	35,768		$	34,858		3%

Cost of sales		1,908			1,640		16		6,180			5,185		19		1,962			1,611		22		5,423			5,250		3
% of revenues		15.7	%		12.8	%			16.4	%		13.8	%			16.0	%		14.3	%			15.2	%		15.1	%

Selling, informational and administrative expenses		3,931			4,036		(3)		12,242			12,227		--		3,751			3,526		6		11,027			10,958		--
% of revenues		32.3	%		31.5	%			32.5	%		32.5	%			30.5	%		31.3	%			30.8	%		31.4	%

Research and development expenses		1,783			1,888		(6)		5,421			5,356		1		1,902			1,739		9		5,187			5,287		(2)
% of revenues		14.6	%		14.7	%			14.4	%		14.2	%			15.5	%		15.4	%			14.5	%		15.2	%

Amortization of intangible assets		836			843		(1)		2,576			2,496		3		798			833		(4)		2,446			2,569		(5)
% of revenues		6.9	%		6.6	%			6.8	%		6.6	%			6.5	%		7.4	%			6.8	%		7.4	%

Merger-related in-process research and development charges		1,390			--		*		1,652			955		73		-			1,390		(100)		513			1,652		(69)
% of revenues		11.4	%		--				4.4	%		2.5	%			*			12.3	%			1.4	%		4.7	%

Restructuring charges and merger-related costs		307			190		62		796			726		10		249			303		(18)		816			782		4
% of revenues		2.5	%		1.5	%			2.1	%		1.9	%			2.0	%		2.7	%			2.3	%		2.2	%

Other (income)/deductions - net		(163)			283		*		669			140		378		(343)			(151)		127		(958)			703		*

Income from continuing operations before provision for taxes on income and minority interests		2,197			3,951		(44)		8,169			10,508		(22)
Income from continuing operations before provision for taxes on income, and minority interests																3,961			2,012		97		11,314			7,657		48
% of revenues		18.0	%		30.8	%			21.7	%		28.0	%			32.3	%		17.9	%			31.6	%		22.0	%

Provision for taxes on income		591			650		(9)		2,815			2,040		38		717			530		35		1,769			2,642		(33)

Effective tax rate		26.9	%		16.5	%			34.4	%		19.4	%			18.1	%		26.4	%			15.6	%		34.5	%
							53
Minority interests		4			3				9			7		33		5			3		69		10			6		68

Income from continuing operations		1,602			3,298		(51)		5,345			8,461		(37)		3,239			1,479		119		9,535			5,009		90
% of revenues		13.1	%		25.7	%			14.2	%		22.5	%			26.4	%		13.1	%			26.7	%		14.4	%

Discontinued operations - net of tax		(13)			43		*		7			75		(91)		123			110		11		353			343		3

Net income	$	1,589		$	3,341		(52)	$	5,352		$	8,536		(37)	$	3,362		$	1,589		112	$	9,888		$	5,352		85
% of revenues		13.0	%		26.0	%			14.2	%		22.7	%			27.4	%		14.1	%			27.6	%		15.4	%

Earnings per common share - Basic:
Earnings per common share - basic:
Income from continuing operations	$	0.22		$	0.44		(50)	$	0.73		$	1.12		(35)	$	0.45		$	0.20		125	$	1.31		$	0.68		93
Discontinued operations - net of tax		--			0.01		*		--			0.01		*		0.02			0.02		--		0.05			0.05		--
Net income	$	0.22		$	0.45		(51)	$	0.73		$	1.13		(35)	$	0.47		$	0.22		114	$	1.36		$	0.73		86

Earnings per common share - Diluted:
Earnings per common share - diluted:
Income from continuing operations	$	0.22		$	0.43		(49)	$	0.72		$	1.11		(35)	$	0.44		$	0.20		120	$	1.30		$	0.67		94
Discontinued operations - net of tax		--			0.01		*		--			0.01		*		0.02			0.02		--		0.05			0.05		--
Net income	$	0.22		$	0.44		(50)	$	0.72		$	1.12		(36)	$	0.46		$	0.22		109	$	1.35		$	0.72		88

Cash dividends paid per common share	$	0.19		$	0.17			$	0.57		$	0.51			$	0.24		$	0.19			$	0.72		$	0.57


* Calculation not meaningful

OVERVIEW OF OUR CONSOLIDATED OPERATING RESULTS

Our Business

We are a ~~research-based,~~ global, ~~pharmaceutical~~research-based company that ~~discovers, develops, manufactures~~is dedicated to better health and ~~markets leading prescription medicines~~greater access to healthcare for ~~humans~~people and ~~animals, as well as many~~their valued animals. Our purpose is to help people live longer, healthier, happier and more productive lives. Our efforts in support of that purpose include the ~~world's best known consumer healthcare products.~~discovery, development, manufacture and marketing of breakthrough medicines; the exploration of ideas that advance the frontiers of science and medicine; and the support of programs dedicated to illness prevention, health and wellness and increased access to quality healthcare. Our ~~longstanding~~ value proposition ~~has been~~is to ~~prove~~demonstrate that our medicines ~~cure or~~can effectively treat disease, including the associated symptoms and suffering, and ~~this remains our core mission. We have expanded our value proposition to also show that our medicines not only~~ can ~~cure or treat disease, but also can markedly improve health~~form the basis for an overall improvement in healthcare systems by ~~reducing overall healthcare costs, improving societies' economic well-being and~~ increasing effective prevention and treatment ~~of disease. We generate revenue through~~and by reducing the need for hospitalization. Our revenues are derived from the sale of our products as well as through alliance agreements, ~~by copromoting~~under which we co-promote products discovered by other companies.

~~Acquisitions~~

On September 14, 2005, we completed the acquisition of all of the outstanding shares of Vicuron Pharmaceuticals, Inc. (Vicuron), a biopharmaceutical company focused on the development of novel anti-infectives, for approximately $1.9 billion in cash (including transaction costs). Vicuron has two products currently under New Drug Application (NDA) review by the U.S. Food and Drug Administration (FDA): anidulafungin for fungal infections and dalbavancin for Gram-positive infections. The allocation of the purchase price includes in-process research and development of approximately $1.4 billion, which was expensed and included in ~~Merger-related in-process research and development charges~~~~, and goodwill of $243 million, which has been allocated to our Human Health segment. Neither of these items is deductible for tax purposes.~~

Our Operating Environment and Response to Key Challenges

WeOur company and our industry continue to face a ~~dynamically challenging and~~number of significant challenges, including a rapidly changing environment in our pharmaceutical business, including the loss of exclusivity of major products, continuing pressures on selective COX-2 inhibitor products, the increasing regulatory scrutiny of drug safety, the adoption of new direct-to-consumer advertising guidelines and lower prescription growth rates and increased competition in certain therapeutic areas.

healthcare environment. Our performance ~~in 2005~~ has been and will continue to be adversely impacted by ~~loss of U.S. exclusivity of four major products -- Diflucan, Neurontin, and Accupril/Accuretic during 2004 and Zithromax in November 2005. In addition, we face~~ the loss of U.S. exclusivity for ~~Zoloft during 2006 and Norvasc and Zyrtec during 2007. These seven products represented 33%~~several of our ~~Human Health~~major products, and many of our other products continue to face strong competition, including from generics, in key markets. Nine products, comprising 31% of our Pharmaceutical revenues and 29% of our total revenues for the year ended December 31, ~~2004. Revenues in~~ 2005, have been, or in the near term will be, affected by loss of U.S. exclusivity: Neurontin, Diflucan and Accupril/Accuretic in 2004; Zithromax in November 2005; Zoloft at the end of June 2006; Norvasc and Zyrtec in 2007; and Camptosar and Inspra in 2008. Further, in accordance with requests from applicable regulatory authorities, we suspended sales of Bextra in the U.S., E.U., Canada and many other countries in early 2005.

Industry-wide, regulatory and pricing environments have created added challenges. We are confronted by increasing regulatory scrutiny of drug safety and efficacy; the adoption of new direct-to-consumer advertising guidelines; and lower prescription growth rates. In addition, we have recently seen a strengthening of the U.S. dollar (as of October 19, 2006), as well as restrictive actions on access and pricing taken by influential decision makers in several large European markets.

As a result, at current exchange rates, we now expect revenues in 2007 and 2008 to be comparable to 2006.

Notwithstanding the challenges, we also ~~been,~~see great opportunities for future growth. There is enormous promise in the science and ~~may~~technology of pharmaceutical research. Further, with an aging population expecting to live longer, healthier lives, we expect that there will be growing demand for our products and services.

We recognize that the world around us is changing dramatically and that we need to accelerate the scope and speed of change to transform Pfizer. Investments in research and development (R&D), enhancements in R&D productivity, focused business development efforts and aggressive cost reductions will continue to ~~be, impacted by publicity~~help us to manage these challenges, to capitalize on the best opportunities presented to us and ~~regulatory actions regarding selective COX-2 inhibitor products (see further discussion in~~to return our company to top-line growth over time.

Our in-line product portfolio and the ~~section "Selected Product Descriptions").~~potential of our new-product pipeline demonstrate our ability to generate new revenues. Our total revenues ~~decreased 5%~~increased 9% in the ~~third quarter of 2005~~three months ended October 1, 2006 and ~~were flat~~increased 3% in the ~~first~~ nine months ~~of 2005~~ended October 1, 2006 as compared to the same periods in ~~2004.~~

~~Partially offsetting these impacts~~2005, in spite of the ~~first nine months~~fact that the loss of ~~2005 was~~U.S. exclusivity for Accupril/Accuretic, Diflucan, Neurontin, Zithromax and Zoloft and the voluntary withdrawal of Bextra accounted for about a 6% and 5% reduction in those period revenues - - demonstrating the solid aggregate performance in ~~the aggregate of~~ the balance of our broad portfolio of patent-protected ~~medicines. Our~~medicines, a portfolio ~~of medicines~~that includes ~~five~~three of the world's 25 ~~best-selling~~best selling medicines, with 11seven medicines that lead their therapeutic areas. ~~Our results reflect two underlying forces. First, Pfizer markets~~Importantly, we have also recognized an aggregate year-over-year increase in revenues from new products launched in 2004, 2005 and within the ~~broadest array~~first nine months of ~~in-line~~2006 of approximately $450 million for the third quarter of 2006 and ~~recently launched products in~~$1.1 billion for the ~~industry;~~first nine months of 2006 and ~~second, Pfizer is a business going through a process of reinventing itself. We~~ are ~~addressing the loss of exclusivity of a number of products by~~ advancing a number of internally developed, in-licensed and ~~copromoted~~co-promoted product candidates. We have launched four new medicines in the U.S. in 2006 --Sutent, Eraxis, Chantix and Exubera. In June 2006, we received an approvable letter from the FDA for Zeven (dalbavancin) and expect approval and launch in 2007. In June 2006, after certain decisions by the FDA, we notified Neurocrine Biosciences, Inc. (Neurocrine) that we are returning the development and marketing rights for indiplon to Neurocrine. (See further discussion in the section "Revenues - Pharmaceutical Revenues.")

We believe we have important competitive advantages that will serve us well and distinguish us from others in our industry. Our product portfolio and pipeline demonstrate the benefits of Pfizer's scale and our skill at leveraging the opportunities it provides us. Scale also enhances our status as 'partner of choice' with other companies who have promising product candidates and technologies, as well as giving us influence as a global purchaser of goods and services. We continue to build on and enhance our ~~Research & Development~~research and development capabilities through acquisitions and ~~collaborations; and through~~collaborations. Through targeted acquisitions, licensing opportunities and internal development, we are augmenting our commercial portfolio. Given the time requirements attendant to and uncertainties inherent in the research and development process, as well as the commercial risk, the timing and magnitude of revenues from these investments are highly uncertain. (See further discussions in the sections "Revenues - Product Developments" and "Overview of Our Consolidated Operating Results - Licensing and New Business Development - - Strategy and Recent Transactions.")

We have also made progress with our Adapting to Scale productivity initiative, which is a ~~focused,~~broad-based, company-wide effort to leverage our scale and strength more robustly and increase our productivity. (See further discussion in the section "Overview of Our Consolidated Operating Results - Productivity Initiatives and Merger-Related Synergies.") We now plan to broaden this initiative in 2007 and 2008 in a bold way to transform our cost structure, resulting in, at current exchange rates, the reduction of 2007 operating expenses to a level below that in 2006, as well as a further reduction in 2008 operating expenses. Our goal is to create a more flexible cost structure, so that it will be easier and less disruptive to adjust expenditures in light of changing market conditions and needs. These savings will be over and above the $4 billion currently projected annual cost savings by 2008 for our Adapting to Scale ~~Productivity Initiative~~productivity initiative.

Licensing and ~~Merger-Related Synergies~~.")New Business Development - Strategy and Recent Transactions

We ~~believe~~are committed to capitalizing on new growth opportunities by advancing our own new-product pipeline, as well as through licensing, co-promotion agreements and acquisitions. Our business development strategy targets a number of growth opportunities, including biologics, oncology, Alzheimer's disease, vaccines and other products and services that seek to provide innovative healthcare solutions.

On August 14, 2006, we entered into a license agreement with Bayer Pharmaceuticals Corporation to acquire exclusive worldwide rights to DGAT-1 inhibitors, an innovative class of compounds that modify lipid metabolism. The lead compound in the class, BAY 74-4113, is a potential treatment for obesity, type 2 diabetes and other related disorders. In June 2006, we acquired the worldwide rights to fesoterodine, a new drug candidate for treating overactive bladder, from Schwarz Pharma AG. In March 2006, we entered into research collaborations with NicOX SA in ophthalmic disorders and NOXXON Pharma AG in obesity. In addition, in November 2005, we entered into a research collaboration with Incyte for CCR2 antagonists for use in a broad range of diseases.

On May 16, 2006, we completed the acquisition of all of the outstanding shares of Rinat Neuroscience Corp. (Rinat), a biologics company with several new central-nervous-system product candidates. In connection with the acquisition, as part of our preliminary purchase price allocation, we recorded $478 million, pre-tax, in Merger-related in-process research and development charges.

On February 28, 2006, we completed the acquisition of the sanofi-aventis worldwide rights, including patent rights and production technology, to manufacture and sell Exubera, an inhaled form of insulin for use in adults with type 1 and type 2 diabetes, and the insulin-production business and facilities located in Frankfurt, Germany, previously jointly owned by Pfizer and sanofi-aventis, for approximately $1.4 billion (including transaction costs). In connection with the acquisition, as part of our final purchase price allocation, we recorded an intangible asset for developed technology rights of approximately $1.0 billion, inventory valued at $218 million and goodwill of approximately $166 million, all of which have been allocated to our Pharmaceutical segment. The amortization of the developed technology rights is primarily included in Cost of Sales. Prior to the acquisition, in connection with our collaboration agreement with sanofi-aventis, we recorded a research and development milestone due to us from sanofi-aventis of approximately $118 million ($71 million, after tax) in the first quarter of 2006 in Research and development expenses upon the approval of Exubera in January 2006 by the Food and Drug Administration (FDA).

Although not yet reflected in these financial statements, as the transactions have not yet been finalized, on September 18, 2006, we entered into a license agreement with TransTech Pharma Inc. to develop and commercialize small- and large- molecule compounds for treatment of Alzheimer's disease and diabetes, and on September 26, 2006, we entered into a license agreement with Quark Biotech Inc. for exclusive worldwide rights to its novel human gene and to molecules for the treatment of age-related macular degeneration (AMD). In addition, on October 6, 2006, we entered into an agreement to acquire PowderMed Ltd., a U.K. company specializing in the emerging science of DNA-based vaccines for the treatment of influenza and chronic viral diseases.

Discontinued Operations

We evaluate our businesses and product lines periodically for strategic fit within our operations. We sold or are in the process of selling the following businesses that do not fit our strategic ~~and operating flexibility allows us to marshal and focus resources when and where they are needed, to change with a changing environment and to recognize and seize emerging opportunities.~~goals:

•	In June 2006, we entered into an agreement to sell our Consumer Healthcare business to Johnson & Johnson for approximately $16.6 billion in cash. This business comprises substantially all of our former Consumer Healthcare segment and other associated amounts, such as purchase-accounting impacts and merger-related costs, and restructuring and implementation costs related to our Adapting to Scale (AtS) productivity initiative, previously reported in the Corporate/Other segment. In addition, certain manufacturing facility assets and liabilities, which were previously part of our Pharmaceutical or Corporate/Other segment, are included in the planned sale of the Consumer Healthcare business. In connection with the decision to sell this business, for all periods presented, the operating results associated with this business that will be discontinued have been reclassified into Discontinued operations - net of tax in the condensed consolidated statements of income, and the assets and liabilities associated with this business that will be sold have been reclassified into Assets/Liabilities of discontinued operations and other assets/liabilities held for sale, as appropriate, on the condensed consolidated balance sheets. The divestiture of the Consumer Healthcare business is expected to close in late 2006 and is subject to customary closing conditions, including receipt of regulatory approvals.

•	In the third quarter of 2005, we sold the last of three European generic pharmaceutical businesses, which we had included in our Pharmaceutical segment, for 4.7 million euros (approximately $5.6 million) and recorded a loss of $3 million ($2 million, net of tax) in Gains on sales of discontinued operations - net of tax in the condensed consolidated statement of income for the three months and nine months ended October 2, 2005.

•	In the first quarter of 2005, we sold the second of three European generic pharmaceutical businesses which had been included in our Pharmaceutical segment for 70 million euros (approximately $93 million) and recorded a gain of $57 million ($36 million, net of tax) in Gains on sales of discontinued operations - net of tax in the condensed consolidated statement of income. In addition, we recorded an impairment charge of $9 million ($6 million, net of tax) related to the last of the three European generic pharmaceutical businesses in Income from discontinued operations - net of tax in the condensed consolidated statement of income for the nine months ended October 2, 2005.

~~Adapting to Scale~~ Productivity ~~Initiative~~Initiatives and Merger-Related Synergies

During 2005 and the ~~second and third quarters~~first nine months of ~~2005,~~2006, we made progress with our multi-year productivity initiative, called Adapting to Scale (AtS), designed to increase efficiency and streamline decision making across the Company. This initiative, ~~first announced~~launched in ~~April~~early 2005, follows the integration of Warner-Lambert and Pharmacia Corporation (Pharmacia), which resulted in ~~the tripling of Pfizer's revenues over the past five years. The integration of those two companies will result in~~ a combined annual expense reduction of approximately $6 billion, inclusive of $4.2 billion in Pharmacia-related synergies that will be achieved this year. The new AtS productivity initiative is expected to yield $4 billion in cost savings on an annual basis by 2008, based on a top-to-bottom business review completed during the first half of 2005.billion.

~~During 2005, we anticipate~~We now expect that cost savings from our AtS productivity initiative will ~~exceed $600 million, greater than previously forecasted, mainly attributable to the Human Health business. We expect that annual cost savings will accelerate over the following three years, with~~be about $2.5 billion in 2006, substantially ahead of our original guidance of about $2 billion ~~in savings targeted for 2006, about $3.5 billion in 2007~~ and, without giving effect to any additional initiatives to transform our cost structure, growing to about $4 billion annually upon completion in ~~2008.~~2008, notwithstanding the planned divestiture of our Consumer Healthcare business and the expense reductions associated with that business. These savings are expected to be realized in procurement, operating expenses and facilities, among other sources. ~~We plan~~Savings realized during the third quarter and first nine months of 2006 total approximately $600 million and $1.8 billion. Without giving effect to ~~use~~any additional initiatives to transform our cost structure, the ~~cost savings we generate, in part,~~Company continues to ~~fund key investments, including new product launches and the development of the many promising new medicines in our pipeline. The Company expects~~expect that the aggregate cost of implementing ~~this~~the AtS productivity initiative through 2008 will be approximately $4 billion to $5 billion on a pre-tax basis.

~~While some projects are already underway, during the fourth quarter~~Projects in various stages of ~~2005, we will continue to accelerate the~~ implementation ~~of changes, including:~~include:

•	Reorganizing Pfizer Global Research & Development (PGRD) to increase efficiency and effectiveness in bringing new therapies to ~~patients-in-need~~patients in need while reducing the cost of research and development. PGRD ~~is being~~has been reorganized into eleven therapeutic ~~categories --~~areas: cardiovascular, metabolic, and endocrine; central nervous system; inflammation; allergy and respiratory; infectious diseases; pain; gastrointestinal and hepatitis; oncology; urology and sexual health; ophthalmology; and dermatology. Each therapeutic area will have three team leaders -- a research leader for compounds not yet in human testing, a development leader for compounds in human testing not yet marketed, and a commercial leader for marketed compounds. Discovery Research will retain its existing structure of six drug-candidate-producing sites. Development will move toward single sites for most therapeutic areas.

•	Enhanced Clinical Trial Design is a key Pfizer initiative aimed at reducing the frequency and cost of clinical trial failures, which is a common issue across the industry. The standardization and broad application of advanced improvements in quantitative techniques, such as pharmacokinetic/pharmacodynamic modeling and computer-based clinical trial simulation, along with use of leading edge statistical techniques including adaptive learning and confirming approaches, have transformed the way we design clinical trials today. Benefits achieved include improvements in positive predictive capacity, efficiency, risk management and knowledge management. Once fully implemented, the Enhanced Clinical Trial Design initiative is expected to yield significant savings and enhance research productivity.

•	Standardization of practices across Research and Development is driving costs down and increasing efficiencies in our research facilities, resulting in significant savings. Centers of emphasis have been built to take advantage of special skill sets, reduce waste and enhance asset utilization. We substantially reduced the number of pilot plants which manufacture the active ingredients for our clinical supplies, making more efficient use of the capacity retained. Clinical supply depots across the globe are being realigned with future needs. For example, across Europe and Canada 26 out of 37 depots have been identified for rationalization, with 15 closures completed through October 1, 2006. A wide range of continuous improvement practices is being applied to enable further productivity improvements in all areas of R&D.

•	Continuing our optimization of ~~Pfizer Global Manufacturing's plant~~Pfizer's network of plants, which began with the acquisition of Pharmacia, to ensure that the Company's manufacturing facilities are aligned with current and future product needs. ~~Since December 2004, Pfizer has announced~~We have focused on innovation and delivering value through a simplified supply network. During 2005 and through the ~~divestiture~~first nine months of ~~facilities in Holland, MI; Angers~~2006, 18 sites were identified for rationalization (Angers and ~~Val-de-Reuil,~~Val de Reuil, France; Arecibo and Cruce Davila, Puerto Rico; Augusta, Georgia; Bangkok, Thailand; Corby and Morpeth, U.K.; Groton, Connecticut; Holland, Michigan; Jakarta, Indonesia; Seoul, Korea; Orangeville, Canada; Parsippany, New Jersey; Tlalpan, Mexico; Tsukuba, Japan; and Stockholm ~~Sweden, as well as other, smaller facilities.~~and Uppsala-Fyrislund, Sweden). In ~~the last few months, Pfizer announced the cessation~~addition, there have been extensive consolidations and realignments of operations resulting in ~~Corby, U.K.~~streamlined operations and ~~Orangeville, Canada; a significant downsizing~~staff reductions. In particular, sites in Lincoln, NE; and that plants in Lititz, PA, Groton, CT, and Inchera and Little Island, Ireland would be restructured. We also determined that the Augusta, GA plant will be closed. The restructuring of the Puerto Rico and Sandwich, U.K. ~~operations will continue, with employment reduction at Barceloneta~~; Lincoln and ~~Arecibo,~~Omaha, Nebraska; Puerto Rico, to occur in the fourth quarter of 2005 in anticipation of cessation of operations at the Arecibo plant in the next few years. The sale of the Cruce Davila, Puerto Rico, plant is also being pursued. Since 2003, Pfizer has announced plans to reduce the number of plants in its global networks by more than 25%.Rico; Lititz, Pennsylvania; and Brooklyn, N.Y. have undergone notable staff reductions.

•	Realigning our European marketing teams and implementing initiatives designed to improve the effectiveness of our field force in Japan. During ~~the third quarter of~~ 2005, we completed a major reorganization of the U.S. field force, reshaping the management structure to be more responsive to commercial trends as the Medicare Prescription Drug Improvement and Modernization Act of 2003 (the Medicare Act) takes effect and driving greater sales-force accountability in preparation for the ~~upcoming~~ launch of new medicines.

•	~~Pursuing~~Continuing to pursue savings in information technology resulting from significant reductions in application software (already significantly reduced from ~~about~~over 8,000 applications at the time of the Pharmacia acquisition in ~~2003 to about 4,000 today, with considerable further reductions planned)~~2003) and data centers (to be reduced from 17 to 4), as well as rationalization of service providers, while enhancing our ability to invest in innovative technology opportunities to further propel our growth. Two of the 17 corporate data centers have now been reduced to local computing facilities, managed remotely from a global operations center. Vendor analysis and selection are currently underway to select a list of global infrastructure service providers. Vendor selection will be completed in the fourth quarter of 2006, with transition to the new service providers occurring in 2007 and 2008.

•

Reducing costs in purchased goods and services. Purchasing initiatives ~~will focus~~are focusing on rationalizing suppliers, leveraging the approximately $16 billion of goods and services that Pfizer purchases annually and improving demand management to optimize levels of outside services needed and strategic sourcing from lower-cost sources. For example, savings from demand management ~~will be~~are being derived in part from reductions in travel, entertainment, consulting and other external service expenses. Facilities savings are being found in site rationalization, energy conservation and renegotiated service contracts.

Given the challenging operating environment, we plan to expand our AtS initiative by undertaking a further transformation of how we invest in our business and manage our costs. As a result of additional initiatives to transform our cost structure, at current exchange rates, we will reduce 2007 operating expenses to a level below that in 2006, and further reduce 2008 operating expenses. Our goal is to create a more flexible cost structure, so that it will be easier and less disruptive to adjust expenditures in consideration of changing market conditions and needs. Specific goals and actions are under development.

REVENUES

~~Total~~Worldwide revenues ~~decreased 5%~~by segment and geographic area for the three months and nine months ended October 1, 2006 and October 2, 2005 follow:

Three Months Ended
Worldwide
U.S.
International
% Change in Revenues
Oct. 1,
Oct. 2,
Oct. 1,
Oct. 2,
Oct. 1,
Oct. 2,
Worldwide
U.S.
International
(millions of dollars)
2006
2005
2006
2005
2006
2005
06/05
06/05
06/05

Pharmaceutical
$
11,485
$
10,547
$
6,380
$
5,615
$
5,105
$
4,932
9
14
3
Animal Health
562
503
260
228
302
275
12
14
10
Other
233
213
68
64
165
149
9
6
11
Total Revenues
$
12,280
$
11,263
$
6,708
$
5,907
$
5,572
^(a)
$
5,356
^(a)
9
14
4
(a)
Includes revenue from Japan of $801 million (7% of total revenues) and $826 million (7% of total revenues) for the three months ended October 1, 2006 and October 2, 2005.
Nine Months Ended
Worldwide
U.S.
International
% Change in Revenues
Oct. 1,
Oct. 2,
Oct. 1,
Oct. 2,
Oct. 1,
Oct. 2,
Worldwide
U.S.
International
(millions of dollars)
2006
2005
2006
2005
2006
2005
06/05
06/05
06/05

Pharmaceutical
$
33,417
$
32,617
$
18,448
$
17,219
$
14,969
$
15,398
2
7
(3)
Animal Health
1,656
1,576
751
710
905
866
5
6
5
Other
695
665
219
206
476
459
5
6
4
Total Revenues
$
35,768
$
34,858
$
19,418
$
18,135
$
16,350
^(b)
$
16,723
^(b)
3
7
(2)
(b)
Includes revenue from Japan of $2.4 billion (7% of total revenues) and $2.6 billion (7% of total revenues) for the nine months ended October 1, 2006 and October 2, 2005.
Pharmaceutical Revenues
Pfizer's pharmaceutical business continued to show solid performance, with our in-line products in the ~~third quarter~~aggregate performing well in a tough operating environment and ~~were flat in the first nine months~~many of ~~2005,~~our new products making important contributions as ~~compared to the same periods in 2004. The~~well, partially offset by revenue ~~decrease reflects~~declines from the loss of exclusivity ~~of key~~on major products and ~~regulatory actions on the selective COX-2 inhibitors and~~ other nonspecific non-steroidal anti-inflammatory drug (NSAID) products, which has resulted in a significant decline in prescription volume in the arthritis market. The decrease also reflects lower prescription growth and increased competition in key markets in the U.S., such as the lipid-lowering market, where the rate of growth in the third quarter declined significantly versus the first half of the year; and the erectile-dysfunction market, which has been in decline compared to 2004. In addition, although we anticipate a positive long-term impact of our initiative designed to increase the efficiency of our U.S. Human Health field force through stronger alignment with our customers (completed in September 2005), the short-term impact was a tempering of revenue performance in the third quarter. Partially offsetting these impacts in the first nine months of 2005 was the solid performance in the aggregate of the balance of our broad portfolio of patent-protected medicines.factors.
~~Changes in foreign exchange rates increased~~Worldwide pharmaceutical revenues in the third quarter of 2005 by $175 million, or 1.4%, and increased revenues in the first nine months of 2005 by $909 million, or 2.4%, compared to the same periods in 2004. The foreign exchange impact onfor the third quarter and first nine months of ~~2005 revenue comparisons~~2006 were $11.5 billion, an increase of 9%, and $33.4 billion, an increase of 2%, compared to the same periods in ~~2004 was~~2005, due primarily to:
•
the solid aggregate performance of our broad portfolio of patent-protected medicines;
•
an aggregate year-over-year increase in revenues from new products launched in 2004, 2005 and within the first nine months of 2006 of approximately $450 million for the third quarter of 2006 and $1.1 billion for the first nine months of 2006;
•
the one-time reversal of a sales deduction accrual related to a favorable development in a pricing dispute in the U.S. of about $170 million;
•
higher U.S. wholesaler inventories in the third quarter of 2006 by about two days compared to the end of the second quarter of 2006, with levels at the end of the third quarter of 2006 at normal levels and comparable to those at the end of the third quarter of 2005; and
•
the favorable impact of changes in the mix of sales rebates in the U.S.,
partially offset by:
•
a decrease in revenue for Zoloft, primarily due to the launch of generic competition in mid-July 2006 after Zoloft lost exclusivity in the U.S. in June 2006 and also due to the earlier loss of exclusivity in many European markets, by $348 million for the third quarter of 2006 and $504 million for the first nine months of 2006;
•
a decrease in revenue from the loss of exclusivity of Zithromax in November 2005 of $302 million for the third quarter of 2006 and $1.1 billion for the first nine months of 2006; and
•
the continued decline in revenue by $39 million for the third quarter of 2006 and $218 million for the first nine months of 2006 of Neurontin, Diflucan and Accupril/Accuretic, which lost U.S. exclusivity in 2004.
Pharmaceutical revenues for the three months ended October 1, 2006, were also impacted by the weakening of the U.S. dollar relative to many foreign currencies, especially the ~~euro. We expect 2005~~euro, which increased revenue by $118 million, while Pharmaceutical revenues for the ~~full year, at current foreign exchange rates, to evidence a modest decline~~nine months ended October 1, 2006, were impacted by the strengthening of the U.S. dollar relative to ~~2004, although a somewhat larger~~many foreign currencies, especially the euro and the Japanese yen, which decreased revenue by $443 million. Finally, the three months and nine months ended October 1, 2006 were also impacted by increased competition and the overall market decline, ~~than previously anticipated, reflecting lower U.S. Human Health revenues.~~
~~The impact of price changes on revenues was 3.2%~~as branded prescriptions in the ~~third quarter of 2005~~U.S. declined 4% and ~~2.8% in~~3% compared to the ~~first~~three months and nine months ofended October 2, 2005.
The loss of patent protection with respect to any of our major products could have a material adverse effect on revenue and net income. We expect a substantial impact from the loss of exclusivity of certain major products over the next few years.Geographically:
•
in the U.S., Pharmaceutical revenues increased 14% and 7% in the three months and nine months ended October 1, 2006 compared to the same periods in 2005, primarily due to revenues from new products, as well as growth in Lipitor and Celebrex sales, the one-time reversal of a sales deduction accrual related to a favorable development in a pricing dispute and higher U.S. wholesaler inventories in the third quarter of 2006 by about two days compared to the end of the second quarter of 2006, partially offset by the loss of exclusivity of Zithromax in November 2005 and Zoloft in June 2006; and
•
in our international markets, Pharmaceutical revenues increased 3% in the three months ended October 1, 2006 compared to the same period in 2005, primarily due to revenues from our new products, as well as growth in Lipitor and Celebrex sales, and the favorable impact of foreign exchange on revenue of $107 million (1%), partially offset by lower revenues from Zoloft due to the loss of exclusivity in many key international markets. Our international Pharmaceutical revenues decreased 3% in the nine months ended October 1, 2006, compared to the same period in 2005, primarily due to the unfavorable impact of foreign exchange on revenue of $422 million (1%) and lower revenues from Zoloft due to the loss of exclusivity in many key international markets.
~~Deductions from Revenues~~
As is typical in the pharmaceutical industry, our gross product sales are subject to a variety of deductions, primarily representing rebates and discounts to government agencies, wholesalers and managed care ~~organizations.~~organizations with respect to our pharmaceutical products. These deductions represent estimates of the related ~~liabilities~~obligations and, as such, judgment is required when estimating the impact of these sales deductions on gross sales for a reporting period. In the third quarter of 2006, we recorded a reversal of a sales deduction accrual related to a favorable development in a pricing dispute in the U.S. of about $170 million. Historically, our adjustments to actual have not been material; on a quarterly basis, not including the adjustment mentioned above, they generally have been less than ~~0.5%~~1% of ~~Human Health~~Pharmaceutical net sales and can result in either a net increase or a net decrease to income.
Rebates under Medicaid and related state programs reduced revenues by $40 million and $414 million in the three months and nine months ended October 1, 2006 and $257 million and $956 million in the three months and nine months ended October 2, 2005. Rebates under Medicare reduced revenues by $253 million and $436 million for the three months and nine months ended October ~~2, 2005~~1, 2006 and ~~$338~~$23 million and ~~$1.0 billion for the three months and nine months ended September 26, 2004. Performance-based contracts also provide for rebates to several customers. Contract rebates reduced revenues by $513~~$37 million ~~and $1.7 billion for~~in the three months and nine months ended October 2, ~~2005~~2005. The decrease in Medicaid and ~~$501~~related state program rebates and the increase in Medicare rebates are due primarily to the impact of the Medicare Act, effective January 1, 2006. Performance-based contract rebates reduced revenues by $393 million and ~~$1.5~~$1.3 billion ~~for~~in the three months and nine months ended ~~September 26, 2004.~~October 1, 2006 and $482 million and $1.6 billion in the three months and nine months ended October 2, 2005. The decrease in performance-based contract rebates is due primarily to the expiration of our contract with Express Scripts Inc. on December 31, 2005 and reduced managed care rebates related to Zithromax, which lost exclusivity in the U.S in November 2005. These contracts are with managed care customers, including health maintenance organizations and pharmacy benefit managers, who receive rebates based on the achievement of contracted performance terms for products. Rebates are product-specific and, therefore, for any given year are impacted by the mix of products sold. Chargebacks (primarily ~~discounts~~reimbursements to ~~federal government agencies)~~wholesalers for honoring contracted prices to third parties) reduced revenues by $382 million and $1.1 billion in the three months and nine months ended October 1, 2006 and $324 million and $916 million ~~for~~in the three months and nine months ended October 2, ~~2005 and $290 million and $864 million for the three months and nine months ended September 26, 2004.~~2005.
Our accruals for Medicaid rebates, Medicare rebates, contract rebates and chargebacks totaled ~~$1.7~~$1.5 billion atas of October ~~2, 2005 and~~1, 2006, a decrease from $1.8 billion as of December 31, ~~2004.~~2005, due primarily to the impact of the Medicare Act.
Pharmaceutical--Selected Product Revenues ~~by Country~~
~~Revenues by country for the third quarter and first nine months of 2005 and the changes from the same periods in 2004 follow:~~

Third Quarter
(millions of dollars)
2005
% of
Revenues
2004
% of
Revenues
%
Change

United States
$
6,395
52.5
%
$
7,377
57.5
%
(13)%
Japan
848
7.0
760
5.9
12
All other
4,946
40.5
4,694
36.6
5
Consolidated
$
12,189
100.0
%
$
12,831
100.0
%
(5)


First Nine Months
(millions of dollars)
2005
% of
Revenues
2004
% of
Revenues
%
Change

United States
$
19,558
51.9
%
$
21,122
56.2
%
(7)%
Japan
2,631
7.0
2,309
6.1
14
All other
15,516
41.1
14,162
37.7
10
Consolidated
$
37,705
100.0
%
$
37,593
100.0
%
--
~~Geographic Revenues by Segment~~
~~Geographic revenues by segment for the third quarter and first nine months of 2005 and the changes from the same periods in 2004 follow:~~

Third Quarter
Revenues
% Change in Revenues
U.S.
International
U.S.
International
(millions of dollars)
2005
2004
2005
2004
05/04
05/04

Human Health
$
5,609
$
6,619
$
4,943
$
4,669
(15)%
6%
Consumer Healthcare
493
453
428
398
9
8
Animal Health
228
231
275
244
(1)
12
Other
65
74
148
143
(14)
4
Total Revenues
$
6,395
$
7,377
$
5,794
$
5,454
(13)
6


First Nine Months
Revenues
% Change in Revenues
U.S.
International
U.S.
International
(millions of dollars)
2005
2004
2005
2004
05/04
05/04

Human Health
$
17,203
$
18,967
$
15,426
$
14,066
(9)%
10%
Consumer Healthcare
1,439
1,290
1,396
1,234
12
13
Animal Health
710
647
866
740
10
17
Other
206
218
459
431
(5)
6
Total Revenues
$
19,558
$
21,122
$
18,147
$
16,471
(7)
10
~~Human Health~~
~~Pfizer's Human Health business continued to show solid performance in many of our products, although challenges to revenue more than offset that performance.~~
Pfizer's Human Health worldwide revenues declined 7% in the third quarter of 2005 compared to the third quarter of 2004 and 1% year-to-date. In the U.S., Human Health revenues declined 15% in the third quarter of 2005 compared to the third quarter of 2004 and 9% year-to-date. The loss of exclusivity on key products (primarily Neurontin) has resulted in a decline in third-quarter worldwide revenues of approximately $800 million and year-to-date worldwide revenues of approximately $2.4 billion in comparison to the same periods in the prior year. The regulatory actions relating to Celebrex and the suspension of sales of Bextra have contributed to an additional decline in third-quarter 2005 selective COX-2 inhibitor worldwide revenues of $754 million (down 67%) and year-to-date selective COX-2 inhibitor worldwide revenues of $2.0 billion (down 62%) in comparison to the same periods in the prior year.
The third quarter of 2005 was also impacted by the overall market decline for branded prescriptions in the U.S. Branded prescriptions in the U.S. declined 3% in the third quarter of 2005 relative to the third quarter of 2004. The third quarter of 2005 also exhibited a significant change in growth trends relative to the first half of the year in a number of U.S. therapeutic markets. Examples include the branded statins market, where total prescriptions grew 7% in the third quarter versus 10% in the first half of 2005, and the erectile-dysfunction market, with total prescriptions declining 7% in the third quarter versus zero growth in the first half of 2005.
Revenue information for several of our major ~~Human Health~~Pharmaceutical products ~~which includes three additional business days in our fiscal calendar in the first quarter and nine months of 2005 compared to the same periods in 2004, follows:~~follow:

Third Quarter
First Nine Months
(millions of dollars)
Product
Primary Indications
2005
% Change
from 2004
2005
% Change
from 2004

Cardiovascular and
metabolic diseases:
Lipitor
Reduction of LDL cholesterol
$2,897
6 %
$8,829
16 %
Norvasc
Hypertension
1,131
9
3,462
8
Cardura
Hypertension/Benign prostatic hyperplasia
132
(12)
441
(4)
Accupril/Accuretic
Hypertension/Congestive heart failure
77
(51)
250
(50)
Caduet
Reduction of LDL cholesterol and hypertension
48
927
121
249
Central nervous
system disorders:
Zoloft
Depression and anxiety disorders
807
1
2,448
2
Neurontin
Epilepsy and post-herpetic neuralgia
155
(80)
498
(78)
Geodon
Schizophrenia and acute manic or mixed episodes associated with bipolar disorder
148
18
430
33
Xanax/Xanax XR
Anxiety/Panic disorders
101
--
306
13
Aricept**
Alzheimer's disease
85
11
255
15
Lyrica
Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy
80
M+
139
M+
Relpax
Migraine headaches
67
42
170
49
Arthritis and pain:
Celebrex
Arthritis pain and inflammation, acute pain
446
(44)
1,258
(45)
Bextra
Arthritis pain and inflammation
(73)
*
(59)
*
Infectious and
respiratory diseases:
Zithromax/Zmax
Bacterial infections
402
19
1,623
38
Zyvox
Bacterial infections
157
30
453
38
Vfend
Fungal infections
106
54
285
40
Diflucan
Fungal infections
103
(52)
370
(54)
Urology:
Viagra
Erectile dysfunction
386
(4)
1,215
1
Detrol/Detrol LA
Overactive bladder
231
--
705
14
Oncology:
Camptosar
Metastatic colorectal cancer
229
81
674
85
Ellence
Breast cancer
86
--
273
7
Aromasin
Breast cancer
63
61
176
88
Ophthalmology:
Xalatan/Xalacom
Glaucoma and ocular hypertension
338
11
1,011
16
Endocrine disorders:
Genotropin
Replacement of human growth hormone
200
14
604
13
All other:
Zyrtec/Zyrtec-D
Allergies
338
2
1,035
10
Alliance revenue:
Aricept, Macugen, Mirapex, Olmetec, Rebif and Spiriva
Alzheimer's disease (Aricept), neovascular (wet) age-related macular degeneration (Macugen), Parkinson's disease (Mirapex), hypertension (Olmetec), multiple sclerosis (Rebif), chronic obstructive pulmonary disease (Spiriva)
267
38
757
59
Three Months Ended
Nine Months Ended
(millions of dollars)
Product
Primary Indications
Oct. 1,
2006

% Change
from 2005

Oct. 1,
2006

% Change
from 2005
Cardiovascular and
metabolic diseases:
Lipitor
Reduction of LDL cholesterol
$3,321
15%
$9,551
8%
Norvasc
Hypertension
1,208
7
3,549
3
Cardura
Hypertension/Benign prostatic hyperplasia
133
1
398
(10)
Caduet
Reduction of LDL cholesterol and hypertension
98
104
255
111
Accupril/Accuretic
Hypertension/Congestive heart failure
61
(21)
198
(21)
Chantix/Champix
Smoking cessation
33
*
33
*
Central nervous
system disorders:
Zoloft
Depression and certain anxiety disorders
459
(43)
1,944
(21)
Lyrica
Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy
340
324
803
480
Geodon/Zeldox
Schizophrenia and acute manic or mixed episodes associated with bipolar disorder
201
36
548
28
Neurontin
Epilepsy and post-herpetic neuralgia
126
(18)
376
(24)
Aricept^(a)
Alzheimer's disease
90
6
260
2
Xanax/Xanax XR
Anxiety/Panic disorders
74
(26)
235
(23)
Relpax
Migraine headaches
72
8
205
21
Arthritis and pain:
Celebrex
Arthritis pain and inflammation, acute pain
537
20
1,499
19
Infectious and
respiratory diseases:
Zyvox
Bacterial infections
206
31
559
23
Zithromax/Zmax
Bacterial infections
104
(74)
529
(67)
Vfend
Fungal infections
132
25
367
29
Diflucan
Fungal infections
109
5
326
(12)
Urology:
Viagra
Erectile dysfunction
423
10
1,207
(1)
Detrol/Detrol LA
Overactive bladder
295
28
810
15
Oncology:
Camptosar
Metastatic colorectal cancer
218
(5)
668
(1)
Ellence
Breast cancer
77
(11)
236
(13)
Aromasin
Breast cancer
84
32
229
30
Sutent
Metastatic renal cell carcinoma (mRCC) and malignant gastrointestinal stromal tumors (GIST)
63
*
115
*
Ophthalmology:
Xalatan/Xalacom
Glaucoma and ocular hypertension
374
11
1,062
5
Endocrine disorders:
Genotropin
Replacement of human growth hormone
198
(1)
586
(3)
All other:
Zyrtec/Zyrtec-D
Allergies
397
17
1,195
15
Alliance revenue:
Aricept, Macugen, Mirapex, Olmetec, Rebif and Spiriva
Alzheimer's disease (Aricept), neovascular (wet) age-related macular degeneration (Macugen), Parkinson's disease (Mirapex), hypertension (Olmetec), multiple sclerosis (Rebif), chronic obstructive pulmonary disease (Spiriva)
336
26
984
30

*^(a)
~~Calculation not meaningful.~~
**
Represents direct sales under license agreement with Eisai Co., Ltd.
M+*
~~Change greater than one-thousand percent.~~ Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.
~~Selected~~Pharmaceutical --Selected Product Descriptions:
•
Lipitor, for the treatment of elevated ~~cholesterol~~LDL-cholesterol levels in the blood, is the most widely used treatment for lowering cholesterol and the best-selling pharmaceutical product of any kind in the ~~world. In our international markets, Lipitor showed revenue growth of 14%~~world, reaching about $9.6 billion in worldwide sales in the ~~third quarter~~first nine months of ~~2005,~~2006, an increase of 8% compared to the ~~third quarter of 2004.~~same period in 2005. In the U.S., sales of $5.9 billion represent growth of 11% over the previous year's first nine months. Internationally, Lipitor ~~revenues grew 1%~~sales in the ~~third quarter~~first nine months of ~~2005,~~2006 increased 4% compared to the ~~third quarter of 2004. This performance reflects~~same period in part an unexpectedly rapid slowdown in the U.S. lipid-lowering market as a whole and marginal Lipitor prescription share erosion during the quarter of one percentage point. Evidence of the substantial lipid-market deceleration can be seen in category new-prescription growth rates for the third quarter of 8% versus first-half growth of 17%, representing more than a 50% drop from robust trends exhibited during the first six months of this year. Despite this market slowdown, Lipitor still accounts for more than 40% of all lipid-lowering prescriptions, a 26.4% advantage versus its next nearest competitor.2005.

~~In September 2005,~~The growth in Lipitor revenue was driven by a combination of factors, including the ~~FDA approved Lipitor use to reduce the risk of stroke and myocardial infarction in patients with type 2 diabetes. The FDA's decision was based on the findings~~impact of the ~~Collaborative Atorvastatin Diabetes Study (CARDS),~~Medicare Act, dosage-form escalation, pricing (including a ~~landmark trial~~favorable development in a pricing dispute in the U.S.) and a return to normal wholesaler inventory levels. We continue to see aggressive competition from branded and generic agents, which will further intensify in the fourth quarter of more than 2,800 patients with type 2 diabetes, near-normal cholesterol, and at least one other risk factor, such as high blood pressure or smoking. CARDS showed that patients using Lipitor experienced 48% fewer strokes than those on placebo. The CARDS study's steering committee stopped2006, particularly when additional generic agents become available in the ~~trial nearly two years earlier than planned because~~U.S. near the end of the ~~clinical benefits among patients who took Lipitor.~~
~~In addition, the FDA expanded the~~year. Lipitor ~~label~~began to ~~include data on the reduction~~face competition in the ~~incidence~~U.S. from generic pravastatin (Pravachol) in April 2006 and generic simvastatin (Zocor) in June 2006, as well as other competitive pressures. In April 2006, we launched a new advertising campaign for Lipitor that highlights its strong benefit profile and advantageous formulary positioning. Scientific data continue to reinforce the trend toward the use of ~~stroke in patients with multiple risk factors, as shown in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) clinical trial. The ASCOT trial found that Lipitor reduced the relative risk~~higher dosages of ~~stroke by 26% compared to placebo. The study involved people with normal or borderline~~statins for greater cholesterol and no prior history of heart disease with controlled high blood pressure and at least three other risk factors for heart disease, such as family history, age over 55, smoking, diabetes, and obesity. Patients with multiple risk factors, including diabetes, face a greater threat of heart attack and stroke. Reducing their risk of such cardiovascular events is extremely important.reduction.

•
Norvasc is the world's most-prescribed branded medicine for treating hypertension. It achieved an increased rate of growth in sales in the first nine months of 2005 compared to same period in 2004 (8% in 2005 as compared to 4% in 2004), despite patent expirations in many European Union (E.U.) countries. Norvasc maintains exclusivity in many major markets globally, including the U.S., Japan, Canada and ~~Australia.~~Australia, but has experienced patent expirations in many E.U. countries. Norvasc sales in the first nine months of 2006 increased 3% over the same period in 2005. See Part II, Other Information; Item 1, Legal Proceedings, of this Form 10-Q for a discussion of certain recent patent litigation relating to Norvasc.
•
Exubera, the first inhaled human insulin therapy for glycemic control received approvals from both the FDA and the European Commission for the treatment of adults with type 1 and type 2 diabetes in January 2006. Millions of people with diabetes are not achieving or maintaining acceptable blood sugar levels, despite the availability of current therapies. Exubera represents a medical advance that offers patients a novel method of introducing insulin into their systems through the lungs. Since May 2006, Exubera has been launched in Germany, Ireland, the U.K. and most recently, the U.S., where the Joslin Diabetes Clinic in Boston, widely recognized as one of the pre-eminent diabetes and research organizations in the world, has recognized Exubera in its diabetes treatment guidelines. Within the U.S., a comprehensive education and training program for physicians is underway. To further support patients and healthcare professionals, Pfizer also provides a 24-hour-a-day, 7-day-a-week call center staffed by healthcare professionals. Similar programs are also in place in European markets where the product has been launched. An expanded roll-out of Exubera to primary-care physicians in the U.S. previously targeted for November 2006, will begin in January 2007. The manufacturing process for Exubera is complex, involving novel technology. We are working at capacity to meet expected demand, while also expanding drug product capacity. Initial supplies of Exubera were available across the U.S. beginning in September 2006.

•
Zoloft ~~is the most-prescribed antidepressant~~, which lost exclusivity in the U.S. in June 2006 and earlier in many European markets, experienced a 21% revenue decline in the first nine months of 2006 compared to the same period in 2005. It is indicated for the treatment of major depressive disorder, panic disorder, obsessive-compulsive disorder (OCD) in adults and children, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD) and social anxiety disorder (SAD). Zoloft is approved for acute and long-term use in all of these indications, with the exception of ~~PMDD, and~~PMDD. It is the only approved agent for the long-term treatment of PTSD and SAD, an important differentiating feature as these disorders tend to be chronic. Zoloft was approved in Japan in April 2006 for the indications of depression/depressed state and panic disorder.

In the U.S., in February 2005, Pfizer implemented FDA instructions that require the makers of all currently marketed antidepressants, including tricyclic agents, monoamine oxidase (MAO) inhibitors, selective serotonin reuptake inhibitors such as Zoloft, selective norepinephrine reuptake inhibitors and atypical antidepressants, to include a black-box warning that antidepressants increased the risk of suicidal thinking and behavior in children and adolescents in pooled, short-term studies. In the nine completed clinical trials of Zoloft involving children and adolescents, which included studies of Zoloft in children diagnosed with depression, OCD, or both, no suicides occurred. The trials found no statistically significant differences between Zoloft-treated children and adolescents and placebo controls in their rates of suicide attempts or ideation.
•
~~Neurontin,~~ for use in adjunctive therapy for epilepsy, is also approved in more than 60 markets for the treatment of a range of neuropathic pain conditions. Neurontin has also been approved for the management of post-herpetic neuralgia (PHN), a, painful condition that affects many people in the aftermath of the viral infection commonly known as shingles. Neurontin was the first oral medication approved in the U.S. for the treatment of PHN.
In the latter half of 2004, Ivax Corporation (Ivax), Alpharma Inc. (Alpharma) and Teva Pharmaceuticals Industries Ltd. (Teva) launched generic versions of Neurontin (gabapentin) at-risk, despite ongoing patent litigation. We are aggressively pursuing our claims of patent infringement against Ivax, Alpharma, Teva and other generic manufacturers. (See Part II, Item 1, ~~Legal Proceedings~~.) Following those at-risk launches, we launched generic gabapentin through Greenstone, our U.S. generic pharmaceutical subsidiary. However, the introduction of generic versions of gabapentin caused a 78% reduction in Neurontin sales for the first nine months of 2005 as compared to the same period in 2004.
•
~~Geodon~~Geodon/Zeldox, a psychotropic agent, is a dopamine and serotonin receptor antagonist indicated for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder. ~~Available~~It is available in both an oral capsule and rapid-acting intramuscular ~~formulation, Geodon has been launched in 54 countries, where more than six million prescriptions have been written for more than one million patients worldwide.~~formulation. In the U.S., Geodon hit an all-time ~~U.S.~~ new prescription share weekly high of 6%7.4% during September 2006. In the past six months, Geodon has become the fastest growing anti-psychotic medication in the ~~third quarter and is now~~U.S. In the ~~second-fastest-growing atypical anti-psychotic medication.~~first nine months of 2006, total Geodon worldwide sales grew 28% compared to the same period in 2005.
The ~~Clinical Antipsychotic Trials of Intervention Effectiveness schizophrenia study, supported by~~U.S. Patent and Trademark Office granted a five-year extension to the ~~National Institute of Mental Health and recently published in the New England Journal of Medicine, confirms that~~ Geodon ~~is an effective anti-psychotic and is less likely~~U.S. patent, extending its exclusivity to worsen weight, lipids, and glucose metabolism than other agents. In fact, Geodon was associated with some improvement in these parameters. These findings are noteworthy because of the higher prevalence of metabolic issues among patients with schizophrenia and are consistent with previous Pfizer-sponsored clinical trials involving Geodon.2012.

•
Lyrica achieved $803 million in worldwide revenue in the first nine months of 2006. In September 2006, Lyrica was approved by the European Commission to treat central nerve pain, which is associated with conditions such as spinal injury, stroke and multiple sclerosis. In addition, in March 2006, it was approved by the European Commission to treat generalized anxiety disorder (GAD) in adults, thereby providing a new treatment option for the approximately 12 million Europeans living with GAD.

Lyrica was approved by the FDA in June 2005 for adjunctive therapy for adults with partial onset epileptic seizures. This ~~latest~~ indication ~~builds~~built on the earlier FDA approval of Lyrica for two of the most common forms of neuropathic ~~pain --~~pain; painful diabetic peripheral neuropathy, a chronic neurologic condition affecting ~~nearly~~about three million Americans, and post-herpetic neuralgia. Lyrica was launched in the U.S., Canada and Italy in September 2005 and is now approved in more than 5060 countries and ~~is currently~~ available in more than 2535 markets. ~~Market penetration has~~More than one million patients have been ~~rapid; after one full year of~~prescribed Lyrica ~~sales, Germany and the U.K. posted~~since its introduction. Lyrica sales shares of 14.2% and 9.5%, respectively, in the anti-epileptic drug market, surpassing those of many established competitors in both countries. Clinical evidence favorable to Lyrica also continues to grow. The September 2005 edition of ~~Epilepsia~~ ~~focused on the medication's lack of interactions with other drugs. Additionally, at the August 2005 meeting~~gained a 9.7% new prescription share of the ~~International Epilepsy Congress, data from an independently conducted meta-analysis showed Lyrica to be among the best~~total U.S. anti-epileptic market in ~~class for treatment~~September 2006, continuing its performance as one of ~~drug-resistant epilepsy.~~Pfizer's most successful pharmaceutical launches.

•
Celebrex and Bextra
~~On April 7, 2005,~~Celebrex achieved a 19% increase in worldwide sales in the ~~FDA announced~~first nine months of 2006 compared to the same period in 2005. In the first nine months of 2006, Celebrex delivered three consecutive quarters of double-digit sales growth and had a ~~decision to require boxed warnings~~monthly new prescription share of potential cardiovascular risk for all COX-2 pain relievers and all prescription NSAIDs, including older non-specific drugs such as ibuprofen and naproxen. On July 29, 2005, Pfizer and the FDA finalized the label changes for Celebrex. The final label contains a boxed warning of potential serious cardiovascular and gastrointestinal risks for Celebrex that are consistent with warnings for all other prescription NSAIDs. The boxed warning provides that Celebrex is contraindicated for patients who recently have undergone coronary artery bypass graft surgery. The label recommends that Celebrex be prescribed at the lowest effective dose for the shortest duration consistent with individual patient treatment goals.10.5% in September 2006. Pfizer is continuing its efforts to ~~conduct additional clinical studies evaluating~~address physicians and patients' questions by clearly communicating the ~~benefits~~risks and ~~risks~~benefits of Celebrex. In addition, the Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen or Naproxen (PRECISION) study, which began enrolling patients in October 2006, will provide further understanding of the comparative cardiovascular safety of Celebrex and some common non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in arthritis patients at risk for, or already suffering from, heart disease.

The market for pain relievers has shown considerable change since the withdrawal of Vioxx in September 2004. Sales of Celebrex began to decline in the late 2004. However, following regulatory reviews of these medicines in February 2005 in both the U.S. and the E.U., the market for prescription pain relievers indicated lower, but stabilizing levels compared to pre-Vioxx withdrawal levels. Revenues from Celebrex in 2005, prior to the FDA's decision in April 2005, were already expected to be significantly lower than in 2004.
~~In September 2005, with full implementation of revised labeling,~~ Pfizer began to ~~focus renewed attention on Celebrex,~~reintroduce branded advertising in the U.S. in April 2006 in alignment with ~~the goal of making the pain reliever available to increased numbers of patients. Celebrex is supported by a large body of scientific~~our new direct-to-consumer (DTC) advertising principles, highlighting Celebrex's strong clinical profile and ~~clinical-trial evidence of efficacy and safety accumulated over 10 years in more than 40,000 patients worldwide.~~benefits. In July 2005, the FDA approved a sixth indication for ~~Celebrex -- ankylosing spondylitis -- a~~Celebrex--ankylosing spondylitis--a form of spinal arthritis that affects more than one million people in the U.S. In August 2006, Celebrex was granted pediatric exclusivity in the U.S., extending its patent protection until May 2014. Strong clinical data continue to support Celebrex as an important medicine for patients with arthritis. The Successive Celecoxib Efficacy and Safety Study (SUCCESS-1), recently published in the American Journal of Medicine, showed that people with osteoarthritis who take Celebrex experience significantly fewer gastrointestinal problems than patients who take NSAIDs.

In ~~June~~ 2005, in accordance with decisions by applicable regulatory authorities, we implemented label changes for Celebrex in the ~~Committee~~U.S. and the E.U., and we suspended sales of Bextra in the U.S., E.U., Canada and many other countries. The revised U.S. label for ~~Human Medicinal Products (CHMP) concluded its COX-2 referral process~~Celebrex contains a boxed warning of potential serious cardiovascular and ~~recommended~~gastrointestinal risks that ~~both~~is consistent with warnings for all other prescription NSAIDS. The revised E.U. labels for Celebrex and ~~Dynastat (parecoxib) remain available to patients. The European Medicines Evaluation Agency (EMEA) has required new labeling for~~ all other COX-2 ~~drugs that includes~~medicines include a restriction on use ~~for~~by patients with established heart disease or stroke and additional warnings to physicians regarding use inby patients with cardiovascular risk factors. ~~This new labeling was implemented for all COX-2 medicines across the E.U. in July of 2005.~~
Further, the FDA decided that while Bextra's cardiovascular risk could not be differentiated from other NSAIDs, the additional, increased risk of rare but serious skin reactions associated with Bextra, already described in its label, warranted its withdrawal from the market. In 2004, we recorded $1.3 billion in revenue for Bextra. We respectfully disagree with the FDA's position regarding the relative risk/benefit profile of Bextra. However, in deference to the regulatory agency's view, we suspended sales of the medicine pending further discussions with the FDA. In addition, at the request of European and other regulators, we suspended sales of Bextra in the E.U., Canada and many other markets around the world.
In connection with the decision to suspend sales of Bextra in the U.S., the E.U., and certain other markets, we recorded certain charges totaling $1.2 billion ($762 million, net of tax) in the first nine months of 2005. These pre-tax charges included $1.1 billion related to the impairment of developed technology rights associated with Bextra and $7 million related to the write-off of machinery and equipment, both of which are included in ~~Other (income)/deductions-net~~~~; $56 million in write-offs of inventory and exit costs, included in~~ ~~Cost of sales~~~~; $8 million related to the costs of administering the suspension of sales, included in~~ ~~Selling, informational and administrative expenses;~~ ~~and $212 million for an estimate of customer returns, primarily included against~~ ~~Revenues.~~ ~~Substantially all of these charges were recorded in the first quarter of 2005.~~
•
Zithromax~~, whose composition of matter patent~~ experienced a 68% decline in the U.S. expires in November 2005, remained the number-one prescribed oral antibiotic during the third quarter of 2005, despite the end of active sales promotion in July, when the U.S. sales force began promoting Zmax. Sales in the U.S. are expected to be adversely affected by the loss of market exclusivity beginning in November 2005.
•
~~Zmax,~~ a single-dose, sustained-release form of azithromycin, was introduced in the U.S. in July 2005. Zmax has surpassed all other recent antibiotic introductions (including line extensions) in week 10 prescription volume, even though the Zmax launch occurred in the summer, before the beginning of the respiratory season. Single-dose Zmax delivers higher azithromycin serum concentrations during the first 24 hours than Zithromax and assures complete compliance compared to multi-dose regimes, demonstrating a clear benefit of the new medication. A supplemental Marketing Authorization Application (MAA) for Zmax was approved in Europe in September 2005.
•
~~Diflucan~~ ~~is a systemic antifungal. The decrease in~~worldwide sales in the first nine months of ~~2005~~2006 compared to the same period ~~in 2004 is mainly due to loss~~ of ~~exclusivity~~2005, reflecting the expiration of its composition-of-matter patent in the U.S. in November 2005 and the end of Pfizer's active sales promotion in July ~~2004.~~2005. During the fourth quarter of 2005, four generic versions of oral solid azithromycin were launched, including an authorized generic by Pfizer's Greenstone subsidiary. Additional generic formulations of azithromycin were launched during 2006, including three oral suspensions and two intravenous versions.
•
Eraxis, an antifungal approved to treat candidemia and other forms of Candida infections (intra-abdominal abscesses and peritonitis), as well as esophageal candidiasis, was launched mid-June 2006 in the U.S. Candidemia is the most deadly of the common hospital-acquired bloodstream infections with a mortality rate of approximately 40%.
•
Viagra remains the leading treatment for erectile dysfunction and one of the world's most recognized pharmaceutical brands, with more than ~~63%~~58% of U.S. total prescriptions in the erectile dysfunction market through September 2006. Viagra sales declined 1% worldwide in the first nine months of 2006 compared to the same period in 2005. We expect to see continued pressure on sales in ~~its market~~the U.S. More than 45 states have either eliminated erectile-dysfunction coverage or have enacted "preferred drug lists" that have the potential to limit Pfizer sales to state Medicaid programs. Effective January 1, 2006, federal funds may not be used for reimbursement of ~~phosphodiesterase-5 (PDE5) inhibitors through August 2005, even as~~erectile-dysfunction medications by the ~~entire market's sales were down for the period.~~Medicaid program. Medicare coverage of Viagra will end in 2007.
Pfizer has introduced new branded and unbranded advertising to encourage men with erectile dysfunction to talk to their physicians about their condition and specifically about Viagra.

•
Sutent is an oral multi-targeted tyrosine kinase inhibitor that combines anti-angiogenic and anti-tumor activity to inhibit the blood supply to tumors and has direct anti-tumor effects. Sutent was approved by the FDA in January 2006 for advanced renal cell carcinoma, including metastatic renal cell carcinoma (collectively, mRCC), and gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib mesylate. Since approval, Sutent has been prescribed to more than 7,500 patients in the U.S. On July 27, 2006, Sutent received conditional marketing authorization from the European Commission for mRCC, after failure of interferon alfa or interleukin-2 therapy, and unresectable and/or metastatic malignant GIST, after failure of imatinib due to resistance or intolerance. This was the first time the European Commission granted a new oncology drug conditional marketing authorization in the European Union. Final approval is contingent on the provision of comprehensive data on Sutent's effect in terms of relevant clinical endpoints, such as progression-free survival in patients with mRCC. In ~~addition, Viagra faces aggressive competition~~October 2006, following evaluation of clinical data submitted by Pfizer, the Committee for Medicinal Products for Human Use (CHMP) recommended a switch from ~~other global brands. Year-to-date 2005 Viagra sales are ahead 1%~~the conditional marketing authorization to a full marketing authorization. It also recommended to extend the indication to first-line treatment of mRCC. Sutent has received approvals or registration in several countries in Asia and Latin America and is expected to launch in many more markets worldwide over ~~last year, and third-quarter 2005~~the coming months. Sutent has recorded $115 million in sales ~~are down 4% from~~worldwide in the same period last year. Pfizer plans to introduce new branded advertising compliant with our direct-to-consumer advertising guidelines to highlight the unique clinical profile for Viagra, as well as new unbranded advertising to address the needsfirst nine months of ~~potential new patients who may be hesitant to try any medication for erectile dysfunction.~~
On July 8, 2005, the FDA approved an update to the Viagra label to reflect rare post-marketing reports of non-arteritic anterior ischemic optic neuropathy (NAION) in patients taking PDE5 inhibitor medications. The updated label notes that in rare instances, men taking PDE5 inhibitors, including Viagra, reported a sudden decrease or loss of vision in one or both eyes and that it is not possible to determine whether these events are related directly to these medicines, to the patient's underlying vascular risk factors, to a combination of these factors, or other factors. Most of the reported NAION cases occurred in Viagra users with underlying anatomic or vascular risk factors associated with the development of NAION.2006.

•
Camptosar ~~is a semisynthetic camptothecin derivative that works by inhibiting the topoisomerase 1 enzyme, which is involved in cancer cell replication. Camptosar~~ is indicated as first-line therapy for metastatic colorectal cancer in combination with 5-fluorouracil and leucovorin. It is also indicated as second-line therapy for patients in whom metastatic colorectal cancer has recurred or progressed despite following initial fluorouracil-based therapy. Camptosar is for intravenous use only. Revenue ~~growth of 85%~~ in the first nine months of ~~2005~~2006 decreased 1% to $668 million compared to the same period in ~~2004 was impacted in part by Pfizer's acquisition of marketing rights to Campto/Camptosar in Europe and Asia (except Japan) in late 2004.~~2005. Among current oncology medications, the National Comprehensive Cancer Network, an alliance of 19 of the world's leading cancer centers, has issued guidelines recommending Camptosar as an option across all lines of treatment for advanced colorectal cancer.

•
Xalatan/Xalacom, a prostaglandin analogue used to lower the intraocular pressure associated with glaucoma and ocular hypertension, is the most-prescribed branded glaucoma medicine in the world. Clinical data showing its advantages in treating ~~intra-ocular~~intraocular pressure compared with beta blockers should support the continued growth of this important medicine. Xalacom, the only fixed combination prostaglandin (Xalatan) and beta blocker, is available primarily in European markets. Xalatan/Xalacom sales grew 5% in the first nine months of 2006 compared to the same period in 2005.

•
Zyrtecprovides strong, rapid and long-lasting relief for seasonal and year-round allergies and hives with once-daily dosing. Zyrtec continues to be the most-prescribed antihistamine in the U.S. in a challenging market. ~~The increase in sales~~Sales increased 15% in the first nine months of ~~2005~~2006 compared to the same period in ~~2004 is attributable~~2005. In February 2006, we began a new DTC advertising campaign featuring new insight that allergy symptoms can worsen over time due to ~~stabilization in the prescription antihistamine market subsequent~~exposure to ~~the Rx to over-the-counter switch of loratadine as the majority of the managed care plans have completed their formulary tier changes in this category.~~
•
~~Macugen~~, a treatment for neovascular (wet) age-related macular degeneration, is a product whose revenues are included in alliance revenues. It was launched in the U.S. in January 2005 and launched in Canada in September 2005. We anticipate that the European Commission will grant marketing authorization for Macugen during the fourth quarter of 2005.new allergens.

•
Caduet,a multi-target single pill combining Norvasc and Lipitor, ~~and Norvasc, has successfully completed the Mutual Recognition Procedure (MRP) in the E.U. and is the first multi-target combination product to receive~~recorded worldwide revenues of $255 million with a ~~broad approval~~growth rate of 111% for prevention of cardiovascular events in the E.U. Caduet is now approved in the following E.U. countries: France, Spain, Portugal, Austria, Iceland, Luxembourg, Cyprus, the Czech Republic, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia and Slovenia. It is indicated for prevention of cardiovascular events in hypertensive patients with three concomitant cardiovascular risk factors, normal to mildly elevated cholesterol levels, without clinically evident coronary heart disease, where combined use of amlodipine and low dose atorvastatin is considered appropriate, and in accordance with current treatment guidelines. The Caduet Marketing Authorization application has been officially withdrawn from the MRP in Belgium, Denmark, Estonia, Ireland, Italy, Netherlands, Norway, the U.K., Sweden, Germany, Finland and Greece. These countries had reservations as to whether the benefit of Caduet, the first cardiovascular, multi-target, fixed combination product, had been demonstrated,based upon current European regulatory guidelines for fixed combination products. As a result, these countries did not mutually recognize the proposed label and Pfizer decided to withdraw the application from these countries. Pfizer will continue to explore regulatory approval opportunities for Caduet.
~~Consumer Healthcare~~
Revenues of our Consumer Healthcare business, which include three additional business days in our fiscal calendar in the first quarter and nine months of 2005 compared to the same periods in 2004, follow:

Third Quarter
First Nine Months
(millions of dollars)
2005
2004
% Change
2005
2004
% Change

Consumer Healthcare
$
921
$
851
8%
$
2,835
$
2,524
12%
~~The increase in Consumer Healthcare revenues in the third quarter and first nine months of 2005, as compared to the same periods in 2004, was attributable to:~~
•
~~the 4% increase in the third quarter and 13% increase in~~ the first nine months of ~~2005~~2006 compared to the same period in ~~sales of Listerine mouthwash, which benefited from~~2005. Caduet was launched in the U.S. ~~launch of Listerine Whitening~~ in ~~April 2005, as well as continued strong performance~~May 2004 and continues to grow at significantly higher rates than the overall U.S. cardiovascular market. Caduet is available in ~~international markets;~~more than 10 other countries. Caduet has now received approvals in 51 markets with drug applications pending in 14 additional markets and applications planned in 10 other countries. During 2006, Caduet is expected to be launched in France, Spain, Australia, Taiwan and Turkey.
•
~~growth from Sudafed and other upper-respiratory products, Zantac, and tobacco dependence products;~~
•
~~inclusion of Purell sales~~Chantix/Champix, the first new prescription treatment for smoking cessation in ~~2005 following the acquisition of the Purell brand~~nearly a decade, became available to patients in ~~November 2004; and~~
•
~~the favorable impact of the weakening of~~ the U.S. ~~dollar relative~~in August 2006. In September 2006, the European Commission approved Champix in Europe for smoking cessation. Chantix/Champix is available with a patient support plan which smokers can customize to ~~many foreign currencies.~~address their individual behavioral triggers as they try to quit smoking.
Animal Health
Revenues of our Animal Health business ~~which include three additional business days in our fiscal calendar~~ in the ~~first quarter~~three months and nine months ~~of 2005~~ended October 1, 2006, compared to the ~~same periods in 2004,~~three months and nine months ended October 2, 2005, follow:
Third Quarter
First Nine Months
Three Months Ended
Nine Months Ended
(millions of dollars)
2005
2004
% Change
2005
2004
% Change
Oct. 1,
2006
Oct. 2,
2005
% Change

Oct. 1,
2006
Oct. 2,
2005
% Change

Livestock products
$
301
$
287
5%
$
958
$
840
14%
$
340
$
301
13%
$
1,011
$
958
6 %
Companion animal products
202
188
8
618
547
13
222
202
10
645
618
4
Total Animal Health
$
503
$
475
6
$
1,576
$
1,387
14
$
562
$
503
12
$
1,656
$
1,576
5
The increase in Animal Health revenues in the ~~third quarter~~three months and ~~first~~ nine months ~~of 2005,~~ended October 1, 2006, as compared to the same periods in ~~2004,~~2005, was primarily attributable to:
•
infor livestock products, the continued performance of Draxxin (for treatment of respiratory disease in cattle and swine) in Europe and in the U.S., as well as Spectramast (antibiotic formulated to treat clinical mastitis) which was launched in the U.S. in May 2005, partially offset by a slowdown in the third quarter due to delay in the U.S. cattle season;; and

•
infor companion animal ~~increased promotional activities throughout our markets resulted in~~products, the performance of Rimadyl (for treatment of pain and inflammation associated with canine osteoarthritis and soft-tissue orthopedic surgery) for the three months ended October 1, 2006, the continued performance of Revolution (a parasiticide for dogs and ~~Clavamox growing at double-digit rates~~cats) for both the~~first~~ three months and nine months ~~of 2005,~~ended October 1, 2006 and ~~the launch of Simplicef (small animal anti-infective) in the U.S. in the fourth quarter of 2004; and~~
•
the favorable impact of the weakening of the U.S. dollar relative to many foreign ~~currencies.~~currencies in the third quarter of 2006;
partially offset by:
•
a decline in U.S. Rimadyl revenues in the first half of 2006 due to lower-than-anticipated NSAID market growth and intense branded competition, as well as increased generic competition in the European companion animal market; and
•
the unfavorable impact of the strengthening of the U.S. dollar relative to many foreign currencies for the first nine months of 2006.
~~COSTS AND EXPENSES~~
~~Cost of Sales~~
Cost of sales grew 16% in the third quarter of 2005 and 19% for the first nine months of 2005, and increased as a percentage of revenues, as compared with the prior year periods. The increases reflect unfavorable geographic, segment and product mix, and adverse changes in production volume, among other factors. In the first quarter of 2005, we also recorded charges for write-offs of inventory and exit costs related to the suspension of Bextra sales (see Note 2, ~~Asset Impairment Charge and Other Costs Associated with the Suspension of Bextra Sales~~).
~~Cost of sales as a percentage of revenues will remain under pressure throughout the remainder of 2005.~~
~~Selling, Informational and Administrative Expenses~~
Selling, informational and administrative expenses decreased 3% in the third quarter and were flat in the first nine months of 2005, as compared to the same periods in 2004, reflecting an increase in merger-related synergies, and the impact of the Company's AtS productivity initiative, partially offset by the unfavorable impact of foreign exchange.
~~Research and Development Expenses~~
Research and development (R&D) expenses decreased 6% in the third quarter and increased 1% in the first nine months of 2005, as compared to the same periods in 2004. The decline in the third quarter of 2005 reflects the initial benefits associated with the AtS productivity initiative and changes in year-over-year timing of various expenses.
Product Developments
We continue to invest in R&D to provide future sources of revenue through the development of new products, as well as through additional uses for existing in-line and alliance products. We have a broad and deep pipeline of medicines in development. However, there are no assurances as to when, or if, we will receive regulatory approval for additional indications for existing products or any of our other products in development.
Certain significant regulatory actions by, and filings pending with, the FDA and other regulatory authorities follow:
Recent FDA Approvals:
Product
Indication

Date Approved

~~Aromasin~~
~~Treatment of early breast cancer in post-menopausal women~~
~~October 2005~~
~~Lipitor~~
~~Reduce the risk of stroke and myocardial infarction in patients with type 2 diabetes~~
~~September 2005~~
~~Norvasc~~
~~For treatment of angiographically documented coronary artery disease~~
~~September 2005~~
~~Celebrex~~
~~For the relief of the signs and symptoms associated with ankylosing spondylitis~~
~~July 2005~~
~~Lyrica~~
~~Add-on therapy for adult epilepsy patients with partial onset seizures~~
~~June 2005~~
~~Revatio~~
~~Oral treatment for adult pulmonary arterial hypertension (PAH)~~
~~June 2005~~
~~Zmax~~
~~Single dose version of Zithromax for acute bacterial sinusitis and community-acquired pneumonia.~~
~~June 2005~~
~~Zyvox~~
~~For the treatment of bacterial infections in pediatric patients~~
~~May 2005~~
~~Depo-SubQ Provera~~
~~Subcutaneous formulations to treat pain associated with endometriosis.~~
~~March 2005~~
~~Ellence~~
~~Adjuvant long-term cancer treatment~~
~~March 2005~~
~~Pending U.S. New Drug Applications (NDAs) and Supplemental Filings:~~
~~Product~~
~~Indication~~
~~Date Submitted~~
~~Sutent~~
~~Treatment of metastatic renal cell carcinoma and malignant gastrointestinal stromal tumors~~
~~August 2005~~
~~Anidulafungin~~
~~Treatment of candidemia and invasive candidiasis~~
~~August 2005~~
~~Treatment of esophageal candidiasis~~
~~May 2005~~
Aricept
Treatment of severe Alzheimer's disease
~~August 2005~~October 2006
Chantix
Nicotine-receptor partial agonist for smoking cessation
May 2006

Genotropin
Treatment of short stature and growth problems resulting from Turner's syndrome
~~June 2005~~April 2006

~~Vfend~~Geodon
~~Pediatric filing~~Liquid oral suspension
~~June 2005~~March 2006

~~Indiplon~~Eraxis
~~Modified-release tablets for treatment~~Treatment of ~~multiple aspects of insomnia~~candidemia and invasive candidiasis
~~May 2005~~February 2006

~~Immediate-release capsules for treatment~~Treatment of ~~multiple aspects of insomnia~~esophageal candidiasis
~~April 2005~~February 2006

Exubera
Inhaled form of insulin for use in adults with type 1 and type 2 diabetes
~~December 2004~~January 2006

~~Oporia~~Sutent
~~Vaginal atrophy~~Treatment of mRCC and GIST
~~December 2004~~January 2006
Pending U.S. New Drug Applications (NDAs) and Supplemental Filings:
Product
Indication
Date Submitted

~~Dalbavancin~~Celebrex
Juvenile rheumatoid arthritis
June 2006
Lipitor
Secondary prevention of cardiovascular (CV) events in patients with established coronary artery disease (CAD)
May 2006
Fesoterodine
Treatment of overactive bladder
March 2006
Vfend
Pediatric filing
June 2005
Zeven (dalbavancin)
Treatment of Gram-positive bacterial infections
December 2004
~~Norvasc~~
~~Reduction of cardiovascular risk, including risk of coronary heart disease, myocardial infarction, cardiovascular procedures and strokes~~
~~August 2004~~
~~Fragmin~~
~~Use in oncology patients to reduce cardiac toxicity associated with chemotherapy~~
~~March 2004~~
~~In September 2005, we~~We received "not-approvable" letters from the FDA for Oporia for the prevention of post-menopausal osteoporosis in September 2005 and for the treatment of vaginal atrophy in January 2006. We are currently in discussions with the FDA regarding these letters, and we continue to develop Oporia. In March 2006, we received a "not-approvable" letter for Fragmin for use in oncology patients, and we are currently in discussions with the FDA regarding this letter as well. In September 2006, an FDA advisory committee recommended that the FDA approve Fragmin for the prevention of blood clots in oncology patients. In September 2005, we received a "not-approvable" letter for Dynastat (parecoxib), an injectable prodrug for valdecoxib for the treatment of acute pain. ~~Pfizer~~We have had discussions with the FDA regarding this letter, and we are developing plans to ~~discuss these "not-approvable" letters with~~address the ~~FDA.~~FDA's concerns.
In ~~September 2005, an FDA advisory committee recommended that~~June 2006, after certain decisions by the FDA, ~~approve~~we notified Neurocrine Biosciences, Inc. (Neurocrine) that we are returning the development and marketing rights for ~~Exubera~~indiplon, ~~an inhaled form of insulin for use~~a product candidate to treat insomnia, to Neurocrine. This includes both the collaboration to develop and co-market indiplon in ~~adults with type 1~~the U.S., as well as Pfizer's exclusive license to develop and ~~type 2 diabetes. The FDA is not obligated to follow the recommendation~~market indiplon outside of the ~~advisory committee.~~ U.S.
In ~~October 2005,~~June 2006, the FDA ~~extended the review period for Exubera to study more data on the diabetes treatment.~~
~~An NDA for~~ ~~Sutent~~, a novel multi-targeted oral compound for treatment of metastatic renal cell carcinoma (mRCC) and malignant gastrointestinal stromal tumors (GIST), was submitted to the FDA on August 10, 2005. The FDA has accepted this submission and granted Sutent priority-review status for this important cancer therapy. Priority designation allows for an expedited review of the NDA filing and is intended for product candidates that may provide a significant improvement compared to marketed products. An MAA for Sutent was also submitted to European regulatory authorities during the quarter.
~~On September 14, 2005, Pfizer completed the acquisition of Vicuron.~~ ~~Anidulafungin~~, one of the key products acquired in the Vicuron acquisition, is a novel, broad-spectrum antifungal agent of the echinocandin class that is currently under review by the FDA. The filing for the treatment of candidemia/invasive candidiasis has been granted priority-review status. In a Phase 3 trial, anidulafungin demonstrated clinical efficacy greater than fluconazole, including disease due to Candida glabrata, with a comparable safety profile in the treatment of candidemia/invasive candidiasis. Pfizer is currently assessing the potential of anidulafungin in treating additional patient populations.
~~The FDA has~~ designated as approvable the NDA for ~~Dalbavancin~~Zeven~~, a new injectable antibiotic to treat Gram-positive infections, which was also acquired in the Vicuron acquisition.~~ (dalbavancin). We now anticipate a ~~rapid and~~ successful resolution of outstanding issues to allow final ~~NDA~~FDA approval and launch in the coming months. The addition of these two medications would broaden Pfizer's existing portfolio of anti-infectives, where the Company has a long history of providing patients and physicians with life-saving medicines.2007.
Other Regulatory Approvals and Filings:

Product
Description of Event
Date Approved

Date Submitted


~~Revatio~~Lyrica
Approval in the E.U. for ~~treating PAH~~the treatment of central neuropathic pain
~~November 2005~~September 2006
--
~~Application submitted in Canada for treating PAH~~
--
~~December 2004~~
~~Geodon~~
Approval in the E.U. for ~~treating manic or mixed episodes~~treatment of ~~moderate severity~~GAD in ~~bipolar disorder~~adults
~~October 2005~~March 2006
--

~~Aromasin~~Chantix/Champix
Approval in the E.U. for ~~treating early breast cancer in post-menopausal women~~smoking cessation
~~August 2005~~September 2006
--

~~Sutent~~Spiriva
Application submitted in the E.U. - Respimat device for chronic obstructive pulmonary disease
--
September 2006
Eraxis
Application submitted in the E.U. for ~~the~~ treatment of ~~metastatic renal cell carcinoma~~candidemia and ~~malignant gastrointestinal stromal tumors~~candidiasis
--
September 2006
Sutent
Application submitted in the E.U. for mRCC as a first-line treatment^(a)
--
August 2006
Approval in Canada for GIST
May 2006
--
Application submitted in Canada for mRCC
--
December 2005
Application submitted in the E.U. for mRCC, as a second-line treatment, and for GIST^(a)
--
August 2005

Aricept
Application submitted in Canada for treatment of severe Alzheimer's disease
--
July 2006
Fragmin
Approval in Canada for ~~fast dissolving tablet~~treatment of medical thromboprophylaxis
July ~~2005~~2006
--

~~Caduet~~Neurontin
Approval in ~~certain E.U. countries~~Japan for ~~cardiovascular event prevention~~treatment of epilepsy
July ~~2005~~2006
--

~~Lyrica~~Genotropin
Approval in Japan for treatment of short stature and growth problems
July 2006
--
Lipitor
Approval in the E.U. for primary prevention of CV events in high coronary heart disease risk patients without established CAD
May 2006
--
Aromasin
Approval in Canada for ~~neuropathic pain~~early breast cancer
~~June 2005~~May 2006
--
Vfend
Approval in Canada for the powder form oral suspension
May 2006
--
Revatio
Approval in Canada for treating pulmonary arterial hypertension
May 2006
--
Zyvox
Approval in Japan for methicillin-resistant Staphylococcus aureus
April 2006
--
Zoloft
Approval in Japan for treatment of depression and panic disorder
April 2006
--
Detrol/Detrol LA/Detrusitol
Approval in Japan for treatment of overactive bladder
April 2006
--
Celebrex
Application submitted in the E.U. for the treatment of ankylosing spondylitis
--
April 2006
Fesoterodine
Application submitted in the E.U. for treatment of overactive bladder
--
March 2006
Chantix/Champix
Application submitted in Canada for smoking cessation
--
February 2006
Exubera
Application submitted in Canada as an inhaled form of insulin for use in adults with type 1 and 2 diabetes
--
April 2006
Approval in the E.U. as an inhaled form of insulin for use in adults with type 1 and 2 diabetes
January 2006
--

Macugen
Approval in ~~Canada and Brazil for age-related macular degeneration (AMD)~~
~~May 2005~~
--
~~Application submitted in Switzerland~~E.U. for AMD
--
January ~~2005~~
~~Application submitted in the E.U. and Australia for AMD~~
--
~~September 2004~~
~~Fragmin~~
~~Approval in the E.U. for treatment of deep vein thrombosis in cancer patients~~
~~April 2005~~2006
--

~~Vfend~~
~~Approval in Japan for treatment of aspergillosis~~
~~April 2005~~
--
~~Approval for treatment of serious, invasive, fluconazole-resistant candida infections and first-line treatment of candidemia in non-neutropenic patients was granted in the E.U.~~
~~January 2005~~
--
~~Zmax~~
~~Application submitted in the E.U. for sustained release~~
--
~~October 2004~~
~~Genotropin~~Somavert
Application submitted in Japan for ~~treatment of short stature and growth problems~~acromegaly
--
~~July 2004~~
~~Neurontin~~
~~Application submitted in Japan for epilepsy~~
--
~~April 2004~~
~~Exubera~~
~~Application submitted in the E.U. as an inhaled form of insulin for use in adults with type 1 and type 2 diabetes~~
--
~~February 2004~~May 2005
~~In September and October of 2005, the CHMP of the European Medicines Evaluation Agency issued positive opinions recommending that marketing authorizations be granted by the European Commission for~~ ~~Macugen~~ ~~and~~ ~~Exubera~~, respectively. The European Commission is not obligated to follow the opinions of the CHMP. The European Commission is expected to act upon the CHMP recommendations for Macugen by the end of 2005 and Exubera in early 2006.
^(a)
On July 27, 2006, Sutent received conditional marketing authorization from the European Commission for mRCC, after failure of interferon alfa or interleukin-2 therapy, and unresectable and/or metastatic malignant GIST, after failure of imatinib due to resistance or intolerance. This was the first time the European Commission granted a new oncology drug conditional marketing authorization in the European Union. Final approval is contingent on the provision of comprehensive data on Sutent's effect in terms of relevant clinical endpoints, such as progression-free survival in patients with mRCC. In October 2006, following evaluation of clinical data submitted by Pfizer, the CHMP recommended a switch from the conditional marketing authorization to a full marketing authorization. It also recommended to extend the indication to first-line treatment of mRCC.
Ongoing or planned clinical trials for additional uses and dosage forms for our products include:
Product
Indication

~~Celebrex~~Geodon/Zeldox
~~Sporadic adenomatous polyposis - a precancerous condition caused by growths (polyps) in the intestines~~Bipolar relapse prevention, bipolar pediatric

~~Camptosar IV~~Lyrica
~~Adjuvant colorectal cancer~~Fibromyalgia, generalized anxiety disorder

~~Gastric~~Sutent
Breast cancer

~~Geodon~~Revatio
~~Bipolar relapse prevention~~
~~Macugen~~
~~Diabetic Macular Edema~~Pediatric pulmonary arterial hypertension

~~Xalatan (new delivery device)~~Macugen
~~Ocular hypertension~~Diabetic macular edema

Zyvox
Catheter-related infections

Bone and joint infections
Drug candidates in late-stage development include ~~varenicline, a nicotine-receptor partial agonist for smoking cessation, which has concluded Phase 3 trials;~~ maraviroc (UK-427,857), a CCR-5 receptor antagonist for HIV; torcetrapib/atorvastatin, a combination CETP inhibitor/statin for heart disease; asenapine, for schizophrenia and bipolar disorder, under co-development with Akzo Nobel's Organon healthcare unit; ~~and~~ Zithromax/chloroquine for treatment of ~~malaria. The Company anticipates filing~~malaria; PF-3512676, a toll-like receptor 9 agonist for non-small cell lung cancer developed in partnership with Coley Pharmaceutical Group, Inc.; and CP-675,206, an ~~NDA with the FDA~~anti-CTLA4 monoclonal antibody for ~~varenicline by the end of 2005.~~melanoma. The FDA has granted fast-track designation for maraviroc's clinical development program. Based on the mixed study results to date for asenapine for the treatment of schizophrenia, Pfizer does not believe that an NDA filing with the FDA will be made in 2007. Following receipt of the data from the final Phase 3 study for schizophrenia, Pfizer will discuss the complete Phase 3 data set with Organon, and an announcement will be made concerning the next steps for asenapine.
Torcetrapib/atorvastatin, which combines the new chemical entity torcetrapib (a CETP inhibitor discovered by Pfizer that raises ~~HDL-cholesterol)~~HDL cholesterol) with atorvastatin (Lipitor), iscontinuing in global Phase 3 clinical trials. This comprehensive 12,000-subject development program includes three comparative atherosclerotic imaging trials (a coronary intravascular ultrasound study and two carotid ultrasound studies), as well as a full range of blood-lipid efficacy studies comparing torcetrapib/atorvastatin to Lipitor, other statins and fibrates. We are in the midst of the blood-lipid efficacy program, and we anticipate completion of the three ongoing imaging trials by the end of this year. Assuming that we see sufficient improvements over the comparative agents in these various studies, we plan to file the torcetrapib/atorvastatin NDA in 2007.
In addition to these Phase 3 studies, the development program includes a definitive mortality and morbidity trial, which has completed enrollment.
The American Heart Association has accepted for presentation at its annual meeting on November 15, 2006, the torcetrapib/atorvastatin program's study results in patients with heterozygous familial hypercholesterolemia (HeFH). In this relatively uncommon condition, which is found in one of every 500 people in the general population and is characterized by high LDL-cholesterol levels, the study primarily investigated the drug's lipid efficacy and safety in comparison to matching doses of Lipitor in 437 patients who were treated for 24 weeks. In this HeFH study, torcetrapib/atorvastatin raised HDL ("good") cholesterol by about 56% and additionally lowered LDL ("bad") cholesterol by about 27% compared to Lipitor alone. Patients in the torcetrapib/atorvastatin group experienced an average increase in systolic blood pressure that was about 2 millimeters greater than the increase experienced by patients in the Lipitor-only group. Generally, in all of the blood-lipid efficacy studies completed to date, torcetrapib/atorvastatin increased HDL cholesterol by 55-60% and additionally lowered LDL cholesterol by 10-15% compared to Lipitor alone. In those studies, patients in the torcetrapib/atorvastatin group experienced an average increase in systolic blood pressure versus the comparator agents of approximately one millimeter above the two-to-three millimeter range that was observed in the Phase 2 studies. It is ~~enrolling 13,000 patients.~~important to note that the Phase 3 results to date are far from complete, covering less than 25% of all patients in the entire torcetrapib/atorvastatin clinical trial program. No final conclusions regarding the efficacy and safety of torcetrapib/atorvastatin can be drawn until we complete the blood lipid-efficacy and imaging studies and do the accompanying statistical analysis. The torcetrapib/atorvastatin studies completed to date vary in duration and size, and preliminary results at this stage may not represent the final results when Phase 3 is completed. We expect to present the results of the three comparative atherosclerotic imaging studies at the American College of Cardiology meeting in March 2007.
Despite effective treatments, cardiovascular disease remains the number one killer worldwide with a residual relative risk of 6060% to 70% after treatment with statins. Therefore, the primary objective of the torcetrapib/atorvastatin development program is to provide clear evidence that substantially raising ~~HDL-cholesterol~~HDL cholesterol and further lowering ~~LDL-cholesterol~~LDL cholesterol can reduce cardiovascular risk beyond what can be achieved with current treatments. Torcetrapib ~~will be~~is being developed with atorvastatin in order to rigorously test this hypothesis and the new CETP inhibition mechanism of action. This development program represents a major commitment by Pfizer to significantly advance the understanding of lipids and atherosclerosis in order to provide an important new tool for patients and prescribers in preventing and treating the global burden of cardiovascular ~~disease~~.
~~The clinical~~disease. In addition to the torcetrapib/atorvastatin development program, ~~for the selective cytotoxic agent edotecarin was terminated in the first quarter of 2005; development rights for edotecarin were returned~~we plan to ~~Banyu Pharmaceuticals, Inc.~~
Pfizer's participation in the clinical development programs for capravirine, a non-nucleoside reverse transcriptase inhibitor for HIV, and Daxas, a phosphodiesterase-4 inhibitor for chronic obstructive pulmonary disease and asthma, was terminated in the second quarter 2005; development rights were returneddevelop torcetrapib as concurrent therapy to ~~Shiongi & Co. Ltd and Altana Pharma, Inc. respectively.~~be used with other statins or lipid-lowering medications.
Additional product-related programs are in various stages of discovery and development.
COSTS AND EXPENSES
Cost of Sales
Cost of sales increased 22% and 3% in the three months and nine months ended October 1, 2006 as compared to the same periods in 2005. Cost of sales as a percentage of revenues increased in the three months ended October 1, 2006, primarily due to the unfavorable impact on expenses of foreign exchange, a concerted focus on inventory-reduction initiatives (exclusive of inventory build-up in advance of new product launches) and higher costs related to our AtS productivity initiative, partially offset by savings related to our AtS productivity initiative. Costs of sales as a percentage of revenues also increased for the nine months ended October 1, 2006, primarily due to higher costs related to our AtS productivity initiative and a concerted focus on inventory-reduction initiatives (exclusive of inventory build-up in advance of new product launches), partially offset by savings related to our AtS productivity initiative, the impact of the second-quarter 2005 inventory write-off of $56 million related to the suspension of Bextra sales.
Selling, Informational and Administrative Expenses
Selling, informational and administrative (SI&A) expenses increased 6% and remained flat in the three months and nine months ended October 1, 2006, as compared to the same periods in 2005. The increase in the three months ended October 1, 2006, reflect higher costs related to our AtS productivity initiative, expenses related to share-based payments and the higher promotional investments in new product launches and in-line product promotional programs during the second half of 2006. For the nine months ended October 1, 2006, such factors were offset by the favorable impact on expenses of foreign exchange. SI&A expense growth comparisons during the first half of 2006 were more favorable than in the second half of the year, since savings from our AtS productivity initiative began to be realized in the third quarter of 2005.
Research and Development Expenses
Research and development (R&D) expenses increased 9% and decreased 2% in the three months and nine months ended October 1, 2006, as compared to the same periods in 2005. The increase reflects increased operational activity, higher costs related to our AtS productivity initiative, expenses related to share-based payments and higher payments related to intellectual property rights, partially offset by savings related to our AtS productivity initiative. The decrease reflects savings related to our AtS productivity initiative and a R&D milestone due to us from sanofi-aventis (approximately $118 million, pre-tax, in the first quarter of 2006). R&D expense growth comparisons during the first half of 2006 were more favorable than in the second half of the year, since savings from our AtS productivity initiative began to be realized in the third quarter of 2005.
Merger-Related In-Process Research and Development Charges
The estimated fair value of ~~merger-related~~ Merger-related in-process research and development charges (IPR&D) is expensed at ~~the~~ acquisition date. ~~In 2005, we expensed $1.7 billion~~IPR&D of ~~IPR&D,~~$513 million, pre-tax, was recorded in the first nine months of 2006, primarily related to our acquisition of Rinat on May 16, 2006, as compared to $1.4 billion and $1.7 billion, pre-tax, recorded in the third quarter and first nine months of 2005, primarily related to our acquisition of Vicuron ~~Pharmaceuticals, Inc.~~ on September 14, 2005 ($1.4 billion) and our acquisition of Idun ~~Pharmaceuticals, Inc.~~ on April 12, 2005 ($250 million). ~~In 2004, we expensed $955 million of IPR&D, primarily related to our acquisition of Esperion Therapeutics, Inc. on February 10, 2004.~~
Adapting to Scale Initiative
~~We incurred the following costs in connection with our Adapting to Scale (AtS) initiative, which was announced in the second quarter of 2005:~~
(millions of dollars)
Three
Months
Ended
Oct. 2,
2005
Nine
Months
Ended
Oct. 2,
2005

Implementation costs^(a)
$
104
$
136
Restructuring charges^(b)
153
174
Total AtS costs
$
257
$
310
^(a)
~~Included in~~ ~~Cost of sales~~ ~~($36 million),~~ ~~Selling, informational and administrative expenses~~ ~~($60 million), and~~ ~~Research and development~~~~expenses~~ ~~($8 million) for the three months ended October 2, 2005, and included in~~ ~~Cost of sales~~ ~~($37 million),~~ ~~Selling, informational and administrative expenses~~ ~~($81 million), and~~ ~~Research and development expenses~~ ~~($18 million) for the nine months ended October 2, 2005.~~
^(b)
~~Included in~~ ~~Restructuring charges and merger-related costs.~~
In connection with the AtS productivity initiative, which was launched in early 2005, Pfizer management has performed a comprehensive review of our processes, organizations, systems and decision-making procedures in a company-wide effort to improve performance and efficiency. WeWithout giving effect to any additional initiatives to transform our cost structure, we continue to expect the costs associated with this multi-year effort to continue through 2008 and to total approximately $4 billion to $5 billion, on a pre-tax basis. We now expect that cost savings from our AtS productivity initiative will be about $2.5 billion in 2006, substantially ahead of our original guidance of about $2 billion and, without giving effect to any additional initiatives to transform our cost structure, growing to about $4 billion annually upon completion in 2008, notwithstanding the planned divestiture of our Consumer Healthcare business and the expense reductions associated with that business. Savings realized during the third quarter and first nine months of 2006 total approximately $600 million and $1.8 billion. The actions associated with the AtS productivity initiative will include restructuring charges, such as asset impairments, exit costs and severance costs (including any related impacts to our benefit plans, including settlements and curtailments) and associated implementation costs, such as accelerated depreciation charges, primarily associated with plant network optimization efforts, and expenses associated with system and process standardization and the expansion of shared ~~services.~~services (see Notes to the Condensed Consolidated Financial Statements - Note 6, Adapting to Scale Productivity Initiative).
~~Through October 2, 2005,~~
We incurred the ~~restructuring charges primarily relate to employee termination~~following costs atin connection with our ~~manufacturing facilities in North America and the implementation costs primarily relate to system and process standardization and to expansion of shared services.~~
~~The components of restructuring costs associated with~~ AtS ~~follow:~~productivity initiative:
(millions of dollars)
Nine
Months
Ended
Oct. 2,
2005
Utilization
Through
Oct. 2,
2005
Accrual at
Oct. 2,
2005
^(a)
Employee termination costs
$
106
$
49
$
57
Asset impairments
62
62
--
Other
6
--
6

$
174
$
111
$
63
Three Months Ended
Nine Months Ended
(millions of dollars)
Oct. 1,
2006
Oct. 2,
2005
Oct. 1,
2006
Oct. 2,
2005

Implementation costs^(a)
$
182
$
100
$
547
$
133
Restructuring charges^(b)
245
151
801
172
Total AtS costs
$
427
$
251
$
1,348
$
305

^(a)
Included in Cost of sales ($50 million), Selling, informational and administrative expenses ($63 million), Research and developmentexpenses ($70 million) and in Other (income)/deductions - net ($1 million income) for the three months ended October 1, 2006 and included in Cost of sales ($278 million), Selling, informational and administrative expenses ($160 million), Research and developmentexpenses ($132 million) and in Other (income)/deductions - net ($23 million income) for the nine months ended October 1, 2006. Included in Cost of sales ($36 million), Selling, informational and administrative expenses ($56 million), and Research and developmentexpenses ($8 million) for the three months ended October 2, 2005 and included in Cost of sales ($37 million), Selling, informational and administrative expenses ($76 million), and Research and development expenses ($20 million) for the nine months ended October 2, 2005.
^(b)
Included in ~~Other current liabilities.~~Restructuring charges and merger-related costs.
~~During the three months ended October 2, 2005, we expensed $85 million for~~ ~~Employee termination costs~~~~, $62 million for~~ ~~Asset impairments~~ ~~and $6 million in~~ ~~Other~~~~. Through October 2, 2005,~~ ~~Employee termination~~ costs represent the approved reduction of the workforce by 922 employees, mainly in manufacturing, sales and research. We notified affected individuals and 903 employees were terminated as of October 2, 2005. ~~Employee termination costs~~ ~~are recorded as incurred and include accrued severance benefits, pension and postretirement benefits.~~ ~~Asset impairments~~ ~~primarily include charges to write down intangible assets, and property, plant and equipment.~~ ~~Other~~ ~~primarily includes costs to exit certain activities.~~
Merger-Related Costs
In connection with acquisitions, we typically restructure and integrate the operations of the acquired companies to eliminate duplicative facilities and reduce costs. In certain instances, legacy Pfizer operations may be impacted by restructuring actions.
We incurred the following merger-related ~~costs primarily in connection with our acquisition of Pharmacia Corporation (Pharmacia), which was completed on April 16, 2003:~~costs:
Three Months Ended
Nine Months Ended
Three Months Ended
Nine Months Ended
(millions of dollars)
(millions of dollars)
Oct. 2,
2005
Sept. 26,
2004
Oct. 2,
2005
Sept. 26,
2004
Oct. 1,
2006
Oct. 2,
2005
Oct. 1,
2006
Oct. 2,
2005

Integration costs^(a)
Integration costs^(a)
$
93
$
113
$
390
$
367
Integration costs^(a)
$
3
$
91
$
8
$
384
Restructuring costs^(a)
61
77
232
359
Restructuring charges
1
61
7
226
Total merger-related costs(a)
Total merger-related costs(a)
$
154
$
190
$
622
$
726
Total merger-related costs(a)
$
4
$
152
$
15
$
610

^(a)
Included in Restructuring charges and merger-related costs.

In connection with the acquisition of Pharmacia, Pfizer management approved plans to restructure and integrate the operations of both legacy Pfizer and legacy Pharmacia to combine operations, eliminate duplicative facilities and reduce costs. Total merger-related expenditures expected to be incurred during 2003 through 2005 to achieve anticipated synergies are about $5.1 billion, on a pre-tax basis, with $5.0 billion incurred through October 2, 2005. The restructuring of our operations as a result of our acquisition of Pharmacia includes consulting, systems integrations,
^(a)
Included in Restructuring charges and merger-related costs. Amounts in 2005 primarily relate to our acquisition of Pharmacia Corporation (Pharmacia), which was completed on April 16, 2003.
Restructuring charges included severance, costs of vacating duplicative facilities, contract termination and other exit costs.
Through April 15, 2004, we recorded restructuring costs associated with employee terminations and exiting certain activities of legacy Pharmacia as liabilities assumed in the purchase business combination and recorded an increase to goodwill. Changes to previous estimates of restructuring costs included as part of the purchase allocation of Pharmacia are recorded as a reduction to goodwill or an expense to operations, as appropriate. Restructuring costs incurred for legacy Pfizer and restructuring costs incurred after April 15, 2004 for legacy Pharmacia are charged to the results of operations.
~~The components of merger-related restructuring costs associated with legacy Pfizer and legacy Pharmacia follow:~~
(millions of dollars)
Total
Utilization
Through
Oct. 2,
2005
^(a)
Accrual at
Oct. 2,
2005
^(b)

Costs capitalized through April 15, 2004:
Employee termination costs
$
1,535
$
1,502
$
33
Other
624
517
107
$
2,159
$
2,019
$
140
Costs expensed:
Employee termination costs
$
590
$
508
$
82
Asset impairments
421
421
--
Other
96
74
22

$
1,107
$
1,003
$
104
^(a)
~~Includes insignificant adjustments to original amounts established.~~
^(b)
~~Included in~~ ~~Other current liabilities.~~
~~During the three months ended October 2, 2005 and September 26, 2004, we expensed $1 million and $53 million for~~ ~~Employee termination costs~~~~, $53 million and $8 million for~~ ~~Asset impairment~~~~, and $7 million and $16 million in~~ ~~Other~~~~. During the first nine months of 2005 and 2004, we expensed $73 million and $201 million for~~ ~~Employee termination costs~~~~, $131 million and $122 million for~~ ~~Asset impairment~~~~, and $22 million and $31 million in~~ ~~Other~~.~~Through October 2, 2005,~~ ~~Employee termination costs~~ represent the approved reduction of the legacy Pfizer and legacy Pharmacia work force by 17,086 employees, mainly in corporate, manufacturing, distribution, sales and research. We notified affected individuals and 16,385 employees were terminated as of October 2, 2005. ~~Employee termination costs~~ ~~are recorded as incurred and include accrued severance benefits and costs associated with change-in-control provisions of certain Pharmacia employment contracts.~~ ~~Asset impairments~~ ~~primarily include charges to write down property, plant and equipment.~~ ~~Other~~ ~~primarily includes costs to exit certain activities of legacy Pfizer and legacy Pharmacia.~~
Other (Income)/Deductions - Net
In the first nine months of 2005, we recorded impairment charges of $1.1 billion related to the developed technology rights for Bextra ~~a selective COX-2 inhibitor,~~ and $7 million related to the write-off of machinery and equipment, ~~(see Note 2,~~ ~~Asset Impairment Charge and Other Costs Associated with the Suspension of Bextra Sales~~), both of which are included in Other (income)/deductions - ~~net~~.
~~In addition, in connection with the suspension of Bextra sales, we recorded $56 million in write-offs of inventory and exit costs, included in~~ ~~Cost of sales~~~~; $8 million related to the costs of administering the suspension of sales, included in~~ ~~Selling, informational and administrative expenses;~~ ~~and $212 million for an estimate of customer returns, primarily included against~~ ~~Revenues.~~net. Substantially all of these charges were recorded in the first quarter of 2005.
In the third quarter of 2004, Pfizer recorded a litigation-related charge of $369 million related to the resolution of claims against Quigley Company, Inc., a wholly owned subsidiary of Pfizer, which is included in ~~Other (income)/deductions - net~~.
PROVISION FOR TAXES ON INCOME
In the ~~first nine months~~third quarter of ~~2005,~~2006, we recorded ~~an income~~a decrease to the 2005 estimated U.S. tax ~~charge of $1.7 billion, included in~~ ~~Provision for taxes on income~~~~, in connection with our decision~~provision related to ~~repatriate about $36.7 billion~~the repatriation of foreign earnings, due primarily to the receipt of information that raised our assessment of the likelihood of prevailing on the technical merits of a certain position and we recognized a tax benefit of $124 million.
On January 25, 2006, the Company was notified by the Internal Revenue Service (IRS) Appeals Division that a resolution had been reached on the matter that we were in ~~accordance with~~ the ~~American Jobs Creation Act~~process of ~~2004~~ ~~(the Jobs Act).~~appealing related to the tax deductibility of a breakup fee paid by the Warner-Lambert Company in 2000. As a result, in the first quarter of 2006 we recorded a tax benefit of approximately $441 million related to the resolution of this issue.
On January 23, 2006, the IRS issued final regulations on Statutory Mergers and Consolidations, which impacted certain prior-period transactions. In the first quarter of ~~2005,~~2006, we recorded ~~an initial estimated income~~a tax ~~charge~~benefit of ~~$2.2 billion based on~~$217 million, reflecting the ~~decision to repatriate $28.3 billion~~total impact of foreign earnings. In the second quarter of 2005, we reduced our original estimate of the tax charge by $863 million and revised the repatriation of foreign earnings to $28.1 billion, principally as a result of guidance issued by the U.S. Treasury in May 2005. In the second quarter of 2005, we also recorded an additional tax charge of $373 million, primarily due to our decision to repatriate an additional $8.6 billion of foreign earnings.these regulations.
In the second quarter of 2005, we recorded a tax benefit of $586 million primarily related to the resolution of certain tax positions.
Our effective tax rate for continuing operations was ~~34.4%~~15.6% for the first nine months of ~~2005~~2006 compared to ~~19.4%~~34.5% in the same period in ~~2004.~~2005. The ~~increase~~lower tax rate for the first nine months of 2006 is primarily due to tax benefits related to the resolution of a tax matter, the change in tax regulations and a decrease in the ~~effective~~2005 estimated U.S. tax provision related to the repatriation of foreign earnings, as discussed above. The higher tax rate for the first nine months of 2005 is primarily due to the ~~previously mentioned tax~~recording of a $1.7 billion charge ~~associated with~~related to our decision to repatriate certain foreign earnings under the ~~repatriation~~American Jobs Creation Act of ~~foreign earnings~~2004 (the Jobs Act) and a $1.7 billion non-deductible charge for IPR&D, primarily relating to our acquisition of Vicuron ~~Pharmaceuticals, Inc.~~ and Idun, ~~Pharmaceuticals, Inc.,~~ partially offset by the tax benefit of $586 million primarily related to the resolution of certain tax positions. (See Notes to Condensed Consolidated Financial Statements--Note 8, Taxes on Income.)
DISCONTINUED OPERATIONS - NET OF TAX
In June 2006, we entered into an agreement to sell our Consumer Healthcare business and this business has been presented as a discontinued operation. Income ~~taxes in~~from discontinued operations, net of tax, increased 12% and 10% for the ~~first~~three months and nine months ~~of 2004 were impacted~~ended October 1, 2006, as compared to the same periods in 2005. The increase in both periods reflects higher net sales from our Consumer Healthcare business, offset by ~~a $955 million non-deductible charge for IPR&D, primarily relating~~higher costs and expenses related to that business, and also reflects losses in 2005 from our ~~acquisition of Esperion.~~
As of October 2, 2005, we intend to continue to permanently reinvest the earnings of our international subsidiaries and, therefore, we have not recorded a U.S. tax provision on the remaining amount of unremitted earnings.other discontinued businesses.
ADJUSTED INCOME
General Description of Adjusted Income Measure
Adjusted income is an alternative view of performance used by management and we believe that investors' understanding of our performance is enhanced by disclosing this performance measure. The Company reports Adjusted income in order to portray the results of our major operations--the discovery, development, manufacture, marketing and sale of prescription medicines for humans and ~~animals, as well as our over-the-counter products--prior~~animals--prior to considering certain income statement elements. We have defined Adjusted income as Net income before ~~discontinued operations,~~ significant impact of purchase accounting for acquisitions, merger-related costs, discontinued operations and certain significant items. The Adjusted income measure is not, and should not be viewed as, a substitute for U.S. GAAP Net income.
The Adjusted income measure is an important internal measurement for Pfizer. We measure the performance of the overall Company on this basis. The following are examples of how the Adjusted income measure is utilized.
•
Senior management receives a monthly analysis of the operating results of our Company that is prepared on an Adjusted income basis;

•
The annual budgets of our Company are prepared on an Adjusted income basis; and

•
Annual and long-term compensation, including annual cash bonuses, merit-based salary adjustments and stock options, for various levels of management, is based on financial measures that include Adjusted income. The Adjusted income measure currently represents a significant portion of target objectives that are utilized to determine the annual compensation for various levels of management, although the actual weighting of the objective may vary by level of management and job responsibility and may be considered in the determination of certain long-term compensation plans. The portion of senior management's bonus, merit-based salary increase and stock option awards based on the Adjusted income measure ranges from 10% to 30%.
Despite the importance of this measure to management in goal setting and performance measurement, we stress that Adjusted income is a non-GAAP financial measure that has no standardized meaning prescribed by U.S. GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted income (unlike U.S. GAAP Net income) may not be comparable with the calculation of similar measures for other companies. Adjusted income is presented solely to permit investors to more fully understand how management assesses the performance of our Company.
We also recognize that, as an internal measure of performance, the Adjusted income measure has limitations and we do not restrict our performance-management process solely to this metric. A limitation of the Adjusted income measure is that it provides a view of our Company's operations without including all events during a period such as the effects of an acquisition, merger-related costs or amortization of purchased intangibles and does not provide a comparable view of our performance to other companies in the pharmaceutical industry. We also use other specifically tailored tools designed to ensure the highest levels of performance in our Company. For example, our R&D organization has productivity targets, upon which its effectiveness is measured. In addition, for senior levels of management, a portion of their long-term compensation is based on U.S. GAAP Net income.
Purchase Accounting Adjustments
Adjusted income is calculated prior to considering certain significant purchase-accounting impacts, such as those related to our acquisitions of Pharmacia, Rinat, Vicuron, Idun, and ~~Esperion~~sanofi-aventis' rights to Exubera, as well as ~~net-asset~~net asset acquisitions. These impacts can include charges for purchased in-process ~~research and development,~~R&D, the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value and the incremental charges related to the amortization of finite-lived intangible assets for the increase to fair value. Therefore, the Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the aforementioned significant charges.
Certain of the purchase-accounting adjustments associated with a business combination, such as the amortization of intangibles acquired in connection with our acquisition of Pharmacia, can occur for up to 40 years (these assets have a weighted-average useful life of approximately 10nine years), but this presentation provides an alternative view of our performance that is used by management to internally assess business performance. We believe the elimination of amortization attributable to acquired intangible assets provides management and investors an alternative view of our business results by trying to provide a degree of parity to internally developed intangible assets for which research and development costs have been previously expensed.
However, a completely accurate comparison of internally developed intangible assets and acquired intangible assets cannot be achieved through Adjusted income. This component of Adjusted income is derived solely with the impacts of the items listed in the first paragraph of this section. We have not factored in the impacts of any other differences in experience that might have occurred if Pfizer had discovered and developed those intangible assets on its own and this approach does not intend to be representative of the results that would have occurred in those circumstances. For example, our research and development costs in total, and in the periods presented, may have been different; our speed to commercialization and resulting sales, if any, may have been different; or our costs to manufacture may have been different. In addition, our marketing efforts may have been received differently by our customers. As such, in total, there can be no assurance that our Adjusted income amounts would have been the same as presented had Pfizer discovered and developed the acquired intangible assets.
Merger-Related Costs
Adjusted income is calculated prior to considering integration and restructuring costs associated with business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate ~~two~~ businesses as a result of the acquisition decision. For additional clarity, only restructuring and integration activities that are associated with a purchase business combination or a net-asset acquisition are included in merger-related costs. We have not factored in the impacts onof synergies that would have resulted had these costs not been incurred.
We believe that viewing income prior to considering these charges provides investors with a useful additional perspective because the significant costs incurred in a business combination result primarily from the need to eliminate duplicate assets, activities or employees--a natural result of acquiring a fully integrated set of activities. For this reason, we believe that the costs incurred to convert disparate systems, to close duplicative facilities or to eliminate duplicate positions (for example, in the context of a business combination) can be viewed differently from those costs incurred in other, more normal business contexts.
The integration and restructuring costs associated with a business combination may occur over several years with the more significant impacts ending within three years of the transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activities can be lengthy. For example, due to the highly regulated nature of the pharmaceutical business, the closure of excess facilities can take several years as all manufacturing changes are subject to extensive validation and testing and must be approved by the FDA. In other situations, we may be required by local laws to obtain approvals prior to terminating certain employees. This approval process can delay the termination action.
Discontinued Operations
Adjusted income is calculated prior to considering the results of operations included in discontinued operations, such as our Consumer Healthcare business which we have agreed to sell, as well as any related gains or losses on the sale of ~~businesses and product lines included in discontinued operations as well as the related results of~~such operations. We believe that this presentation is meaningful to investors because, while we review our businesses and product lines ~~on an ongoing basis~~periodically for strategic fit with our operations, we do not build or run our businesses with an intent to sell them.
Certain Significant Items
Adjusted income is calculated prior to considering certain significant items. Certain significant items represent substantive, unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be a major non-acquisition-related restructuring charge and associated implementation costs for a program which is specific in nature with a defined term, such as those related to our ~~Adapting to Scale~~AtS productivity initiative; costs associated with a significant recall of one of our products; charges related to sales or disposals of products or facilities that do not qualify as discontinued operations as defined by U.S. GAAP; certain intangible asset impairments; adjustments related to the resolution of certain tax positions; the impact of adopting certain significant, event-driven tax legislation, such as charges attributable to the repatriation of foreign earnings in accordance with the Jobs Act; or possible charges related to legal matters, such as certain of those discussed in Legal Proceedings in our Form 10-K and in Part II: Other Information; Item 1, Legal Proceedings included in our Form 10-Q filings. Normal, ongoing defense costs of the Company or settlements and accruals on legal matters made in the normal course of our business would not be considered a certain significant item.
Reconciliation
A reconciliation between Net income, as reported under U.S. GAAP, and Adjusted income follows:
Third Quarter
First Nine Months
Three Months Ended
Nine Months Ended
(millions of dollars)
2005
2004
% Incr./
(Decr.)
2005
2004
% Incr./
(Decr.)
Oct. 1,
2006
Oct. 2,
2005
% Incr./
(Decr.)

Oct. 1,
2006
Oct. 2,
2005
% Incr./
(Decr.)

Reported Net income
$
1,589
$
3,341
(52)%
$
5,352
$
8,536
(37)%
Reported net income
$
3,362
$
1,589
112 %
$
9,888
$
5,352
85 %
Purchase accounting adjustments - net of tax
1,963
521
276
3,401
2,558
33
566
1,962
(71)
2,232
3,398
(34)
Merger-related costs - net of tax
67
112
(40)
397
463
(14)
4
65
(95)
9
385
(98)
Discontinued operations - net of tax
13
(43)
*
(7)
(75)
(91)
(123)
(110)
11
(353)
(343)
3
Certain significant items - net of tax
179
229
(22)
2,092
269
678
113
172
(35)
159
2,085
(92)
Adjusted income
$
3,811
$
4,160
(8)
$
11,235
$
11,751
(4)
$
3,922
$
3,678
7
$
11,935
$
10,877
10

*
~~Calculation not meaningful.~~
Certain amounts and percentages may reflect rounding adjustments.
Adjusted income as shown above excludes the following items:
Third Quarter
First Nine Months
Three Months Ended
Nine Months Ended
(millions of dollars)
2005
2004
2005
2004
Oct. 1,
2006
Oct. 2,
2005

Oct. 1,
2006
Oct. 2,
2005

Purchase accounting adjustments, pre-tax:
In-process research and development charges^(a)
$
1,390
$
--
$
1,652
$
955
$
--
$
1,390
$
513
$
1,652
Intangible amortization and other^(b)
811
827
2,494
2,450
803
808
2,414
2,487
Total purchase accounting adjustments, pre-tax
2,201
827
4,146
3,405
803
2,198
2,927
4,139
Income taxes
(238)
(306)
(745)
(847)
(237)
(236)
(695)
(741)
Total purchase accounting adjustments - net of tax
1,963
521
3,401
2,558
566
1,962
2,232
3,398
Merger-related costs, pre-tax:
Integration costs^(c)
93
113
390
367
3
91
8
384
Restructuring costs^(c)
61
77
232
359
Restructuring charges^(c)
1
61
7
226
Total merger-related costs, pre-tax
154
190
622
726
4
152
15
610
Income taxes
(87)
(78)
(225)
(263)
--
(87)
(6)
(225)
Total merger-related costs - net of tax
67
112
397
463
4
65
9
385
Discontinued operations, pre-tax:
Loss/(income) from discontinued operations^(d)
10
3
44
(42)
Income from discontinued operations^(d)
(178)
(174)
(493)
(465)
Gains on sales of discontinued operations^(d)
(7)
(65)
(72)
(68)
(6)
(7)
(37)
(72)
Total discontinued operations, pre-tax
3
(62)
(28)
(110)
(184)
(181)
(530)
(537)
Income taxes
10
19
21
35
61
71
177
194
Total discontinued operations - net of tax
13
(43)
(7)
(75)
(123)
(110)
(353)
(343)
Certain significant items, pre-tax
Asset impairment charges and other costs associated with the suspension of selling Bextra^(e)
3
--
1,216
--
Litigation-related charge^(f)
--
369
--
369
Operating results of divested legacy Pharmacia research facility^(g)
--
--
--
64
Restructuring charges--Adapting to Scale^(c)
153
--
174
--
Implementation costs--Adapting to Scale^(h)
104
--
136
--
Asset impairment charges ^(e)
--
3
--
1,216
Sanofi-aventis research and development milestone^(f)
--
--
(118)
--
Restructuring charges - Adapting to Scale^(c)
245
151
801
172
Implementation costs - Adapting to Scale^(g)
182
100
547
133
Gain on disposals of investments and other^(h)
(86)
--
(160)
--
Total certain significant items, pre-tax
260
369
1,526
433
341
254
1,070
1,521
Income taxes
(81)
(140)
(547)
(164)
(104)
(82)
(346)
(549)
Resolution of certain tax positions⁽ⁱ⁾
--
--
(586)
--
--
--
(441)
(586)
Tax impact of the repatriation of foreign earnings⁽ⁱ⁾
--
--
1,699
--
(124)
--
(124)
1,699
Total certain significant items - net of tax
179
229
2,092
269
113
172
159
2,085
Total purchase accounting adjustments, merger-related costs, discontinued operations and certain significant items - net of tax

$
2,222
$
819
$
5,883
$
3,215

$
560
$
2,089
$
2,047
$
5,525

^(a)
Included in Merger-related in-process research and development charges.
^(b)
Included primarily in Amortization of intangible assets.
^(c)
Included in Restructuring charges and merger-related costs.
^(d)
~~Included in~~ Discontinued operations - net of ~~tax.~~tax includes $124 million and $123 million related to the Consumer Healthcare business for the three months ended October 1, 2006 and October 2, 2005 and $335 million and $336 million for the nine months ended October 1, 2006 and October 2, 2005. These amounts do not include a prospective gain on the planned divestiture.
^(e)
Included in Selling, informational and administrative expenses ($3 million) for the three months ended October 2, 2005, and included in Cost of sales ($56 million), Selling informational and administrative expenses ($8 million) andOther (income)/deductions - net($ ($1.2 billion) for the nine months ended October 2, 2005.
^(f)
Included in Research and development expenses.~~Other (income)/deductions - net.~~
^(g)
Included in Cost of sales ($50 million), Selling, informational and administrative expenses ($63 million), Research and development ~~expenses.~~
^(h)
expenses ($70 million) and in Other (income)/deductions - net ($1 million income) for the three months ended October 1, 2006 and included in Cost of sales ($278 million), Selling, informational and administrative expenses ($160 million), Research and developmentexpenses ($132 million) and in Other (income)/deductions - net ($23 million income) for the nine months ended October 1, 2006. Included in Cost of sales ($36 million), Selling, informational and administrative expenses ($6056 million), and Research and development expenses ($8 million) for the three months ended October 2, 2005 and included in Cost of sales ($37 million), Selling, informational and administrative expenses~~($81~~ ($76 million), and Research and development expenses ($1820 million) for the nine months ended October 2, 2005.
^(h)
Included in Other (income)/deductions - net.
(i)
Included in Provision for taxes on income.
FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES
Net Financial ~~Asset Position~~Assets
Our net financial asset position follows:
(millions of dollars)
Oct. 2,
2005
Dec. 31,
2004
Oct. 1,
2006
Dec. 31,
2005

Financial assets:
Cash and cash equivalents
$
959
$
1,808
$
1,177
$
2,247
Short-term investments
12,430
18,085
11,654
19,979
Short-term loans
611
653
460
510
Long-term investments and loans
2,784
3,873
2,845
2,497
Total financial assets
16,784
24,419
16,136
25,233
Debt:
Short-term borrowings
6,729
11,266
2,508
11,589
Long-term debt
5,414
7,279
5,561
6,347
Total debt
12,143
18,545
8,069
17,936
Net financial assets
$
4,641
$
5,874
$
8,067
$
7,297
We rely largely on operating cash flow, short-term commercial paper borrowings and long-term debt to provide for the working capital needs of our operations, including our R&D activities. In addition, the proceeds from the repatriation of foreign earnings are being utilized to finance domestic activities over a multi-year time horizon, thereby reducing our reliance on domestic short-term borrowings. Our international borrowings will increase over the course of 2005 in order to fund the repatriation of foreign earnings. We believe that we have the ability to obtain both short-term and long-term debt to meet our financing needs for the foreseeable future.
~~Expected Impact of Repatriation of Foreign Earnings~~
Based on our decision to repatriate foreign earnings totaling about $36.7 billion in accordance with the Jobs Act, the use of proceeds includes domestic expenditures relating to advertising and marketing activities, research and development activities, capital assets and other asset acquisitions and non-executive compensation in accordance with the provisions of the Jobs Act (as in effect on October 2, 2005). As of October 2, 2005, we have completed the repatriation of approximately $23 billion. At October 2, 2005, our international subsidiaries held cash and cash equivalents and short-term investments totaling in excess of $3 billion. Additionally, our international subsidiaries are expected to generate cash flows during 2005, which, together with third-party borrowings as required, will be available to fund the balance of the repatriation.
Investments
Our short-term and long-term investments consist primarily of high-quality, liquid investment-grade available-for-sale debt securities. Wherever possible, cash management is centralized and intercompany financing is used to provide working capital to our operations. Where local restrictions prevent intercompany financing, working capital needs are met through operating cash flows and/or external borrowings. Our portfolio of short-term investments was reduced in the first nine months of 2006 and the proceeds were primarily used to pay down short-term borrowings.
Long-Term Debt ~~Capacity~~
~~Our short-term borrowings are rated P-1 by~~In May 2006, we decided to exercise Pfizer's option to call, at par-value plus accrued interest, $1 billion of senior unsecured floating-rate notes, which were included in Long-term debt as of December 31, 2005. Notice to call was given to the Trustees and the notes were redeemed in the third quarter of 2006.
On February 22, 2006, we issued the following Japanese yen fixed-rate bonds, to be used for general corporate purposes:
•
$508 million equivalent, senior unsecured notes, due February 2011, which pay interest semi-annually, beginning on August 22, 2006, at a rate of 1.2%; and
•
$466 million equivalent, senior unsecured notes, due February 2016, which pay interest semi-annually, beginning on August 22, 2006, at a rate of 1.8%.
The notes were issued under a $5 billion debt shelf registration filed with the SEC in November 2002. Such yen debt is designated as a hedge of our yen net investments.
Credit Ratings
Two major corporate debt-rating organizations, Moody's Investors ~~Service~~Services (Moody's) and ~~A-1+ by~~ Standard & Poor's (S&P)~~. Our~~, assign ratings to our short-term and long-term debt. The following chart reflects the current ratings assigned to the Company's senior unsecured non-credit enhanced long-term debt ~~is rated Aaa~~and commercial paper issued directly by ~~Moody's and AAA~~the Company or by ~~S&P. Moody's and S&P are major corporate debt-rating organizations.~~ affiliates with a guarantee from the Company by each of these agencies:
Long-Term-Debt
Name of Rating Agency
Commercial Paper
Rating
Outlook
Moody's
P-1
Aaa
Negative
S&P
A1+
AAA
Stable
In early April 2005, following the market withdrawal of Bextra and the FDA's decision requiring new labeling for Celebrex, Moody's placed our Aaa rating under review for possible downgrade. The review was completed in June 2005 when Moody's removed Pfizer from review status and reaffirmed our Aaa rating. However, Moody's maintained our rating outlook as negative. ~~S&P has~~Following our announcement in June 2006 of the agreement to sell our Consumer Healthcare business and our target to purchase up to $17 billion of Pfizer stock in 2006 and 2007, Moody's again reaffirmed our ~~AAA~~Aaa rating ~~and maintains~~with a negative outlook. The negative outlook reflects Moody's concern that disappointing product sales, potential setbacks in the development of key pipeline products, or a shift towards a more aggressive financial profile, including higher levels of acquisition activity, could result in Pfizer's financial metrics falling below those appropriate for a Aaa-rated company.
S&P views our rating outlook as ~~stable.~~stable, while they note a slowdown in sales and earnings growth as a result of major patent expirations and increased competition. S&P relies on Pfizer's excellent position in the worldwide pharmaceutical market, highlighted by our diverse drug portfolio and deep product pipeline, together with our superior financial profile and cash-generating ability.
Our superior credit ratings are primarily based on our diversified product portfolio, ~~our~~ strong operating cash flow, ~~our~~ substantial financial assets, ~~our~~ strong late-stage product pipeline and ~~on our~~ desire to maintain a prudent financial profile. Our access to financing at favorable rates would be affected by a substantial downgrade in our credit ratings.
Debt Capacity
We have available lines of credit and revolving-credit agreements with a group of banks and other financial intermediaries. We maintain cash balances and short-term investments in excess of our commercial paper and other short-term borrowings. At October ~~2, 2005,~~1, 2006, we had access to ~~$3.0~~$3.6 billion of lines of credit, of which ~~$1.1~~$1.2 billion expire within one year. Of these lines of credit, ~~$2.8~~$3.3 billion are unused, of which our lenders have committed to loan us ~~$1.7~~$2.1 billion at our request. ~~$1.5~~$2.0 billion of the unused lines of credit, ~~relate~~which expire in 2011, may be used to support our commercial paper borrowings.
AtAs of October ~~2, 2005,~~1, 2006, we had the ability to borrow approximately ~~$2.0~~$1 billion by issuing debt securities under our existing debt shelf registration statement filed with the SEC in November 2002.
~~Long-Term Debt~~
~~In July 2005, we decided to exercise Pfizer's option to call, at par-value plus accrued interest, $1 billion of senior unsecured floating-rate notes, which were included in~~ ~~Long-term debt~~ ~~at December 31, 2004. Notice to call was given to the Trustees and the notes were redeemed in September 2005.~~
Goodwill and Other Intangible Assets
At October ~~2, 2005,~~1, 2006, goodwill totaled ~~$23.8~~$21.1 billion ~~(21%~~(19% of our total assets) and other intangible assets, net of accumulated amortization, totaled ~~$29.0~~$25.3 billion ~~(26%~~(23% of our total assets). The largest components of goodwill and other intangible assets were acquired in connection with our acquisition of Pharmacia. ~~Other~~In the first quarter of 2006, we acquired the sanofi-aventis worldwide rights, including patent rights and production technology, to manufacture and sell Exubera. In connection with the acquisition, we recorded an intangible asset for developed technology rights of approximately $1.0 billion and goodwill of approximately $166 million. Finite-lived intangible assets, ~~included $23.0~~net, include $21.0 billion ofrelated to developed technology rights and ~~$3.9~~$802 million related to brands. Indefinite-lived intangible assets include $3.0 billion ~~of indefinite-lived~~related to brands.
The developed technology rights primarily represent the amortized acquisition-date fair value of the commercialized products that we acquired from Pharmacia. We acquired a well-diversified portfolio of developed technology rights across the therapeutic categories displayed in the table of major ~~Human Health~~Pharmaceutical products in the "Revenues" section of MD&A. While the Arthritis and Pain therapeutic category represents about ~~28%~~27% of the total value of developed technology rights at October ~~2, 2005,~~1, 2006, the balance of the value is evenly distributed across the following ~~Human Health~~Pharmaceutical therapeutic product categories: Ophthalmology; Oncology; Urology; Infectious and Respiratory Diseases; Endocrine Disorders categories; and, as a group, the Cardiovascular and Metabolic Diseases; Central Nervous System Disorders and All Other categories.
SELECTED MEASURES OF LIQUIDITY AND CAPITAL RESOURCES
The following table sets forth certain relevant measures of our liquidity and capital resources:

Oct. 2,
2005
Dec. 31,
2004

Cash and cash equivalents and short-term investments and loans (millions of dollars)
$
14,000
$
20,546

Working capital (millions of dollars)^(a)
$
12,373
$
13,236

Current ratio^(b)
1.61:1
1.50:1

Shareholders' equity per common share^(c)
$
9.11
$
9.19

^(a)
Working capital includes assets and liabilities held for sale at October 2, 2005 and December 31, 2004.
^(b)
Current ratio is the proportion of current assets to current liabilities.
^(c)
Represents total shareholders' equity divided by the actual number of common shares outstanding (which excludes treasury shares and those held by our employee benefit trust).
(millions of dollars, except ratios and per common share data)
Oct. 1,
2006
Dec. 31,
2005

Cash and cash equivalents and short-term investments and loans
$
13,291
$
22,736

Working capital^(a)
$
21,033
$
18,423

Ratio of current assets to current liabilities
2.19:1
1.65:1

Shareholders' equity per common share^(b)
$
9.70
$
8.98
^(a)
Working capital includes assets of discontinued operations and other assets held for sale of $6.8 billion and $6.7 billion and liabilities of discontinued operations and other liabilities held for sale of $1.4 billion and $1.2 billion, as of October 1, 2006 and December 31, 2005.
^(b)
Represents total shareholders' equity divided by the actual number of common shares outstanding (which excludes treasury shares and those held by our employee benefit trust).
The ~~decrease~~increase in working capital ~~from~~as of October 1, 2006 as compared to December 31, ~~2004 to October 2,~~ 2005 was primarily ~~reflects:~~due to:
•
~~payment~~the timing of ~~cash dividends on common and preferred stock, net~~dividend accruals of ~~dividends payable at December 31, 2004 -- $2.8~~$1.8 billion;

•
~~purchases~~an increase in inventories of $689 million, which is primarily due to the acquisition of sanofi-aventis' Exubera inventory, the build-up of inventory in advance of product launches and the impact of foreign exchange, partially offset by the impact of our ~~common stock -- $3.4 billion;~~inventory-reduction initiative;

•
~~net cash paid to acquire Vicuron Pharmaceuticals, Inc.~~the impact of a change in the mix of the U.S. sales rebate accrual of about $370 million; and ~~other smaller businesses -- $2.1 billion;~~

•
~~payment~~a general reduction in payables and accruals of ~~floating-rate notes --$1.0 billion;~~about $1.3 billion, primarily reflecting timing of payments and accruals;

partially offset by:
•
~~purchases~~the expected timing of ~~property, plant and equipment -- $1.5~~tax obligations of about $1.3 billion; and

•
~~purchases~~a decrease in net current financial assets of ~~other assets --$392~~$364 million primarily due to the redemption of short-term investments, partially offset by the pay down of short-term borrowings.
~~partially offset by:~~
~~cash from current-period operations.~~
Net Cash Provided by Operating Activities
During the first nine months of ~~2005,~~2006, net cash provided by ~~continuing~~ operating activities was ~~$10.0~~$13.1 billion, as compared to ~~$10.4~~$10.0 billion in the same period of ~~2004.~~2005. The ~~decrease~~increase in net cash provided by operating activities was primarily ~~driven by lower current period income from operations,~~attributable to:
•
higher tax payments in 2005 of $1.7 billion, primarily related to the repatriation of foreign earnings in 2005, and
•
higher current period net income, adjusted for non-cash items, reflecting, among other things, the timing of receipts and payments in the ordinary course of business.
The estimated net ~~of non-cash items, partially offset by the timing of receipts and payments in the ordinarily course of business. In the~~ cash flows ~~statement,~~ ~~Other~~ ~~includes adjustments for non-cash items such as valuation adjustments.~~provided by operating activities associated with discontinued operations were not significant.
Net Cash Provided ~~by/(Used in)~~by Investing Activities
During the first nine months of ~~2005,~~2006, net cash provided by investing activities was ~~$2.7~~$4.7 billion, as compared to ~~net cash used of $6.7~~$2.7 billion in the same period in ~~2004.~~2005. The ~~change from net cash used~~increase in ~~2004 to~~ net cash provided by investing activities was primarily attributable to:
•
higher net redemptions of investments in 2006 (a positive change in cash and cash equivalents of $1.9 billion); in 2006, the proceeds of which were utilized to repay debt and in 2005, the proceeds of which were used to fund the repatriation of foreign earnings as a result of the Jobs Act, and
•
the acquisition of Rinat and sanofi-aventis' rights to Exubera in 2006 compared to the acquisition of Vicuron and Idun in 2005 (a decreased use of cash of $115 million).
The estimated net cash flows used in investing activities associated with discontinued operations were not significant.
Net Cash Used in Financing Activities
During the first nine months of 2006, net cash used in financing activities was $18.8 billion, as compared to $13.5 billion in the same period in 2005. The increase in net cash used in financing activities was primarily attributable to:
•
net ~~redemptions~~repayments of $9.7 billion on total borrowings in 2006, compared to $6.3 billion ~~from investments~~ in 2005,
•
an increase in cash dividends paid of $1.0 billion in 2006 as compared to 2005, primarily ~~used~~due to ~~provide funds for~~an increase in the ~~repatriation~~dividend rate, and
•
higher purchases of ~~foreign earnings~~common stock in ~~accordance with the Jobs Act~~2006 of $4.5 billion as compared to ~~net purchases of $4.6~~$3.4 billion ~~of investments~~ in ~~2004,~~2005,

partially offset by:

•
higher proceeds from ~~sales~~the exercise of ~~businesses and product lines of $108 million in 2005 as compared to $1.2 billion in 2004; and~~
•
~~net cash used for acquisitions in 2005 of $2.1 billion as compared to $1.4 billion in 2004.~~stock options.
~~Net Cash Used~~
The estimated net cash flows used in ~~Financing Activities~~financing activities associated with discontinued operations were not significant.
In June 2005, we announced a $5 billion share-purchase program which is being funded by operating cash flows. During the first nine months of ~~2005, net cash used in financing activities was $13.5~~2006, we purchased approximately 172 million shares under that program for approximately $4.5 billion. In June 2006, the Board of Directors increased our share-purchase authorization from $5 billion ~~as compared~~ to ~~$3.3 billion in the same period in 2004. The increase in net cash used in financing activities in 2005 was primarily attributable to:~~$18 billion.
•
net repayments of $6.3 billion on total borrowings in 2005 (funds from the repatriation of foreign earnings were used to finance domestic activities, thereby reducing our reliance on short-term borrowings) as compared to total net borrowings of $4.4 billion in 2004,
•
~~an increase in cash dividends paid of $356 million as compared to the first nine months of 2004 due to an increase in the dividend rate and~~
•
~~a decrease of $568 million in the proceeds from the exercise of stock options,~~
~~partially offset by:~~
•
~~a decrease of $1.4 billion in purchases of our common stock in 2005 as compared to the same period in 2004.~~
In October 2004, we announced a $5 billion share-purchase ~~program. We~~program, which we completed ~~this share-purchase program by purchasing approximately $2.4 billion of the Company's stock~~ in the second quarter of ~~2005.~~2005 and was funded from operating cash flows. In ~~June 2005, Pfizer's Board of Directors authorized a new $5 billion share-purchase program. During~~total, under the ~~third quarter of 2005,~~October 2004 program, we purchased approximately ~~4.3~~185 million shares of common stock at a cost of approximately $111 million under the new program. The Company has purchased nearly 126 million shares of common stock, at a cost of approximately $3.4 billion, during 2005. We remain committed to completing this newly authorized $5 billion share-purchase program.shares.
OFF-BALANCE SHEET ARRANGEMENTS
In the ordinary course of business and in connection with the sale of assets and businesses, we often indemnify our counterparties against certain liabilities that may arise in connection with a transaction or related to activities prior to a transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters, and patent infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not ~~generally~~ paid significant amounts under these provisions and atas of October ~~2, 2005,~~1, 2006, recorded amounts for the estimated fair value of these indemnifications are not ~~material.~~significant.
Certain of our ~~copromotion~~co-promotion or license agreements ~~include additional provisions that~~ give our ~~alliance~~licensors or partners the ~~right~~rights to negotiate for, or in some cases to obtain, under certain financial conditions, ~~copromotion~~co-promotion or other rights in specified countries with respect to certain of our products.
RECENTLY ~~ISSUED~~ADOPTED ACCOUNTING STANDARDS
~~Share-Based Payment~~
~~In December 2004,~~On January 1, 2006, we adopted the ~~Financial Accounting Standards Board (FASB) issued~~provisions of Statement of Financial Accounting Standards (SFAS) No. 123R, Share-Based Payment,~~. SFAS~~as supplemented by the guidance provided by SEC Staff Accounting Bulletin No.107, issued in March 2005. (SFAS 123R replaces SFAS 123,Stock-Based Compensation, issued in 1995.) (See Notes to Condensed Consolidated Financial Statements - Note 4, Adoption of New Accounting Standards, and Note 14, Share-Based Payments.)
RECENTLY ISSUED ACCOUNTING STANDARDS
In September 2006, the FASB issued SFAS No. 158, Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans (an amendment of FASB Statements No. 87, 88, 106, and 132R). SFAS ~~123R~~158 requires an employer to recognize the funded status of its defined benefit pension and postretirement plans on its statement of financial position and to recognize as a component of other comprehensive income, net of taxes, the gains or losses and prior service credits that arise during the ~~fair value~~period but are not recognized as components of net periodic benefit costs. Upon initial adoption, SFAS 158 requires the ~~grant~~recognition of ~~employee stock options be reported as an expense. We plan to adopt SFAS 123R, when required, beginning in the first quarter~~previously unrecognized actuarial gains and losses, prior service costs or credits and net transition amounts within Accumulated other comprehensive income, net of ~~2006. (We had previously disclosed an intention to adopt, when required, in mid-2005, but the SEC delayed the required effective date). Determining the impact~~tax. The provisions of SFAS 123R on our future results of operations requires a number of complex estimates about future events. For example, such an assessment would require a prediction about the number of options to be granted, primarily in February of next year, and a forecast,158 are effective as of the ~~grant date,~~end of fiscal year 2006. Based on current information, we estimate that the adoption of SFAS 158 will have the effect of decreasing our ~~stock price,~~Total Assets by approximately $2.0 billion, increasing our Total liabilities by approximately $2.5 billion and reducing our Total shareholders' equity by approximately $4.5 billion, all on a pre-tax basis. We expect the ~~market-based stock price volatility and the risk-free interest rate, all of which can be highly variable and difficult to predict. As such, currently, we cannot reasonably estimate the~~net deferred tax impact of ~~SFAS 123R on our results of operations in 2006.~~these adjustments to approximate 37%.
~~Conditional Asset Retirement Obligations~~
In ~~March 2005,~~June 2006, the FASB issued Interpretation No. ~~47,~~48 (FIN 48), Accounting for ~~Conditional Asset Retirement Obligations~~Uncertainty in Income Taxes ~~(FIN 47)~~, an interpretation of SFAS 109, Accounting for Income Taxes. FIN ~~47 clarifies~~48 provides guidance relative to the recognition, derecognition and measurement of tax positions for financial statement purposes. Historically, our policy has been to account for uncertainty in income taxes based on whether we determined that ~~conditional obligations meet~~our tax position is "probable" of being sustained. FIN 48 requires the accounting be determined based on if it is "more likely than not" that a tax position will be sustained -- a lower level of certainty. Upon adoption of FIN 48, any gains or losses would be recorded as an adjustment to the opening balance of retained earnings. We are currently in the process of evaluating the impact on the financial statements of adopting FIN 48. We expect to adopt the standard when required in 2007.
In September 2006, the FASB issued SFAS No. 157 Fair Value Measurements. SFAS 157 provides guidance for, among other things, the definition of ~~an asset retirement obligation in SFAS 143,~~ ~~Accounting for Asset Retirement Obligations~~~~, and therefore should be recognized if their~~ fair value ~~is reasonably estimable.~~and the methods used to measure fair value. The provisions of SFAS 157 are effective for fiscal years beginning after November 15, 2007. We ~~plan to adopt FIN 47~~are currently in the ~~fourth quarter~~process of ~~2005. We do not expect~~evaluating the ~~provisions~~impact of ~~FIN 47 to have a material impact~~adopting SFAS 157 on our ~~consolidated~~ financial statements.
OUTLOOK
Results in ~~2005~~2006 have been, and results over the next few years will continue to be, impacted by the loss of U.S. exclusivity of ~~four major products--Diflucan, Neurontin, and Accupril/Accuretic during 2004 and Zithromax in November 2005. Revenues~~certain key products since the beginning of 2004. Results also have been, and may continue to be, impacted by ~~publicity and regulatory actions regarding selective COX-2 inhibitors, as well as lower prescription growth and~~ increased competition in key ~~markets~~markets. In addition, we have recently seen a variability of the U.S. dollar relative to other currencies and restrictive actions on access and pricing taken by influential decision makers in several large European markets. As a result of these near-term challenges, at current exchange rates, we are now expecting revenues in 2007 and 2008 to be comparable to 2006, as compared to our previous forecast of modest revenue growth over the period.
The growth of four products--Lipitor, Celebrex, Lyrica and Geodon--is contributing significantly to our 2006 revenues. At current exchange rates, we are committed to achieving our full-year 2006 revenue targets for these four products and continue to expect 2006 aggregate revenues to be comparable to overall revenues in 2005. At current exchange rates we target Lipitor sales of about $13 billion; Celebrex revenues of about $2 billion; Geodon revenues of about $800 million; and Lyrica revenues of more than $1 billion in 2006.
We continue to forecast 2006 adjusted diluted EPS of about $2.00. Reported diluted EPS for 2006 is now forecast at about $1.63, reflecting the impact of an equity sale in the ~~U.S., such~~third quarter as well as a decrease of the ~~lipid-lowering market~~estimated 2005 U.S. tax provision related to the repatriation of foreign earnings as discussed in the "Provision for Taxes on Income" section. We expect the cost of sales pre-tax component of adjusted income as a percentage of revenues to remain under pressure in the fourth quarter of 2006 and we now expect the ~~erectile-dysfunction market. Full-year~~cost of sales pre-tax component of adjusted income as a percentage of revenues ~~are expected~~this year to ~~evidence a modest decline relative~~be comparable to ~~2004, although a somewhat larger decline than previously anticipated, reflecting lower Human Health revenues.~~2005. We continue to expect the SI&A pre-tax component of adjusted income to be about $15.4 billion in 2006. We now expect the R&D pre-tax component of adjusted income to be about $7.4 billion. We continue to expect our cash flow from operations to exceed $16 billion in 2006.
~~In 2005, we anticipate Pharmacia merger-related synergies~~We now expect AtS-related cost savings in excess of ~~approximately $4.2~~$2.5 billion in 2006, an increase of ~~$600 million~~at least $1.7 billion over ~~2004 synergies. We also expect to achieve approximately $600 million in cost savings from our AtS productivityinitiative during~~ 2005 ~~greater than previously forecasted, mainly attributable to the Human Health business.~~savings.
Given these and other factors, a reconciliation, at current exchange rates ~~we expect 2005~~and reflecting management's current assessment for 2006, of forecasted 2006 Adjusted income ~~of $14.2 to $14.4 billion,~~and Adjusted diluted EPS ~~of $1.92~~ to ~~$1.94,~~forecasted 2006 reported Net income ~~of $7.5 to $7.7 billion,~~ and reported diluted EPS ~~of $1.02 to $1.04,~~follows:
($ billions, except per-share amounts)
Net Income^(a)
Diluted EPS^(a)

Forecasted Adjusted income/diluted EPS
~$14.7
~$2.00
Purchase accounting impacts, net of tax
(2.9)
(0.39)
Adapting to scale costs, net of tax
(1.1)
(0.15)
Income from discontinued operations, net of tax^(b)
0.5
0.07
Equity sales/other
0.2
0.02
Tax impact of the repatriation of foreign earnings
0.2
0.02
Resolution of certain tax positions
0.4
0.06
Forecasted reported Net income/diluted EPS
~$12.0
~$1.63
^(a)
Includes the Consumer Healthcare business as discontinued operations and excludes the effects of other business-development transactions not completed as of the endof the third quarter of 2006 and the potential impact from a substantial prospective gain on the divestiture of our Consumer Healthcare business.
^(b)
Primarily reflects the reclassification of our Consumer Healthcare business to discontinued operations.
Our forecasted financial performance is subject to a number of factors and uncertainties--as described in the ~~"Cautionary~~"Forward Looking Information and Factors That May Affect Future Results" section below. The forecasted Adjusted income and diluted EPS ranges, as well as the forecasted reported Net income and diluted EPS ranges, are subject to a number of factors and uncertainties--changes in prescription growth rates and increased competition in key therapeutic markets and geographies; Adapting to Scale restructuring activities; the timing and rate of commercial acceptance of new-product launches; changes in the geographic, product, and segment mix of our revenues and income; changes in foreign exchange; the timing of regulatory actions; and other factors. Some of these factors and uncertainties may persist over ~~the~~our planning horizon. ~~We are currently assessing these factors and other variables as part of our annual planning process and have withdrawn our previously provided financial guidance for 2006 and 2007.~~
~~A reconciliation of forecasted 2005 Adjusted income and Adjusted diluted EPS to forecasted 2005 reported Net income and reported diluted EPS follows:~~
($ billions, except per-share amounts)
Net Income
Diluted EPS

Forecasted Adjusted income/diluted EPS
$14.2 - $14.4
$1.92 - $1.94
Intangible amortization and other
(2.3)
(.32)
In-process R&D charges (primarily Vicuron & Idun)
(1.7)
(.22)
Merger-related costs/productivity-initiative costs
(.9)
(.13)
Equity gains
.1
.02
Asset-impairment charges and other costs associated with the suspension of selling Bextra
(.8)
(.10)
Tax impact on repatriation of foreign earnings
(1.7)
(.23)
Resolution of certain tax positions
.6
.08
Forecasted reported Net income/diluted EPS
$  7.5 - $  7.7
$1.02 - $1.04
Pfizer's estimates of 2005 reported Net income of approximately $7.5 billion to $7.7 billion and reported diluted earnings per share of approximately $1.02 to $1.04, have been revised from the prior guidance of $9.1 billion and about $1.24. The revision is principally attributable to in-process R&D charges of $1.4 billion ($0.19 per share) related to the acquisition of Vicuron during the third quarter of 2005 and revised expectations (reflective of a lower revenue outlook, partially offset by greater expected savings associated with the Adapting to Scale productivity initiative and other expense revisions, and a lower effective tax rate), partially offset by anticipated gains on the sale of equity investments.
~~We expect to spend about $7.6 billion on research and development in 2005 and approximately $2.2 billion in capital expenditures for the full year 2005.~~
~~CAUTIONARY~~FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS
Our disclosure and analysis in this report, including but not limited to the information discussed in the Outlook section above, contain forward-looking information about our Company's financial results and estimates, business prospects, in-line products and ~~products in research~~product candidates that involve substantial risks and ~~uncertainties.~~uncertainties, including, without limitation, information about the Company's agreement to sell its Consumer Healthcare business to Johnson & Johnson, as well as about the Company's stock-purchase plans. From time to time, we also may provide oral or written forward-looking statements in other materials we release to the public. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historic or current facts. They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "target," "forecast" and other words and terms of similar meaning in connection with any discussion of future operating or financial ~~performance.~~performance or business prospects. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, and financial results. Among the factors that could cause actual results to differ materially are the following:
•
the success of research and development activities;

•
decisions by regulatory authorities regarding whether and when to approve our drug applications as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of our products;

•
the speed with which regulatory authorizations, pricing approvals, and product launches may be achieved;

•
competitive developments affecting our current growth products;

•
the ability to successfully market both new and existing products domestically and internationally;

•
difficulties or delays in manufacturing;

•
trade buying patterns;

•
the ability to meet generic and branded competition after the loss of patent protection for our products and competitor products;

•
the impact of existing and future regulatory provisions on product exclusivity;

•
trends toward managed care and healthcare cost containment;

•
possible U.S. legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare, the importation of prescription drugs that are marketed outside the U.S. and sold at prices that are regulated by governments of various foreign countries, and the involuntary approval of prescription medicines for over-the-counter use;

•
the potential impact of the Medicare Prescription Drug, Improvement and Modernization Act of 2003;

•
legislation or regulations in markets outside the U.S. affecting product pricing, reimbursement or access;

•
contingencies related to actual or alleged environmental contamination;

•
claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates;

•
legal defense costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent protection, governmental investigations, ongoing efforts to explore various means for resolving asbestos litigation and other legal proceedings;

•
the Company's ability to protect its patents and other intellectual property both domestically and internationally;

•
interest rate and ~~foreign currency exchange rate~~foreign-currency exchange-rate fluctuations;

•
governmental laws and regulations affecting domestic and foreign operations, including tax obligations;

•
changes in U.S. generally accepted accounting principles;

•
any changes in business, political and economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas;

•
growth in costs and expenses;

•
changes in our product, segment and geographic mix; and

•
the impact of acquisitions, divestitures, restructurings, product withdrawals and other unusual items, including our ability to ~~integrate and to obtain the anticipated results and synergies from our acquisition of Pharmacia, and our ability to~~ realize the projected benefits of our Adapting to Scale multi-year productivity ~~initiative.~~initiative, including the benefits of the planned broadening of this initiative in 2007 and 2008, and the ability of the Company and Johnson & Johnson to satisfy the conditions to closing the sale of the Company's Consumer Healthcare business, including receiving the required regulatory approvals.
We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could ~~vary~~differ materially from past results and those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements.
We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Forms 10-Q, 8-K and 10-K reports to the Securities and Exchange Commission. Our Form 10-K filing for the ~~2004~~2005 fiscal year listed various important factors that could cause actual results to differ materially from expected and historic results. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. Readers can find them in Part I, Item 11A, of that filing under the heading ~~"Cautionary~~"Risk Factors and Cautionary Factors That May Affect Future Results." We incorporate that section of that Form 10-K in this filing and investors should refer to it. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.
This report includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data.
Legal Proceedings and Contingencies
We and certain of our subsidiaries are involved in various patent, product liability, consumer, commercial, securities, environmental and tax litigations and claims; government investigations; and other legal proceedings that arise from time to time in the ordinary course of our business. We do not believe any of them will have a material adverse effect on our financial position.
We record accruals for such contingencies to the extent that we conclude their occurrence is probable and the related damages are estimable. If a range of liability is probable and estimable and some amount within the range appears to be a better estimate than any other amount within the range, we accrue that amount. If a range of liability is probable and estimable and no amount within the range appears to be a better estimate than any other amount within the range, we accrue the minimum of such probable range. Many claims involve highly complex issues relating to causation, label warnings, scientific evidence, actual damages and other matters. Often these issues are subject to substantial uncertainties and, therefore, the probability of loss and an estimation of damages are difficult to ascertain. Consequently, we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for these contingencies. These assessments can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Our assessments are based on estimates and assumptions that have been deemed reasonable by management. Litigation is inherently unpredictable, and excessive verdicts do occur. Although we believe we have substantial defenses in these matters, we could in the future incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period.
Patent claims include challenges to the coverage and/or validity of our patents on various products or processes. Although we believe we have substantial defenses to these challenges with respect to all our material patents, there can be no assurance as to the outcome of these matters, and a loss in any of these cases could result in a loss of patent protection for the drug at issue, which could lead to a significant loss of sales of that drug and could materially affect future results of operations.
Item 3.  Quantitative and Qualitative Disclosures About Market Risk.
Information required by this item is incorporated by reference from the discussion under the heading Financial Risk Management in our 2005 Financial Report, which is filed as exhibit 13 to our 2005 Form 10-K. We currently invest and borrow primarily on a short-term or effectively variable-rate basis.
Item 4.  Controls and Procedures.
As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act)). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.
During our most recent fiscal quarter, there has not ~~occurred~~been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. However, we do wish to highlight some changes which, taken together, are expected to have a favorable impact on our controls over a multi-year period. We continue to pursue a multi-year initiative to outsource some transaction-processing activities within certain accounting processes and are migrating to a consistent enterprise resource planning system across the organization. These are enhancements of ongoing activities to support the growth of our financial shared service capabilities and standardize our financial systems. None of these initiatives is in response to any identified deficiency or weakness in our internal control over financial reporting.
PART II - OTHER INFORMATION
Item 1.  Legal ~~Proceedings.~~Proceedings
Certain legal proceedings in which we are involved are discussed in Note 1718 to the consolidated financial statements included in our ~~2004~~2005 Financial Report; Part I, Item 3, of our Annual Report on Form 10-K for the year ended December 31, ~~2004;~~2005; and Part II, Item 1, of our Quarterly Reports on Form 10-Q for the quarters ended April 32 and July ~~3, 2005.~~2, 2006. The following discussion is limited to certain recent developments concerning our legal proceedings and should be read in conjunction with those earlier Reports. Unless otherwise indicated, all proceedings discussed in those earlier Reports remain outstanding. Reference also is made to the Legal Proceedings and Contingencies section in Part I, Item 2, of this Form 10-Q.
Patent Matters
~~Lipitor (atorvastatin)~~Norvasc (amlodipine)
As previously reported, ~~our patent rights to Lipitor are being challenged in various countries. On October 12,~~between 2002 and 2005, in an action brought by generic manufacturer Ranbaxy Ltd., the United Kingdom's High Court of Justice upheld our basic U.K. patent for Lipitor, which expires in 2011, but ruled that a second patent covering the calcium salt of atorvastatin, which expires in 2010, is invalid. Both sides intend to appeal the decision. If upheld on appeal, the decision will prohibit Ranbaxy from introducing a generic version of atorvastatin in the U.K. before the expiration of our basic patent in 2011.
The trial of our Lipitor patent-infringement action against Ranbaxy in the U.S. District Court for the District of Delaware was held in late 2004. While a decision is possible later this year, the court has not indicated when it intends to issue its judgment.
~~Neurontin (gabapentin)~~
~~As previously reported, in 2000, 2001 and 2003, Warner-Lambert~~we brought patent infringement suits in various federal courts against several ~~generic~~ manufacturers that ~~had~~have filed abbreviated new drug applications with the FDA asserting the invalidity and non-infringement of our gabapentin (Neurontin) low-lactam patent. These suits were consolidated for pre-trial purposes in the U.S. District Court for the District of New Jersey. The defendant generic manufacturers filed various summary judgment motions asserting invalidity and non-infringement on a number of grounds. In August 2005, the court, while denying eight of the ten summary judgment motions, granted two motions for summary judgment of non-infringement. It is expected that both sides will appeal the decision.
Neurontin has faced generic competition in the U.S. since last year. The FDA granted approval to a number of manufacturers for their generic gabapentin products, and the manufacturers began to market those products, in 2004.
~~Xalatan (lantanoprost)~~
~~As previously reported, in November 2001, a generic manufacturer notified Pharmacia that it had filed an abbreviated new drug application with the FDA~~ seeking ~~approval~~ to market a ~~product containing latanoprost,~~generic version of amlodipine besylate, which ~~Pharmacia markets as Xalatan. In December 2001, Pharmacia filed suit against~~is the ~~generic manufacturer~~salt form contained in Norvasc. Our patent for amlodipine besylate is being challenged in all of the ~~U.S. District Court~~suits, and our basic patent for amlodipine also is being challenged in one of the District of New Jersey alleging infringement of various patents relating to latanoprost that are held by or licensed to Pharmacia. The generic manufacturer admitted infringement but claimed that these patents are invalid and unenforceable.suits.
In ~~July 2004,~~ the ~~court held that two~~first of ~~the three patents in suit are valid, infringed and enforceable, and it issued an injunction blocking sale of the generic product until the expiration of the later-expiring~~these actions to go to trial, which involved only our amlodipine besylate patent, in March 2011. The generic manufacturer appealed the decision with respect to these two patents. The third patent, which also expires in March 2011, was held unenforceable. We appealed the decision with respect to the third patent. In July 2005, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court's decision as to all three patents, thereby blocking sale of the generic product until March 2011. In October 2005, the Federal Circuit denied the generic manufacturer's request for an en banc review of the three-member panel decision.
~~Product Liability Matters~~
~~Rezulin~~
As previously reported, in April 2001, Louisiana Health Service Indemnity Company and Eastern States Health and Welfare Fund filed a consolidated complaint against Warner-Lambert in the U.S. District Court for the Southern District of New York purportedly on behalf of a class consisting of all health benefit providers that paid for or reimbursed patients for the purchase of Rezulin between February 1997 and April 2001. In September 2005, the court granted Warner-Lambert's motion for summary judgment and dismissed the complaint. In November 2005, the plaintiffs appealed the decision.
~~Viagra~~
A number of lawsuits, including purported class actions, have been filed against us in various federal and state courts alleging that Viagra causes certain types of visual injuries. The plaintiffs in the purported class actions seek to represent nationwide and certain statewide classes of Viagra users. All of the actions seek damages for personal injury, and the purported class actions also seek medical monitoring.
~~Commercial Matters~~
~~Lipitor~~
Beginning in September 2005, a number of purported class actions have been filed against us in various federal courts alleging claims relating to the promotion of Lipitor. In each of the actions, the plaintiffs seek to represent a nationwide class consisting of women (regardless of age) and men over age 65 who in each case had no history of heart disease or diabetes and who purchased Lipitor within the last four years. In certain of the actions, the plaintiffs also seek to represent health insurers, employee benefit plans and other third-party payors that paid for Lipitor used by individuals in either of the aforementioned two groups. The plaintiffs in these actions allege that the Company engaged in false and misleading advertising in violation of state consumer protection laws by allegedly promoting Lipitor for the prevention of heart disease in the aforementioned two groups. The actions seek monetary and injunctive relief, including treble damages. In addition, a purported class action on behalf of residents of the Province of Quebec has been filed against us in Canada that asserts claims under Canadian law and seeks relief substantially similar to the claims asserted and the relief sought in the U.S. actions.
~~Celebrex and Bextra~~
As previously reported, the Company is a defendant in a number of product liability, consumer fraud, securities, fiduciary duty and ERISA (Employee Retirement Income Security Act of 1974) actions, including purported class and derivative actions, relating to Celebrex and Bextra. Certain current and former officers, directors and employees of Pfizer and Pharmacia also are named as defendants in some of those actions. In June 2005, the federal securities, fiduciary duty and ERISA actions were transferred to the U.S. District Court for the Southern District of New York for consolidated pre-trial proceedings. In September 2005, the federal product liability and consumer fraud actions were transferred toJanuary 2006 the U.S. District Court for the Northern District of ~~California for consolidated pre-trial proceedings.~~
~~Other Matters~~
Illinois held that our amlodipine besylate patent is valid and infringed by the generic manufacturer Torpharm/Apotex Inc.'s product. The ~~Department~~court issued an injunction prohibiting Torpharm/Apotex from marketing its generic amlodipine besylate product before the expiration of ~~Justice~~
~~The U.S. Department of Justice has informed us that it is investigating Pharmacia's former contractual relationship with a health care intermediary.~~
~~We have received requests for information and documents from~~our amlodipine besylate patent (including the additional six-month pediatric exclusivity period) in September 2007. In February 2006, Torpharm/Apotex appealed the decision to the U.S. ~~Department~~Court of ~~Justice relating~~Appeals for the Federal Circuit.
Similarly, in the second of these actions to ~~certain physician payments budgeted~~go to trial, which also involved only our ~~prescription pharmaceutical products.~~amlodipine besylate patent, in August 2006 the U.S. District Court for the Middle District of North Carolina held that our amlodipine besylate patent is valid and infringed by generic manufacturer Synthon Pharmaceuticals, Inc.'s product. The court issued an injunction prohibiting Synthon from marketing its generic amlodipine besylate product before September 2007. In September 2006, Synthon appealed the decision to the U.S. Court of Appeals for the Federal Circuit.
~~Importation Cases~~
AsSeparately, as previously reported, in ~~2004 a number of purported class actions were~~November 2005 Synthon IP filed an action against us in the U.S. District Court for the Eastern District of ~~Minnesota~~Virginia alleging that ~~Pfizer~~our sales of Norvasc and ~~several other pharmaceutical manufacturers violated federal and state civil antitrust laws by conspiring~~Caduet infringe Synthon's patent relating to ~~prevent~~ the ~~importation~~manufacture of brand-name prescription drugs from Canada. These suits all were consolidated into a single action, which sought to represent a nationwide class consisting of all persons who purchased or reimbursed patients for the purchase of prescription drugs manufactured and marketed by defendants that also are available in Canada.amlodipine. In August ~~2005,~~2006, the ~~court granted the defendants' motion~~jury held that Synthon's patent is invalid and is not infringed by our sales of Norvasc and Caduet. The decision is subject to dismiss this action, and the plaintiffs have appealed the decision. The previously reported California state court action by a number of independent pharmacists in California that asserts similar claims under California antitrust and unfair business practices laws is still pending. The defendants' motion to dismiss the California action was partially granted and partially denied in July 2005.possible appeal.
~~Environmental Matters~~Government Investigations
As previously reported, in ~~July~~ 2005 we received a request from the ~~U.S. Environmental Protection Agency (EPA) proposed a civil penalty in the amount of $275,000 to settle certain alleged violations~~staff of the ~~Federal Clean Air Act at~~Securities and Exchange Commission (the "Commission") for information and documents concerning our ~~Kalamazoo, Michigan facility~~COX-2 franchise. In August 2006, we received a letter from the staff notifying us that ~~were identified~~this investigation has been terminated and that no enforcement action has been recommended by the ~~EPA during an inspection in 2004. In September 2005, this matter was resolved pursuant~~staff to ~~a settlement that provides for a $47,250 civil penalty and a commitment to undertake two supplemental environmental projects at~~ the ~~facility. Corrective actions have been implemented.~~Commission.
Tax Matters
On January 25, 2006, the Company was notified by the IRS Appeals Division that a resolution had been reached on the matter that we were in the process of appealing related to the tax deductibility of a breakup fee paid by Warner-Lambert Company in 2000. As a result, in the first nine months of 2006 we recorded a tax benefit of approximately $441 million related to the resolution of this issue.
In the second quarter of 2005, we recorded a tax benefit of $586 million primarily related to the resolution of certain tax positions. In addition, we believe that the IRS audits of the Pfizer Inc. tax returns for the years 1999-2001 and the Warner-Lambert Company tax returns for the years 1999 through the date of the merger with Pfizer (June 19, 2000) are substantially complete. In connection with those audits, we are currently in the process of appealing one matter related to the tax deductibility of a breakup fee paid by Warner-Lambert Company in 2000.
The IRS ~~has commenced the audit~~is currently conducting audits of the Pfizer Inc. tax returns for the years 2002, 2003 and 2004. The 2005 and 2006 tax ~~year is~~years are also currently under audit ~~as we are voluntary participants in~~under the IRS Compliance Assurance ~~Program, which results in~~Process, a recently introduced real-time ~~tax audits.~~audit process.
~~As previously disclosed, with~~With respect to Pharmacia Corporation, ~~(formerly known as Monsanto Company),~~ the IRS has completed ~~and closed its income tax return examinations and appeals through 1999 and has commenced the audit~~audits of the tax returns for the years 2000 through 2002 and is currently conducting an audit for the year 2003 through the date of the merger with Pfizer (April 16, 2003).
We periodically reassess the likelihood of assessments resulting from audits of federal, state and foreign income tax filings. We believe that our accruals for tax liabilities are adequate for all open years.
Item 1A.  Risk Factors.
There have been no material changes from the risk factors disclosed in Part 1, Item 1A, of our 2005 Form 10-K.
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.
This table provides certain information with respect to our purchases of shares of Pfizer's common stock during the ~~fiscal third quarter of 2005:~~three months ended October 1, 2006:
Issuer Purchases of Equity Securities^(a)
Issuer Purchases of Equity Securities^(a)
Issuer Purchases of Equity Securities^(a)

Period
Total Number of
Shares Purchased^(b)
Average Price
Paid per Share^(b)
Total Number of
Shares Purchased as
Part of Publicly
Announced Plan^(a)
Approximate Dollar
Value of Shares that
May Yet Be Purchased
Under the Plan^(a)
Total Number of
Shares Purchased^(b)
Average Price
Paid per Share^(b)
Total Number of
Shares Purchased as
Part of Publicly
Announced Plan^(a)
Approximate Dollar
Value of Shares that
May Yet Be Purchased
Under the Plan^(a)
July 4, 2005 through July 31, 2005
24,708
$26.64
---
$5,000,000,000
August 1, 2005 through August 31, 2005
1,642,722
$25.28
1,584,100
$4,960,003,230
September 1, 2005 through
October 2, 2005
2,814,503
$25.63
2,755,400
$4,889,364,758
July 3, 2006 through
July 31, 2006
6,595,881
$24.91
6,539,300
$15,344,343,763
August 1, 2006 through
August 31, 2006
47,571,739
$26.38
47,336,500
$14,095,266,386
September 1, 2006 through
October 1, 2006
38,766,119
$28.00
38,745,083
$13,010,454,666
Total
4,481,933
$25.51
4,339,500
92,933,739
$26.95
92,620,883

^(a)
On June 23, 2005, Pfizer announced that the Board of Directors authorized a $5 billion share-purchase plan (the "2005 Stock Purchase Plan"). On June 26, 2006, Pfizer announced that the Board of Directors increased the authorized amount of shares to be purchased under the 2005 Stock Purchase Plan from $5 billion to $18 billion.

^(b)
In addition to purchases under the 2005 Stock Purchase Plan, this column reflects the following transactions during the ~~fiscal third quarter of 2005:~~three months ended October 1, 2006: (i) the deemed surrender to Pfizer of ~~79,419~~214,471 shares of common stock to pay the exercise price and to satisfy tax withholding obligations in connection with the exercise of employee stock options, (ii) the open-market purchase by the trustee of ~~57,434~~83,891 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who were granted performance-contingent share awards and who deferred receipt of such awards and (iii) the surrender to Pfizer of ~~5,580~~14,494 shares of common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock issued to employees.
Item 3.  Defaults Upon Senior Securities.
None
Item 4.  Submission of Matters to a Vote of Security Holders
None
Item 5.  Other Information.
None
Item 6.
Exhibits.

1)  Exhibit 12
-
Computation of Ratio of Earnings to Fixed Charges

2)  Exhibit 15
-
Accountants' Acknowledgment

3)  Exhibit 31.1
-
Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

4)  Exhibit 31.2
-
Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

5)  Exhibit 32.1
-
Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

6)  Exhibit 32.2
-
Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
~~PFIZER INC. AND SUBSIDIARY COMPANIES~~
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.
Pfizer Inc.
(Registrant)


Dated:  November ~~9, 2005~~3, 2006
/s/ Loretta V. Cangialosi

Loretta V. Cangialosi, Vice President, Controller
(Principal Accounting Officer and
Duly Authorized Officer)
Exhibit 12
PFIZER INC. AND SUBSIDIARY COMPANIES
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
Nine
Months
Ended
Oct. 2,
Year Ended December 31,
Nine
Months
Ended
Oct. 1,
Year Ended December 31,
(in millions, except ratios)
2005

2004
2003
2002
2001
2000
2006

2005
2004
2003
2002
2001

Determination of earnings:
Income from continuing operations before provision for taxes on income, minority interests and cumulative effect of change in accounting principles
$
8,169
$
14,007
$
3,246
$
11,766
$
9,963
$
5,471
Income from continuing operations before provision for taxes on income, minority interests and cumulative effect of a change in accounting principles
$
11,314
$
10,800
$
13,456
$
2,816
$
11,247
$
9,469
Less:
Minority interests
9
10
3
6
14
13
10
12
7
1
3
12
Adjusted income
8,160
13,997
3,243
11,760
9,949
5,458
Income adjusted for minority interest
11,304
10,788
13,449
2,815
11,244
9,457
Add:
Fixed charges
471
510
442
322
305
444
519
630
505
438
318
301
Total earnings as defined
$
8,631
$
14,507
$
3,685
$
12,082
$
10,254
$
5,902
$
11,823
$
11,418
$
13,954
$
3,253
$
11,562
$
9,758

Fixed charges:
Interest expense ^(a)
$
347
$
347
$
270
$
251
$
266
$
381
$
399
$
471
$
347
$
270
$
251
$
266
Preferred stock dividends ^(b)
11
12
10
--
--
--
11
14
12
10
--
--
Rents ^(c)
113
151
162
71
39
63
109
145
146
158
67
35
Fixed charges
471
510
442
322
305
444
519
630
505
438
318
301

Capitalized interest
12
12
20
28
56
46
22
17
12
20
28
56

Total fixed charges
$
483
$
522
$
462
$
350
$
361
$
490
$
541
$
647
$
517
$
458
$
346
$
357

Ratio of earnings to fixed charges
17.9
27.8
8.0
34.5
28.4
12.0
21.9
17.6
27.0
7.1
33.4
27.3
All financial information reflects ~~as applicable,~~ the following ~~businesses and product lines~~ as discontinued ~~operations:~~operations for all periods presented: the Consumer Healthcare business; for 2006, 2005, 2004 and 2003: certain European generics businesses; and for 2004 and 2003: our in-vitro allergy and autoimmune diagnostics testing, and surgical ~~ophthalmic, certain European generic pharmaceutical,~~ophthalmics.
All financial information reflects the following as discontinued operations for 2003, 2002, and 2001: our confectionery, shaving and fish-care products businesses, ~~certain non-core consumer healthcare products lines (primarily marketed in Europe) and~~as well as the Estrostep, Loestrin and femhrt women's health product ~~lines.~~
~~Historical ratios of earnings to fixed charges reflect revisions to historical period's rent expense,~~lines for all the ~~impact of which was not significant to any period.~~years presented.
^(a)
Interest expense includes amortization of debt premium, discount and expenses.

^(b)
Preferred stock dividends are from our Series A convertible perpetual preferred stock held by an Employee Stock Ownership Plan assumed in connection with our acquisition of Pharmacia.

^(c)
Rents included in the computation consist of one-third of rental expense which we believe to be a conservative estimate of an interest factor in our leases, which are not material.
Exhibit 15
ACCOUNTANTS' ACKNOWLEDGMENT
To the Shareholders and Board of Directors of Pfizer Inc:
We hereby acknowledge our awareness of the incorporation by reference of our report dated November ~~9, 2005,~~3, 2006, included within the Quarterly Report on Form 10-Q of Pfizer Inc. for the quarter ended October ~~2, 2005,~~1, 2006, in the following Registration Statements:
- Form S-8 dated October 27, 1983 (File No. 2-87473),
- Form S-8 dated March 22, 1990 (File No. 33-34139),
- Form S-8 dated January 24, 1991 (File No. 33-38708),
- Form S-8 dated November 18, 1991 (File No. 33-44053),
- Form S-8 dated May 27, 1993 (File No. 33-49631),
- Form S-8 dated May 19, 1994 (File No. 33-53713),
- Form S-8 dated October 5, 1994 (File No. 33-55771),
- Form S-8 dated December 20, 1994 (File No. 33-56979),
- Form S-8 dated March 29, 1996 (File No. 333-02061),
- Form S-8 dated September 25, 1997 (File No. 333-36371),
- Form S-8 dated April 24, 1998 (File No. 333-50899),
- Form S-8 dated April 22, 1999 (File No. 333-76839),
- Form S-8 dated June 19, 2000 (File No. 333-90975),
- Form S-8 dated June 19, 2000 (File No. 333-39606),
- Form S-8 dated June 19, 2000 (File No. 333-39610),
- Form S-3 dated October 20, 2000 (File No. 333-48382),
- Form S-8 dated April 27, 2001 (File No. 333-59660),
- Form S-8 dated April 27, 2001 (File No. 333-59654),
- Form S-3 dated October 30, 2002 (File No. 333-100853),
- Form S-3 dated December 16, 2002 (File No. 33-56435),
- Form S-8 dated April 16, 2003 (File No. 333-104581),
- Form S-8 dated April 16, 2003 (File No. 333-104582),
- Form S-8 dated November 18, 2003 (File No. 333-110571),
- Form S-8 dated December 18, 2003 (File No. 333-111333),
- Form S-8 dated April 26, 2004 (File No.333-114852), and
- Form S-3 dated March 1, 2005 (File No. 333-123058).
Pursuant to Rule 436(c) under the Securities Act of 1933, such report is not considered a part of a registration statement prepared or certified by an accountant or a report prepared or certified by an accountant within the meaning of Sections 7 and 11 of that Act.
KPMG LLP
New York, New York
November ~~9, 2005~~3, 2006
Exhibit 31.1
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, ~~Henry A. McKinnell,~~Jeffrey B. Kindler, certify that:
1.
I have reviewed this report on Form 10-Q of Pfizer Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:  November ~~9, 2005~~3, 2006

/s/ ~~Henry A. McKinnell~~Jeffrey B. Kindler
~~Henry A. McKinnell~~Jeffrey B. Kindler
~~Chairman of the Board and~~ Chief Executive Officer
Exhibit 31.2
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Alan G. Levin, certify that:
1.
I have reviewed this report on Form 10-Q of Pfizer Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:  November ~~9, 2005~~3, 2006

/s/ Alan G. Levin
Alan G. Levin
Senior Vice President and Chief Financial Officer
Exhibit 32.1
Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U. S. C. Section 1350, I, ~~Henry A. McKinnell,~~Jeffrey B. Kindler, hereby certify that, to the best of my knowledge, the Quarterly Report of Pfizer Inc. on Form 10-Q for the quarter ended October ~~2, 2005~~1, 2006 (the "Report") fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.

/s/ ~~Henry A. McKinnell~~Jeffrey B. Kindler
~~Henry A. McKinnell~~Jeffrey B. Kindler
~~Chairman of the Board and~~ Chief Executive Officer
November ~~9, 2005~~3, 2006
This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
Exhibit 32.2
Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U. S. C. Section 1350, I, Alan G. Levin, hereby certify that, to the best of my knowledge, the Quarterly Report of Pfizer Inc. on Form 10-Q for the quarter ended October ~~2, 2005~~1, 2006 (the "Report") fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.
/s/ Alan G. Levin
Alan G. Levin
Senior Vice President and Chief Financial Officer
November ~~9, 2005~~3, 2006
This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

(millions of dollars)		Oct. 2, 2005		Dec. 31, 2004

Finished goods	$	2,600	$	2,643
Work-in-process		2,714		2,703
Raw materials and supplies		1,242		1,314
Total inventories	$	6,556	$	6,660

(millions of dollars)		Human Health		Consumer Healthcare		Animal Health		Other		Total

Balance, December 31, 2004	$	20,966	$	2,701	$	79	$	10	$	23,756
Other^(a)		13		62		(25)		--		50
Balance, October 2, 2005	$	20,979	$	2,763	$	54	$	10	$	23,806

		Three Months Ended
		Worldwide				U.S.				International					% Change in Revenues
		Oct. 1,		Oct. 2,		Oct. 1,		Oct. 2,		Oct. 1,			Oct. 2,		Worldwide	U.S.	International
(millions of dollars)		2006		2005		2006		2005		2006			2005		06/05	06/05	06/05

Pharmaceutical	$	11,485	$	10,547	$	6,380	$	5,615	$	5,105		$	4,932		9	14	3
Animal Health		562		503		260		228		302			275		12	14	10
Other		233		213		68		64		165			149		9	6	11
Total Revenues	$	12,280	$	11,263	$	6,708	$	5,907	$	5,572	^(a)	$	5,356	^(a)	9	14	4

•	the solid aggregate performance of our broad portfolio of patent-protected medicines;

•	an aggregate year-over-year increase in revenues from new products launched in 2004, 2005 and within the first nine months of 2006 of approximately $450 million for the third quarter of 2006 and $1.1 billion for the first nine months of 2006;

•	the one-time reversal of a sales deduction accrual related to a favorable development in a pricing dispute in the U.S. of about $170 million;

•	higher U.S. wholesaler inventories in the third quarter of 2006 by about two days compared to the end of the second quarter of 2006, with levels at the end of the third quarter of 2006 at normal levels and comparable to those at the end of the third quarter of 2005; and

•	the favorable impact of changes in the mix of sales rebates in the U.S.,


partially offset by:

•	a decrease in revenue for Zoloft, primarily due to the launch of generic competition in mid-July 2006 after Zoloft lost exclusivity in the U.S. in June 2006 and also due to the earlier loss of exclusivity in many European markets, by $348 million for the third quarter of 2006 and $504 million for the first nine months of 2006;

•	a decrease in revenue from the loss of exclusivity of Zithromax in November 2005 of $302 million for the third quarter of 2006 and $1.1 billion for the first nine months of 2006; and

•	the continued decline in revenue by $39 million for the third quarter of 2006 and $218 million for the first nine months of 2006 of Neurontin, Diflucan and Accupril/Accuretic, which lost U.S. exclusivity in 2004.

•	in the U.S., Pharmaceutical revenues increased 14% and 7% in the three months and nine months ended October 1, 2006 compared to the same periods in 2005, primarily due to revenues from new products, as well as growth in Lipitor and Celebrex sales, the one-time reversal of a sales deduction accrual related to a favorable development in a pricing dispute and higher U.S. wholesaler inventories in the third quarter of 2006 by about two days compared to the end of the second quarter of 2006, partially offset by the loss of exclusivity of Zithromax in November 2005 and Zoloft in June 2006; and

•	in our international markets, Pharmaceutical revenues increased 3% in the three months ended October 1, 2006 compared to the same period in 2005, primarily due to revenues from our new products, as well as growth in Lipitor and Celebrex sales, and the favorable impact of foreign exchange on revenue of $107 million (1%), partially offset by lower revenues from Zoloft due to the loss of exclusivity in many key international markets. Our international Pharmaceutical revenues decreased 3% in the nine months ended October 1, 2006, compared to the same period in 2005, primarily due to the unfavorable impact of foreign exchange on revenue of $422 million (1%) and lower revenues from Zoloft due to the loss of exclusivity in many key international markets.

		Third Quarter		First Nine Months
(millions of dollars) Product	Primary Indications	2005	% Change from 2004	2005	% Change from 2004

Cardiovascular and metabolic diseases:
Lipitor	Reduction of LDL cholesterol	$2,897	6 %	$8,829	16 %
Norvasc	Hypertension	1,131	9	3,462	8
Cardura	Hypertension/Benign prostatic hyperplasia	132	(12)	441	(4)
Accupril/Accuretic	Hypertension/Congestive heart failure	77	(51)	250	(50)
Caduet	Reduction of LDL cholesterol and hypertension	48	927	121	249
Central nervous system disorders:
Zoloft	Depression and anxiety disorders	807	1	2,448	2
Neurontin	Epilepsy and post-herpetic neuralgia	155	(80)	498	(78)
Geodon	Schizophrenia and acute manic or mixed episodes associated with bipolar disorder	148	18	430	33
Xanax/Xanax XR	Anxiety/Panic disorders	101	--	306	13
Aricept**	Alzheimer's disease	85	11	255	15
Lyrica	Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy	80	M+	139	M+
Relpax	Migraine headaches	67	42	170	49
Arthritis and pain:
Celebrex	Arthritis pain and inflammation, acute pain	446	(44)	1,258	(45)
Bextra	Arthritis pain and inflammation	(73)	*	(59)	*
Infectious and respiratory diseases:
Zithromax/Zmax	Bacterial infections	402	19	1,623	38
Zyvox	Bacterial infections	157	30	453	38
Vfend	Fungal infections	106	54	285	40
Diflucan	Fungal infections	103	(52)	370	(54)
Urology:
Viagra	Erectile dysfunction	386	(4)	1,215	1
Detrol/Detrol LA	Overactive bladder	231	--	705	14
Oncology:
Camptosar	Metastatic colorectal cancer	229	81	674	85
Ellence	Breast cancer	86	--	273	7
Aromasin	Breast cancer	63	61	176	88
Ophthalmology:
Xalatan/Xalacom	Glaucoma and ocular hypertension	338	11	1,011	16
Endocrine disorders:
Genotropin	Replacement of human growth hormone	200	14	604	13
All other:
Zyrtec/Zyrtec-D	Allergies	338	2	1,035	10
Alliance revenue:
Aricept, Macugen, Mirapex, Olmetec, Rebif and Spiriva	Alzheimer's disease (Aricept), neovascular (wet) age-related macular degeneration (Macugen), Parkinson's disease (Mirapex), hypertension (Olmetec), multiple sclerosis (Rebif), chronic obstructive pulmonary disease (Spiriva)	267	38	757	59

*^(a)	~~Calculation not meaningful.~~
**	Represents direct sales under license agreement with Eisai Co., Ltd.
M+*	~~Change greater than one-thousand percent.~~ Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.

•	Lipitor, for the treatment of elevated ~~cholesterol~~LDL-cholesterol levels in the blood, is the most widely used treatment for lowering cholesterol and the best-selling pharmaceutical product of any kind in the ~~world. In our international markets, Lipitor showed revenue growth of 14%~~world, reaching about $9.6 billion in worldwide sales in the ~~third quarter~~first nine months of ~~2005,~~2006, an increase of 8% compared to the ~~third quarter of 2004.~~same period in 2005. In the U.S., sales of $5.9 billion represent growth of 11% over the previous year's first nine months. Internationally, Lipitor ~~revenues grew 1%~~sales in the ~~third quarter~~first nine months of ~~2005,~~2006 increased 4% compared to the ~~third quarter of 2004. This performance reflects~~same period in part an unexpectedly rapid slowdown in the U.S. lipid-lowering market as a whole and marginal Lipitor prescription share erosion during the quarter of one percentage point. Evidence of the substantial lipid-market deceleration can be seen in category new-prescription growth rates for the third quarter of 8% versus first-half growth of 17%, representing more than a 50% drop from robust trends exhibited during the first six months of this year. Despite this market slowdown, Lipitor still accounts for more than 40% of all lipid-lowering prescriptions, a 26.4% advantage versus its next nearest competitor.2005.

	~~In September 2005,~~The growth in Lipitor revenue was driven by a combination of factors, including the ~~FDA approved Lipitor use to reduce the risk of stroke and myocardial infarction in patients with type 2 diabetes. The FDA's decision was based on the findings~~impact of the ~~Collaborative Atorvastatin Diabetes Study (CARDS),~~Medicare Act, dosage-form escalation, pricing (including a ~~landmark trial~~favorable development in a pricing dispute in the U.S.) and a return to normal wholesaler inventory levels. We continue to see aggressive competition from branded and generic agents, which will further intensify in the fourth quarter of more than 2,800 patients with type 2 diabetes, near-normal cholesterol, and at least one other risk factor, such as high blood pressure or smoking. CARDS showed that patients using Lipitor experienced 48% fewer strokes than those on placebo. The CARDS study's steering committee stopped2006, particularly when additional generic agents become available in the ~~trial nearly two years earlier than planned because~~U.S. near the end of the ~~clinical benefits among patients who took Lipitor.~~

	~~In addition, the FDA expanded the~~year. Lipitor ~~label~~began to ~~include data on the reduction~~face competition in the ~~incidence~~U.S. from generic pravastatin (Pravachol) in April 2006 and generic simvastatin (Zocor) in June 2006, as well as other competitive pressures. In April 2006, we launched a new advertising campaign for Lipitor that highlights its strong benefit profile and advantageous formulary positioning. Scientific data continue to reinforce the trend toward the use of ~~stroke in patients with multiple risk factors, as shown in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) clinical trial. The ASCOT trial found that Lipitor reduced the relative risk~~higher dosages of ~~stroke by 26% compared to placebo. The study involved people with normal or borderline~~statins for greater cholesterol and no prior history of heart disease with controlled high blood pressure and at least three other risk factors for heart disease, such as family history, age over 55, smoking, diabetes, and obesity. Patients with multiple risk factors, including diabetes, face a greater threat of heart attack and stroke. Reducing their risk of such cardiovascular events is extremely important.reduction.

•	Norvasc is the world's most-prescribed branded medicine for treating hypertension. It achieved an increased rate of growth in sales in the first nine months of 2005 compared to same period in 2004 (8% in 2005 as compared to 4% in 2004), despite patent expirations in many European Union (E.U.) countries. Norvasc maintains exclusivity in many major markets globally, including the U.S., Japan, Canada and ~~Australia.~~Australia, but has experienced patent expirations in many E.U. countries. Norvasc sales in the first nine months of 2006 increased 3% over the same period in 2005. See Part II, Other Information; Item 1, Legal Proceedings, of this Form 10-Q for a discussion of certain recent patent litigation relating to Norvasc.

•	Exubera, the first inhaled human insulin therapy for glycemic control received approvals from both the FDA and the European Commission for the treatment of adults with type 1 and type 2 diabetes in January 2006. Millions of people with diabetes are not achieving or maintaining acceptable blood sugar levels, despite the availability of current therapies. Exubera represents a medical advance that offers patients a novel method of introducing insulin into their systems through the lungs. Since May 2006, Exubera has been launched in Germany, Ireland, the U.K. and most recently, the U.S., where the Joslin Diabetes Clinic in Boston, widely recognized as one of the pre-eminent diabetes and research organizations in the world, has recognized Exubera in its diabetes treatment guidelines. Within the U.S., a comprehensive education and training program for physicians is underway. To further support patients and healthcare professionals, Pfizer also provides a 24-hour-a-day, 7-day-a-week call center staffed by healthcare professionals. Similar programs are also in place in European markets where the product has been launched. An expanded roll-out of Exubera to primary-care physicians in the U.S. previously targeted for November 2006, will begin in January 2007. The manufacturing process for Exubera is complex, involving novel technology. We are working at capacity to meet expected demand, while also expanding drug product capacity. Initial supplies of Exubera were available across the U.S. beginning in September 2006.

•	Zoloft ~~is the most-prescribed antidepressant~~, which lost exclusivity in the U.S. in June 2006 and earlier in many European markets, experienced a 21% revenue decline in the first nine months of 2006 compared to the same period in 2005. It is indicated for the treatment of major depressive disorder, panic disorder, obsessive-compulsive disorder (OCD) in adults and children, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD) and social anxiety disorder (SAD). Zoloft is approved for acute and long-term use in all of these indications, with the exception of ~~PMDD, and~~PMDD. It is the only approved agent for the long-term treatment of PTSD and SAD, an important differentiating feature as these disorders tend to be chronic. Zoloft was approved in Japan in April 2006 for the indications of depression/depressed state and panic disorder.

	In the U.S., in February 2005, Pfizer implemented FDA instructions that require the makers of all currently marketed antidepressants, including tricyclic agents, monoamine oxidase (MAO) inhibitors, selective serotonin reuptake inhibitors such as Zoloft, selective norepinephrine reuptake inhibitors and atypical antidepressants, to include a black-box warning that antidepressants increased the risk of suicidal thinking and behavior in children and adolescents in pooled, short-term studies. In the nine completed clinical trials of Zoloft involving children and adolescents, which included studies of Zoloft in children diagnosed with depression, OCD, or both, no suicides occurred. The trials found no statistically significant differences between Zoloft-treated children and adolescents and placebo controls in their rates of suicide attempts or ideation.

•	~~Neurontin,~~ for use in adjunctive therapy for epilepsy, is also approved in more than 60 markets for the treatment of a range of neuropathic pain conditions. Neurontin has also been approved for the management of post-herpetic neuralgia (PHN), a, painful condition that affects many people in the aftermath of the viral infection commonly known as shingles. Neurontin was the first oral medication approved in the U.S. for the treatment of PHN.

	In the latter half of 2004, Ivax Corporation (Ivax), Alpharma Inc. (Alpharma) and Teva Pharmaceuticals Industries Ltd. (Teva) launched generic versions of Neurontin (gabapentin) at-risk, despite ongoing patent litigation. We are aggressively pursuing our claims of patent infringement against Ivax, Alpharma, Teva and other generic manufacturers. (See Part II, Item 1, ~~Legal Proceedings~~.) Following those at-risk launches, we launched generic gabapentin through Greenstone, our U.S. generic pharmaceutical subsidiary. However, the introduction of generic versions of gabapentin caused a 78% reduction in Neurontin sales for the first nine months of 2005 as compared to the same period in 2004.

•	~~Geodon~~Geodon/Zeldox, a psychotropic agent, is a dopamine and serotonin receptor antagonist indicated for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder. ~~Available~~It is available in both an oral capsule and rapid-acting intramuscular ~~formulation, Geodon has been launched in 54 countries, where more than six million prescriptions have been written for more than one million patients worldwide.~~formulation. In the U.S., Geodon hit an all-time ~~U.S.~~ new prescription share weekly high of 6%7.4% during September 2006. In the past six months, Geodon has become the fastest growing anti-psychotic medication in the ~~third quarter and is now~~U.S. In the ~~second-fastest-growing atypical anti-psychotic medication.~~first nine months of 2006, total Geodon worldwide sales grew 28% compared to the same period in 2005.

	The ~~Clinical Antipsychotic Trials of Intervention Effectiveness schizophrenia study, supported by~~U.S. Patent and Trademark Office granted a five-year extension to the ~~National Institute of Mental Health and recently published in the New England Journal of Medicine, confirms that~~ Geodon ~~is an effective anti-psychotic and is less likely~~U.S. patent, extending its exclusivity to worsen weight, lipids, and glucose metabolism than other agents. In fact, Geodon was associated with some improvement in these parameters. These findings are noteworthy because of the higher prevalence of metabolic issues among patients with schizophrenia and are consistent with previous Pfizer-sponsored clinical trials involving Geodon.2012.

•	Lyrica achieved $803 million in worldwide revenue in the first nine months of 2006. In September 2006, Lyrica was approved by the European Commission to treat central nerve pain, which is associated with conditions such as spinal injury, stroke and multiple sclerosis. In addition, in March 2006, it was approved by the European Commission to treat generalized anxiety disorder (GAD) in adults, thereby providing a new treatment option for the approximately 12 million Europeans living with GAD.

	Lyrica was approved by the FDA in June 2005 for adjunctive therapy for adults with partial onset epileptic seizures. This ~~latest~~ indication ~~builds~~built on the earlier FDA approval of Lyrica for two of the most common forms of neuropathic ~~pain --~~pain; painful diabetic peripheral neuropathy, a chronic neurologic condition affecting ~~nearly~~about three million Americans, and post-herpetic neuralgia. Lyrica was launched in the U.S., Canada and Italy in September 2005 and is now approved in more than 5060 countries and ~~is currently~~ available in more than 2535 markets. ~~Market penetration has~~More than one million patients have been ~~rapid; after one full year of~~prescribed Lyrica ~~sales, Germany and the U.K. posted~~since its introduction. Lyrica sales shares of 14.2% and 9.5%, respectively, in the anti-epileptic drug market, surpassing those of many established competitors in both countries. Clinical evidence favorable to Lyrica also continues to grow. The September 2005 edition of ~~Epilepsia~~ ~~focused on the medication's lack of interactions with other drugs. Additionally, at the August 2005 meeting~~gained a 9.7% new prescription share of the ~~International Epilepsy Congress, data from an independently conducted meta-analysis showed Lyrica to be among the best~~total U.S. anti-epileptic market in ~~class for treatment~~September 2006, continuing its performance as one of ~~drug-resistant epilepsy.~~Pfizer's most successful pharmaceutical launches.

•	Celebrex and Bextra

	~~On April 7, 2005,~~Celebrex achieved a 19% increase in worldwide sales in the ~~FDA announced~~first nine months of 2006 compared to the same period in 2005. In the first nine months of 2006, Celebrex delivered three consecutive quarters of double-digit sales growth and had a ~~decision to require boxed warnings~~monthly new prescription share of potential cardiovascular risk for all COX-2 pain relievers and all prescription NSAIDs, including older non-specific drugs such as ibuprofen and naproxen. On July 29, 2005, Pfizer and the FDA finalized the label changes for Celebrex. The final label contains a boxed warning of potential serious cardiovascular and gastrointestinal risks for Celebrex that are consistent with warnings for all other prescription NSAIDs. The boxed warning provides that Celebrex is contraindicated for patients who recently have undergone coronary artery bypass graft surgery. The label recommends that Celebrex be prescribed at the lowest effective dose for the shortest duration consistent with individual patient treatment goals.10.5% in September 2006. Pfizer is continuing its efforts to ~~conduct additional clinical studies evaluating~~address physicians and patients' questions by clearly communicating the ~~benefits~~risks and ~~risks~~benefits of Celebrex. In addition, the Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen or Naproxen (PRECISION) study, which began enrolling patients in October 2006, will provide further understanding of the comparative cardiovascular safety of Celebrex and some common non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in arthritis patients at risk for, or already suffering from, heart disease.

	The market for pain relievers has shown considerable change since the withdrawal of Vioxx in September 2004. Sales of Celebrex began to decline in the late 2004. However, following regulatory reviews of these medicines in February 2005 in both the U.S. and the E.U., the market for prescription pain relievers indicated lower, but stabilizing levels compared to pre-Vioxx withdrawal levels. Revenues from Celebrex in 2005, prior to the FDA's decision in April 2005, were already expected to be significantly lower than in 2004.

	~~In September 2005, with full implementation of revised labeling,~~ Pfizer began to ~~focus renewed attention on Celebrex,~~reintroduce branded advertising in the U.S. in April 2006 in alignment with ~~the goal of making the pain reliever available to increased numbers of patients. Celebrex is supported by a large body of scientific~~our new direct-to-consumer (DTC) advertising principles, highlighting Celebrex's strong clinical profile and ~~clinical-trial evidence of efficacy and safety accumulated over 10 years in more than 40,000 patients worldwide.~~benefits. In July 2005, the FDA approved a sixth indication for ~~Celebrex -- ankylosing spondylitis -- a~~Celebrex--ankylosing spondylitis--a form of spinal arthritis that affects more than one million people in the U.S. In August 2006, Celebrex was granted pediatric exclusivity in the U.S., extending its patent protection until May 2014. Strong clinical data continue to support Celebrex as an important medicine for patients with arthritis. The Successive Celecoxib Efficacy and Safety Study (SUCCESS-1), recently published in the American Journal of Medicine, showed that people with osteoarthritis who take Celebrex experience significantly fewer gastrointestinal problems than patients who take NSAIDs.

	In ~~June~~ 2005, in accordance with decisions by applicable regulatory authorities, we implemented label changes for Celebrex in the ~~Committee~~U.S. and the E.U., and we suspended sales of Bextra in the U.S., E.U., Canada and many other countries. The revised U.S. label for ~~Human Medicinal Products (CHMP) concluded its COX-2 referral process~~Celebrex contains a boxed warning of potential serious cardiovascular and ~~recommended~~gastrointestinal risks that ~~both~~is consistent with warnings for all other prescription NSAIDS. The revised E.U. labels for Celebrex and ~~Dynastat (parecoxib) remain available to patients. The European Medicines Evaluation Agency (EMEA) has required new labeling for~~ all other COX-2 ~~drugs that includes~~medicines include a restriction on use ~~for~~by patients with established heart disease or stroke and additional warnings to physicians regarding use inby patients with cardiovascular risk factors. ~~This new labeling was implemented for all COX-2 medicines across the E.U. in July of 2005.~~

	Further, the FDA decided that while Bextra's cardiovascular risk could not be differentiated from other NSAIDs, the additional, increased risk of rare but serious skin reactions associated with Bextra, already described in its label, warranted its withdrawal from the market. In 2004, we recorded $1.3 billion in revenue for Bextra. We respectfully disagree with the FDA's position regarding the relative risk/benefit profile of Bextra. However, in deference to the regulatory agency's view, we suspended sales of the medicine pending further discussions with the FDA. In addition, at the request of European and other regulators, we suspended sales of Bextra in the E.U., Canada and many other markets around the world.

	In connection with the decision to suspend sales of Bextra in the U.S., the E.U., and certain other markets, we recorded certain charges totaling $1.2 billion ($762 million, net of tax) in the first nine months of 2005. These pre-tax charges included $1.1 billion related to the impairment of developed technology rights associated with Bextra and $7 million related to the write-off of machinery and equipment, both of which are included in ~~Other (income)/deductions-net~~~~; $56 million in write-offs of inventory and exit costs, included in~~ ~~Cost of sales~~~~; $8 million related to the costs of administering the suspension of sales, included in~~ ~~Selling, informational and administrative expenses;~~ ~~and $212 million for an estimate of customer returns, primarily included against~~ ~~Revenues.~~ ~~Substantially all of these charges were recorded in the first quarter of 2005.~~

•	Zithromax~~, whose composition of matter patent~~ experienced a 68% decline in the U.S. expires in November 2005, remained the number-one prescribed oral antibiotic during the third quarter of 2005, despite the end of active sales promotion in July, when the U.S. sales force began promoting Zmax. Sales in the U.S. are expected to be adversely affected by the loss of market exclusivity beginning in November 2005.

•	~~Zmax,~~ a single-dose, sustained-release form of azithromycin, was introduced in the U.S. in July 2005. Zmax has surpassed all other recent antibiotic introductions (including line extensions) in week 10 prescription volume, even though the Zmax launch occurred in the summer, before the beginning of the respiratory season. Single-dose Zmax delivers higher azithromycin serum concentrations during the first 24 hours than Zithromax and assures complete compliance compared to multi-dose regimes, demonstrating a clear benefit of the new medication. A supplemental Marketing Authorization Application (MAA) for Zmax was approved in Europe in September 2005.

•	~~Diflucan~~ ~~is a systemic antifungal. The decrease in~~worldwide sales in the first nine months of ~~2005~~2006 compared to the same period ~~in 2004 is mainly due to loss~~ of ~~exclusivity~~2005, reflecting the expiration of its composition-of-matter patent in the U.S. in November 2005 and the end of Pfizer's active sales promotion in July ~~2004.~~2005. During the fourth quarter of 2005, four generic versions of oral solid azithromycin were launched, including an authorized generic by Pfizer's Greenstone subsidiary. Additional generic formulations of azithromycin were launched during 2006, including three oral suspensions and two intravenous versions.

•	Eraxis, an antifungal approved to treat candidemia and other forms of Candida infections (intra-abdominal abscesses and peritonitis), as well as esophageal candidiasis, was launched mid-June 2006 in the U.S. Candidemia is the most deadly of the common hospital-acquired bloodstream infections with a mortality rate of approximately 40%.

•	Viagra remains the leading treatment for erectile dysfunction and one of the world's most recognized pharmaceutical brands, with more than ~~63%~~58% of U.S. total prescriptions in the erectile dysfunction market through September 2006. Viagra sales declined 1% worldwide in the first nine months of 2006 compared to the same period in 2005. We expect to see continued pressure on sales in ~~its market~~the U.S. More than 45 states have either eliminated erectile-dysfunction coverage or have enacted "preferred drug lists" that have the potential to limit Pfizer sales to state Medicaid programs. Effective January 1, 2006, federal funds may not be used for reimbursement of ~~phosphodiesterase-5 (PDE5) inhibitors through August 2005, even as~~erectile-dysfunction medications by the ~~entire market's sales were down for the period.~~Medicaid program. Medicare coverage of Viagra will end in 2007.

	Pfizer has introduced new branded and unbranded advertising to encourage men with erectile dysfunction to talk to their physicians about their condition and specifically about Viagra.


•	Sutent is an oral multi-targeted tyrosine kinase inhibitor that combines anti-angiogenic and anti-tumor activity to inhibit the blood supply to tumors and has direct anti-tumor effects. Sutent was approved by the FDA in January 2006 for advanced renal cell carcinoma, including metastatic renal cell carcinoma (collectively, mRCC), and gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib mesylate. Since approval, Sutent has been prescribed to more than 7,500 patients in the U.S. On July 27, 2006, Sutent received conditional marketing authorization from the European Commission for mRCC, after failure of interferon alfa or interleukin-2 therapy, and unresectable and/or metastatic malignant GIST, after failure of imatinib due to resistance or intolerance. This was the first time the European Commission granted a new oncology drug conditional marketing authorization in the European Union. Final approval is contingent on the provision of comprehensive data on Sutent's effect in terms of relevant clinical endpoints, such as progression-free survival in patients with mRCC. In ~~addition, Viagra faces aggressive competition~~October 2006, following evaluation of clinical data submitted by Pfizer, the Committee for Medicinal Products for Human Use (CHMP) recommended a switch from ~~other global brands. Year-to-date 2005 Viagra sales are ahead 1%~~the conditional marketing authorization to a full marketing authorization. It also recommended to extend the indication to first-line treatment of mRCC. Sutent has received approvals or registration in several countries in Asia and Latin America and is expected to launch in many more markets worldwide over ~~last year, and third-quarter 2005~~the coming months. Sutent has recorded $115 million in sales ~~are down 4% from~~worldwide in the same period last year. Pfizer plans to introduce new branded advertising compliant with our direct-to-consumer advertising guidelines to highlight the unique clinical profile for Viagra, as well as new unbranded advertising to address the needsfirst nine months of ~~potential new patients who may be hesitant to try any medication for erectile dysfunction.~~

	On July 8, 2005, the FDA approved an update to the Viagra label to reflect rare post-marketing reports of non-arteritic anterior ischemic optic neuropathy (NAION) in patients taking PDE5 inhibitor medications. The updated label notes that in rare instances, men taking PDE5 inhibitors, including Viagra, reported a sudden decrease or loss of vision in one or both eyes and that it is not possible to determine whether these events are related directly to these medicines, to the patient's underlying vascular risk factors, to a combination of these factors, or other factors. Most of the reported NAION cases occurred in Viagra users with underlying anatomic or vascular risk factors associated with the development of NAION.2006.

•	Camptosar ~~is a semisynthetic camptothecin derivative that works by inhibiting the topoisomerase 1 enzyme, which is involved in cancer cell replication. Camptosar~~ is indicated as first-line therapy for metastatic colorectal cancer in combination with 5-fluorouracil and leucovorin. It is also indicated as second-line therapy for patients in whom metastatic colorectal cancer has recurred or progressed despite following initial fluorouracil-based therapy. Camptosar is for intravenous use only. Revenue ~~growth of 85%~~ in the first nine months of ~~2005~~2006 decreased 1% to $668 million compared to the same period in ~~2004 was impacted in part by Pfizer's acquisition of marketing rights to Campto/Camptosar in Europe and Asia (except Japan) in late 2004.~~2005. Among current oncology medications, the National Comprehensive Cancer Network, an alliance of 19 of the world's leading cancer centers, has issued guidelines recommending Camptosar as an option across all lines of treatment for advanced colorectal cancer.

•	Xalatan/Xalacom, a prostaglandin analogue used to lower the intraocular pressure associated with glaucoma and ocular hypertension, is the most-prescribed branded glaucoma medicine in the world. Clinical data showing its advantages in treating ~~intra-ocular~~intraocular pressure compared with beta blockers should support the continued growth of this important medicine. Xalacom, the only fixed combination prostaglandin (Xalatan) and beta blocker, is available primarily in European markets. Xalatan/Xalacom sales grew 5% in the first nine months of 2006 compared to the same period in 2005.

•	Zyrtecprovides strong, rapid and long-lasting relief for seasonal and year-round allergies and hives with once-daily dosing. Zyrtec continues to be the most-prescribed antihistamine in the U.S. in a challenging market. ~~The increase in sales~~Sales increased 15% in the first nine months of ~~2005~~2006 compared to the same period in ~~2004 is attributable~~2005. In February 2006, we began a new DTC advertising campaign featuring new insight that allergy symptoms can worsen over time due to ~~stabilization in the prescription antihistamine market subsequent~~exposure to ~~the Rx to over-the-counter switch of loratadine as the majority of the managed care plans have completed their formulary tier changes in this category.~~

•	~~Macugen~~, a treatment for neovascular (wet) age-related macular degeneration, is a product whose revenues are included in alliance revenues. It was launched in the U.S. in January 2005 and launched in Canada in September 2005. We anticipate that the European Commission will grant marketing authorization for Macugen during the fourth quarter of 2005.new allergens.

•	Caduet,a multi-target single pill combining Norvasc and Lipitor, ~~and Norvasc, has successfully completed the Mutual Recognition Procedure (MRP) in the E.U. and is the first multi-target combination product to receive~~recorded worldwide revenues of $255 million with a ~~broad approval~~growth rate of 111% for prevention of cardiovascular events in the E.U. Caduet is now approved in the following E.U. countries: France, Spain, Portugal, Austria, Iceland, Luxembourg, Cyprus, the Czech Republic, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia and Slovenia. It is indicated for prevention of cardiovascular events in hypertensive patients with three concomitant cardiovascular risk factors, normal to mildly elevated cholesterol levels, without clinically evident coronary heart disease, where combined use of amlodipine and low dose atorvastatin is considered appropriate, and in accordance with current treatment guidelines. The Caduet Marketing Authorization application has been officially withdrawn from the MRP in Belgium, Denmark, Estonia, Ireland, Italy, Netherlands, Norway, the U.K., Sweden, Germany, Finland and Greece. These countries had reservations as to whether the benefit of Caduet, the first cardiovascular, multi-target, fixed combination product, had been demonstrated,based upon current European regulatory guidelines for fixed combination products. As a result, these countries did not mutually recognize the proposed label and Pfizer decided to withdraw the application from these countries. Pfizer will continue to explore regulatory approval opportunities for Caduet.

•	~~the 4% increase in the third quarter and 13% increase in~~ the first nine months of ~~2005~~2006 compared to the same period in ~~sales of Listerine mouthwash, which benefited from~~2005. Caduet was launched in the U.S. ~~launch of Listerine Whitening~~ in ~~April 2005, as well as continued strong performance~~May 2004 and continues to grow at significantly higher rates than the overall U.S. cardiovascular market. Caduet is available in ~~international markets;~~more than 10 other countries. Caduet has now received approvals in 51 markets with drug applications pending in 14 additional markets and applications planned in 10 other countries. During 2006, Caduet is expected to be launched in France, Spain, Australia, Taiwan and Turkey.

•	~~growth from Sudafed and other upper-respiratory products, Zantac, and tobacco dependence products;~~

•	~~inclusion of Purell sales~~Chantix/Champix, the first new prescription treatment for smoking cessation in ~~2005 following the acquisition of the Purell brand~~nearly a decade, became available to patients in ~~November 2004; and~~

•	~~the favorable impact of the weakening of~~ the U.S. ~~dollar relative~~in August 2006. In September 2006, the European Commission approved Champix in Europe for smoking cessation. Chantix/Champix is available with a patient support plan which smokers can customize to ~~many foreign currencies.~~address their individual behavioral triggers as they try to quit smoking.

•	infor livestock products, the continued performance of Draxxin (for treatment of respiratory disease in cattle and swine) in Europe and in the U.S., as well as Spectramast (antibiotic formulated to treat clinical mastitis) which was launched in the U.S. in May 2005, partially offset by a slowdown in the third quarter due to delay in the U.S. cattle season;; and

•	infor companion animal ~~increased promotional activities throughout our markets resulted in~~products, the performance of Rimadyl (for treatment of pain and inflammation associated with canine osteoarthritis and soft-tissue orthopedic surgery) for the three months ended October 1, 2006, the continued performance of Revolution (a parasiticide for dogs and ~~Clavamox growing at double-digit rates~~cats) for both the~~first~~ three months and nine months ~~of 2005,~~ended October 1, 2006 and ~~the launch of Simplicef (small animal anti-infective) in the U.S. in the fourth quarter of 2004; and~~

•	the favorable impact of the weakening of the U.S. dollar relative to many foreign ~~currencies.~~currencies in the third quarter of 2006;

partially offset by:

•	a decline in U.S. Rimadyl revenues in the first half of 2006 due to lower-than-anticipated NSAID market growth and intense branded competition, as well as increased generic competition in the European companion animal market; and

•	the unfavorable impact of the strengthening of the U.S. dollar relative to many foreign currencies for the first nine months of 2006.

Product	Indication	Date Approved

~~Aromasin~~	~~Treatment of early breast cancer in post-menopausal women~~	~~October 2005~~

~~Lipitor~~	~~Reduce the risk of stroke and myocardial infarction in patients with type 2 diabetes~~	~~September 2005~~

~~Norvasc~~	~~For treatment of angiographically documented coronary artery disease~~	~~September 2005~~

~~Celebrex~~	~~For the relief of the signs and symptoms associated with ankylosing spondylitis~~	~~July 2005~~

~~Lyrica~~	~~Add-on therapy for adult epilepsy patients with partial onset seizures~~	~~June 2005~~

~~Revatio~~	~~Oral treatment for adult pulmonary arterial hypertension (PAH)~~	~~June 2005~~

~~Zmax~~	~~Single dose version of Zithromax for acute bacterial sinusitis and community-acquired pneumonia.~~	~~June 2005~~

~~Zyvox~~	~~For the treatment of bacterial infections in pediatric patients~~	~~May 2005~~

~~Depo-SubQ Provera~~	~~Subcutaneous formulations to treat pain associated with endometriosis.~~	~~March 2005~~

~~Ellence~~	~~Adjuvant long-term cancer treatment~~	~~March 2005~~

~~Product~~	~~Indication~~	~~Date Submitted~~

~~Sutent~~	~~Treatment of metastatic renal cell carcinoma and malignant gastrointestinal stromal tumors~~	~~August 2005~~

~~Anidulafungin~~	~~Treatment of candidemia and invasive candidiasis~~	~~August 2005~~
	~~Treatment of esophageal candidiasis~~	~~May 2005~~

Aricept	Treatment of severe Alzheimer's disease	~~August 2005~~October 2006

Chantix	Nicotine-receptor partial agonist for smoking cessation	May 2006

Genotropin	Treatment of short stature and growth problems resulting from Turner's syndrome	~~June 2005~~April 2006

~~Vfend~~Geodon	~~Pediatric filing~~Liquid oral suspension	~~June 2005~~March 2006

~~Indiplon~~Eraxis	~~Modified-release tablets for treatment~~Treatment of ~~multiple aspects of insomnia~~candidemia and invasive candidiasis	~~May 2005~~February 2006
	~~Immediate-release capsules for treatment~~Treatment of ~~multiple aspects of insomnia~~esophageal candidiasis	~~April 2005~~February 2006

Exubera	Inhaled form of insulin for use in adults with type 1 and type 2 diabetes	~~December 2004~~January 2006

~~Oporia~~Sutent	~~Vaginal atrophy~~Treatment of mRCC and GIST	~~December 2004~~January 2006

Product	Indication	Date Submitted

~~Dalbavancin~~Celebrex	Juvenile rheumatoid arthritis	June 2006

Lipitor	Secondary prevention of cardiovascular (CV) events in patients with established coronary artery disease (CAD)	May 2006

Fesoterodine	Treatment of overactive bladder	March 2006

Vfend	Pediatric filing	June 2005

Zeven (dalbavancin)	Treatment of Gram-positive bacterial infections	December 2004

~~Norvasc~~	~~Reduction of cardiovascular risk, including risk of coronary heart disease, myocardial infarction, cardiovascular procedures and strokes~~	~~August 2004~~

~~Fragmin~~	~~Use in oncology patients to reduce cardiac toxicity associated with chemotherapy~~	~~March 2004~~

Product	Description of Event	Date Approved	Date Submitted

~~Revatio~~Lyrica	Approval in the E.U. for ~~treating PAH~~the treatment of central neuropathic pain	~~November 2005~~September 2006	--
	~~Application submitted in Canada for treating PAH~~	--	~~December 2004~~

~~Geodon~~	Approval in the E.U. for ~~treating manic or mixed episodes~~treatment of ~~moderate severity~~GAD in ~~bipolar disorder~~adults	~~October 2005~~March 2006	--

~~Aromasin~~Chantix/Champix	Approval in the E.U. for ~~treating early breast cancer in post-menopausal women~~smoking cessation	~~August 2005~~September 2006	--

~~Sutent~~Spiriva	Application submitted in the E.U. - Respimat device for chronic obstructive pulmonary disease	--	September 2006

Eraxis	Application submitted in the E.U. for ~~the~~ treatment of ~~metastatic renal cell carcinoma~~candidemia and ~~malignant gastrointestinal stromal tumors~~candidiasis	--	September 2006

Sutent	Application submitted in the E.U. for mRCC as a first-line treatment^(a)	--	August 2006
	Approval in Canada for GIST	May 2006	--
	Application submitted in Canada for mRCC	--	December 2005
	Application submitted in the E.U. for mRCC, as a second-line treatment, and for GIST^(a)	--	August 2005

Aricept	Application submitted in Canada for treatment of severe Alzheimer's disease	--	July 2006

Fragmin	Approval in Canada for ~~fast dissolving tablet~~treatment of medical thromboprophylaxis	July ~~2005~~2006	--

~~Caduet~~Neurontin	Approval in ~~certain E.U. countries~~Japan for ~~cardiovascular event prevention~~treatment of epilepsy	July ~~2005~~2006	--

~~Lyrica~~Genotropin	Approval in Japan for treatment of short stature and growth problems	July 2006	--

Lipitor	Approval in the E.U. for primary prevention of CV events in high coronary heart disease risk patients without established CAD	May 2006	--

Aromasin	Approval in Canada for ~~neuropathic pain~~early breast cancer	~~June 2005~~May 2006	--

Vfend	Approval in Canada for the powder form oral suspension	May 2006	--

Revatio	Approval in Canada for treating pulmonary arterial hypertension	May 2006	--

Zyvox	Approval in Japan for methicillin-resistant Staphylococcus aureus	April 2006	--

Zoloft	Approval in Japan for treatment of depression and panic disorder	April 2006	--

Detrol/Detrol LA/Detrusitol	Approval in Japan for treatment of overactive bladder	April 2006	--

Celebrex	Application submitted in the E.U. for the treatment of ankylosing spondylitis	--	April 2006

Fesoterodine	Application submitted in the E.U. for treatment of overactive bladder	--	March 2006

Chantix/Champix	Application submitted in Canada for smoking cessation	--	February 2006

Exubera	Application submitted in Canada as an inhaled form of insulin for use in adults with type 1 and 2 diabetes	--	April 2006
	Approval in the E.U. as an inhaled form of insulin for use in adults with type 1 and 2 diabetes	January 2006	--

Macugen	Approval in ~~Canada and Brazil for age-related macular degeneration (AMD)~~	~~May 2005~~	--
	~~Application submitted in Switzerland~~E.U. for AMD	--	January ~~2005~~
	~~Application submitted in the E.U. and Australia for AMD~~	--	~~September 2004~~

~~Fragmin~~	~~Approval in the E.U. for treatment of deep vein thrombosis in cancer patients~~	~~April 2005~~2006	--

~~Vfend~~	~~Approval in Japan for treatment of aspergillosis~~	~~April 2005~~	--
	~~Approval for treatment of serious, invasive, fluconazole-resistant candida infections and first-line treatment of candidemia in non-neutropenic patients was granted in the E.U.~~	~~January 2005~~	--

~~Zmax~~	~~Application submitted in the E.U. for sustained release~~	--	~~October 2004~~

~~Genotropin~~Somavert	Application submitted in Japan for ~~treatment of short stature and growth problems~~acromegaly	--	~~July 2004~~

~~Neurontin~~	~~Application submitted in Japan for epilepsy~~	--	~~April 2004~~

~~Exubera~~	~~Application submitted in the E.U. as an inhaled form of insulin for use in adults with type 1 and type 2 diabetes~~	--	~~February 2004~~May 2005

Product	Indication

~~Celebrex~~Geodon/Zeldox	~~Sporadic adenomatous polyposis - a precancerous condition caused by growths (polyps) in the intestines~~Bipolar relapse prevention, bipolar pediatric

~~Camptosar IV~~Lyrica	~~Adjuvant colorectal cancer~~Fibromyalgia, generalized anxiety disorder

~~Gastric~~Sutent	Breast cancer

~~Geodon~~Revatio	~~Bipolar relapse prevention~~

~~Macugen~~	~~Diabetic Macular Edema~~Pediatric pulmonary arterial hypertension

~~Xalatan (new delivery device)~~Macugen	~~Ocular hypertension~~Diabetic macular edema

Zyvox	Catheter-related infections
	Bone and joint infections

^(a)	~~Includes insignificant adjustments to original amounts established.~~
^(b)	~~Included in~~ ~~Other current liabilities.~~

•	Senior management receives a monthly analysis of the operating results of our Company that is prepared on an Adjusted income basis;

•	The annual budgets of our Company are prepared on an Adjusted income basis; and

•	Annual and long-term compensation, including annual cash bonuses, merit-based salary adjustments and stock options, for various levels of management, is based on financial measures that include Adjusted income. The Adjusted income measure currently represents a significant portion of target objectives that are utilized to determine the annual compensation for various levels of management, although the actual weighting of the objective may vary by level of management and job responsibility and may be considered in the determination of certain long-term compensation plans. The portion of senior management's bonus, merit-based salary increase and stock option awards based on the Adjusted income measure ranges from 10% to 30%.

^(a)	Included in Merger-related in-process research and development charges.
^(b)	Included primarily in Amortization of intangible assets.
^(c)	Included in Restructuring charges and merger-related costs.
^(d)	~~Included in~~ Discontinued operations - net of ~~tax.~~tax includes $124 million and $123 million related to the Consumer Healthcare business for the three months ended October 1, 2006 and October 2, 2005 and $335 million and $336 million for the nine months ended October 1, 2006 and October 2, 2005. These amounts do not include a prospective gain on the planned divestiture.
^(e)	Included in Selling, informational and administrative expenses ($3 million) for the three months ended October 2, 2005, and included in Cost of sales ($56 million), Selling informational and administrative expenses ($8 million) andOther (income)/deductions - net($ ($1.2 billion) for the nine months ended October 2, 2005.
^(f)	Included in Research and development expenses.~~Other (income)/deductions - net.~~
^(g)	Included in Cost of sales ($50 million), Selling, informational and administrative expenses ($63 million), Research and development ~~expenses.~~
^(h)	expenses ($70 million) and in Other (income)/deductions - net ($1 million income) for the three months ended October 1, 2006 and included in Cost of sales ($278 million), Selling, informational and administrative expenses ($160 million), Research and developmentexpenses ($132 million) and in Other (income)/deductions - net ($23 million income) for the nine months ended October 1, 2006. Included in Cost of sales ($36 million), Selling, informational and administrative expenses ($6056 million), and Research and development expenses ($8 million) for the three months ended October 2, 2005 and included in Cost of sales ($37 million), Selling, informational and administrative expenses~~($81~~ ($76 million), and Research and development expenses ($1820 million) for the nine months ended October 2, 2005.
^(h)	Included in Other (income)/deductions - net.
(i)	Included in Provision for taxes on income.

		Long-Term-Debt
Name of Rating Agency	Commercial Paper	Rating	Outlook

Moody's	P-1	Aaa	Negative
S&P	A1+	AAA	Stable

			Oct. 2, 2005		Dec. 31, 2004

Cash and cash equivalents and short-term investments and loans (millions of dollars)		$	14,000	$	20,546

Working capital (millions of dollars)^(a)		$	12,373	$	13,236

Current ratio^(b)			1.61:1		1.50:1

Shareholders' equity per common share^(c)		$	9.11	$	9.19

^(a)	Working capital includes assets and liabilities held for sale at October 2, 2005 and December 31, 2004.
^(b)	Current ratio is the proportion of current assets to current liabilities.
^(c)	Represents total shareholders' equity divided by the actual number of common shares outstanding (which excludes treasury shares and those held by our employee benefit trust).

(millions of dollars, except ratios and per common share data)		Oct. 1, 2006		Dec. 31, 2005

Cash and cash equivalents and short-term investments and loans	$	13,291	$	22,736

Working capital^(a)	$	21,033	$	18,423

Ratio of current assets to current liabilities		2.19:1		1.65:1

Shareholders' equity per common share^(b)	$	9.70	$	8.98

^(a)	Working capital includes assets of discontinued operations and other assets held for sale of $6.8 billion and $6.7 billion and liabilities of discontinued operations and other liabilities held for sale of $1.4 billion and $1.2 billion, as of October 1, 2006 and December 31, 2005.
^(b)	Represents total shareholders' equity divided by the actual number of common shares outstanding (which excludes treasury shares and those held by our employee benefit trust).

•	~~payment~~the timing of ~~cash dividends on common and preferred stock, net~~dividend accruals of ~~dividends payable at December 31, 2004 -- $2.8~~$1.8 billion;

•	~~purchases~~an increase in inventories of $689 million, which is primarily due to the acquisition of sanofi-aventis' Exubera inventory, the build-up of inventory in advance of product launches and the impact of foreign exchange, partially offset by the impact of our ~~common stock -- $3.4 billion;~~inventory-reduction initiative;

•	~~net cash paid to acquire Vicuron Pharmaceuticals, Inc.~~the impact of a change in the mix of the U.S. sales rebate accrual of about $370 million; and ~~other smaller businesses -- $2.1 billion;~~

•	~~payment~~a general reduction in payables and accruals of ~~floating-rate notes --$1.0 billion;~~about $1.3 billion, primarily reflecting timing of payments and accruals;

partially offset by:

•	~~purchases~~the expected timing of ~~property, plant and equipment -- $1.5~~tax obligations of about $1.3 billion; and

•	~~purchases~~a decrease in net current financial assets of ~~other assets --$392~~$364 million primarily due to the redemption of short-term investments, partially offset by the pay down of short-term borrowings.

•	higher tax payments in 2005 of $1.7 billion, primarily related to the repatriation of foreign earnings in 2005, and

•	higher current period net income, adjusted for non-cash items, reflecting, among other things, the timing of receipts and payments in the ordinary course of business.

•	higher net redemptions of investments in 2006 (a positive change in cash and cash equivalents of $1.9 billion); in 2006, the proceeds of which were utilized to repay debt and in 2005, the proceeds of which were used to fund the repatriation of foreign earnings as a result of the Jobs Act, and

•	the acquisition of Rinat and sanofi-aventis' rights to Exubera in 2006 compared to the acquisition of Vicuron and Idun in 2005 (a decreased use of cash of $115 million).

•	net ~~redemptions~~repayments of $9.7 billion on total borrowings in 2006, compared to $6.3 billion ~~from investments~~ in 2005,

•	an increase in cash dividends paid of $1.0 billion in 2006 as compared to 2005, primarily ~~used~~due to ~~provide funds for~~an increase in the ~~repatriation~~dividend rate, and

•	higher purchases of ~~foreign earnings~~common stock in ~~accordance with the Jobs Act~~2006 of $4.5 billion as compared to ~~net purchases of $4.6~~$3.4 billion ~~of investments~~ in ~~2004,~~2005,

partially offset by:

•	higher proceeds from ~~sales~~the exercise of ~~businesses and product lines of $108 million in 2005 as compared to $1.2 billion in 2004; and~~

•	~~net cash used for acquisitions in 2005 of $2.1 billion as compared to $1.4 billion in 2004.~~stock options.